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Abstract
The Escherichia coli enzyme nitroreductase has been proposed as a candidate for the 
Gene-Directed Enzyme Prodrug Therapy approach in treating cancer. Structural studies on the 
enzyme were instigated in a first step towards improving enzyme activity. The enzyme was 
crystallized with the substrate analogue, nicotinic acid, and the structures of three crystal 
forms obtained. The fold has a mixed a/P structure, with a molecule of nicotinic acid bound 
next to the FMN cofactor. Several active site residues were identified as candidates for 
mutation. This procedure produced many mutant enzymes with increased catalytic activity. 
One double and four single mutants were chosen from these and crystal structures determined. 
The resulting information from this, and the establishment of a proof of principle, provides 
the basis for iterative cycles of enzyme improvement.
The human hydroxysteroid dehydrogenase AKR1C3 has been proposed to play a role in 
prostaglandin metabolism. Its inhibition by non-steroidal anti-inflammatory drugs may be 
important in a tumour differentiation strategy. AKR1C3 was crystallized, and the structure 
solved with bound nucleotide cofactor and several inhibitors, including the drugs 
indomethacin and flufenamic acid. Having obtained information on drug binding to AKR1C3, 
selective inhibitors can be designed, avoiding inhibition of "housekeeping" enzymes such as 
cyclo-oxygenases.
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CHAPTER 1
INTRODUCTION TO NITROREDUCTASE AND ITS USE IN GENE THERAPY 
1.1 Discovery of E. coli Nitroreductases
Nitrofurazone (see Figure 1.1) is an antimicrobial agent (Dodd and Stillman, 1944) used to 
treat topical infections in burns victims. Nitrofurazone and its derivatives (e.g. nitrorurantoin) 
are also used in bladder and urinary tract infections. In characterising Escherichia coli strains 
that possess resistance to nitrofurazone, it was observed that these resistant strains were 
deficient in nitroreductase activity (McCalla et al., 1971). Upon further investigation, the 
nitroreductase activity ofE. coli could be divided into an oxygen-insensitive (type I) and an 
oxygen-sensitive (type II) component (McCalla et al., 1975). The oxygen-sensitive enzymes 
are only able to catalyze the reduction of nitrocompounds under anaerobic conditions. These 
type II enzymes transfer two electrons to a substrate via sequential one electron steps, which 
are sensitive to oxygen, and can form superoxide in a futile cycle (McCalla et al., 1970). The 
type I enzymes are insensitive to oxygen as they transfer the two electrons to the substrate in a 
single step (Zenno et al. 1996a).
Type I nitroreductase activity was found to be responsible for nitrofurazone activation (Asnis, 
1975), and can be further subdivided into one major component that uses NADPH as an 
electron donor (termed nfsA, (McCalla et al., 1978), and two minor components that can use 
either NADH or NADPH as an electron donor (termed nfsB/nfnB and nfsC, (Bryant et al., 
1981). Electrons from the nucleotides are used to reduce the enzyme substrates. Later studies 
implicated different mutants of nfsA and nfsB in different nitrofurazone-resistant bacterial 
strains (Whiteway et al., 1998). Resistance to nitrofurans can often occur in a stepwise
H H
nitrofurazone nitrofurantoin
2,4,6-trinitrotoluene 
O
1,4-benzoquinone
CH
Figure 1.1. Chemical structures of a variety of NTR substrates. NTR is able to reduce a broad spectrum of 
compounds (see text of this Chapter), usually quinones or nitroaromatics. Figure produced using ISIS draw 
(MDL Information Systems, San Leandro, CA).
mode of activation of nitrofurazone by nitroreductases is discussed in further detail in Chapter 
7. From hereafter in the text, nfsB will be referred to as NTR.
Homologues to the type I nitroreductases ofE. coli are found in Salmonella typhimurium 
(Watanabe et al. 1990) and Enterobacter cloacae (Bryant et al. 199la), and are often referred 
to as "classical nitroreductases". The S. typhimurium enzymes are important activators of 
toxic compounds in the Ames test (Rosenkranz et al. 1981). A homologue of NTR in 
Helicobacter pylori (rdxA) is known to be mutated in strains resistant to the broad-range 
anti-infective drug metronidazole (Land and Johnson 1999). Metronidazole has a similar 
structure to nitrofurazone, possessing an aromatic five-membered ring with a nitro group.
Most of the literature concentrates on nfsA and NTR, with nfsC and the type II 
nitroreductases not yet mapped to the E. coli genome. NfsA and NTR share 7 % amino acid 
sequence identity, and are flavoenzymes, using FMN as the prosthetic group (Anlezark et al. 
1992). They exhibit ping-pong kinetics (schematic in Figure 1.2), and are known to reduce a 
broad-range of quinones and nitroaromatics (Anlezark et al. 1992). These two enzymes also 
show homology to flavin reductases found in luminescent bacteria, nfsA with the FRP protein 
of Vibrio harveyi (Lei et al. 1994), and NTR with the Frasel protein of Vibrio fischeri (Zenno 
et al. 1994). Flavin reductases catalyze the reduction of flavins, which are then oxidised in 
tandem with long-chain aldehydes in bio luminescence reactions. The structure of Frasel has 
been determined (Koike et al. 1998), and shown to be structurally similar to the NADH 
oxidase ofThermus thermophilus (NOX, Hecht et al. 1995). A sequence alignment of this 
family of flavoenzymes is provided in Figure 1.3.
a) NAD(P)H NAD(P)+
b)
C7M N3
C8M
Figure 1.2. Flavin nomenclature and ping-pong mechanism, a) The reductive half (1) and oxidative (2) 
half-reactions of the ping-pong mechanism. In reaction 1 the flavin is reduced by NAD(P)H and alters the 
chemistry of the N5-C4A-C10-N1 bonding interactions. In reaction 2 the flavin then uses this reducing power to 
convert a substrate, Sub, into SubH2 , re-oxidising the flavin back to its original state. Both half-reactions involve 
the transfer of 2e" and 2H+ . The flavin cofactor is capable of accepting or donating one electron, and the one 
electron reduced species is referred to as a semiquinone. a) also shows the anionic state possible in reduced 
flavin, b) The numbering system of the isoalloxazine ring. X refers to the FMN ribityl or FAD dinucleotide tail.
1 SO
entcl —————MDI ISVALKRHST KAFDASKKLT AEE&EKIKTL LQYSPSSTNS
salty —————MDI VSVALQRYST KAFDPSKKLT AEE&DKIKTL LQYSPSSTNS
nfsB —————MDI ISVALKRHST KAFDASKKLT PEQ&EQIKTL LQYSPSSTNS
frase ——~~~THPI IHDLENRYTS KKYDPSKKVS QEDLAVLLEA LRLSASSINS
nox MEATLPVLDA KTAALKRRSI RRYRKDPVPE GLLREILEAA LR.APSAWNL
51 100
entcl QPWHFIVAST EEGKARVAKS AAGTYVFNER KMLDASHWV FCAKTAMDDA
salty QPWHFIVAST EEGKARVAKS AAGNYTFNER KMLDASHWV FC&KTAMDDA
nfsB QPWHFIVAST EEGKARVAKS AAGNYVFNER KMLDASHWV FCAKTAMDDV
frase QPWKFIVIES DAAKQRMHDS FANMHQFNQP HIKACSHVIL FANKLSYTRD
nox QPWRIWVRD PATKRALREA A. ... .FGQ& HVEEAPWLV LYADLEDALA
101 150
entcl WLERWDQEE ADGRFNTPEA KAANHKGRTY FADMHRVDLK DDDQWMAKQV
salty WLERWDQED ADGRFATPEA KAANDKGRRF FADMHRVSLK DDHQWMAKQV
nfsB WLKLWDQED ADGRFATPEA KAANDKGRKF FADMHRKDLH DDAEWMAKQV
frase DYDWLSKAV ADKRITEEQK EAAFASFK. . FVELNCDENG EHKAWTKPQA
nox HLDEVIHPGV QGER. . . . .R EAQKQAIQRA FAAMGQEARK . . .AWASGQS
151 200
entcl YLNVGNFLLG VGAMGLDAVP lEGFDAAILD EEFGLKEKGF TSLVWPVG.
salty YLNVGNFLLG VAAMGLDAVP IEGFDAEVLD AEFGLKEKGY TSLVWPVG.
nfsB YLNVGNFLLG VAALGLDAVP lEGFDAAILD AEFGLKEKGY TSLVWPVG.
frase YLALGNALHT LARLNIDSTT MEGIDPELLS EIFADELKGY ECHVALAIGY
nox YILLGYLLLL LEAYGLGSVP MLGFDPERVR AILGLPSR.. .AAIPALVAL
201 225
entcl HHSVEDFNAT LPKSRLPLST IVTEC
salty HHSVEDFNAG LPKSRLPLET TLTEV
nfsB HHSVEDFNAT LPKSRLPQNI TLTEV
frase HHPSEDYNAS LPKSRKAFED VITIL
nox GYPAEE. . .G YPSHRLPLER WLWR
Figure 1.3. Sequence alignment of NTR and homologues. Amino acids are represented by the standard single 
letter code. Key : entcl, classical nitroreductase of E. cloacae; salty, classical nitroreductase ofS. typhimurium; 
nfsB (NTR), minor oxygen-insensitive nitroreductase of E. coli; frase, flavin reductase of V. fischeri; NOX, 
NADH oxidase of T. thermophilus. The sequences are numbered according to NOX. The sequence alignment 
was produced in GCG using PILEUP (GCG 1998).
NTR has been mapped to 13 min on the E. coli chromosome (Blattner et al. 1997), cloned and 
characterised (Zenno et al. 1996a). NTR has a molecular weight of 23.9 kDa, and can also use 
FAD as a cofactor, although it is associated with FMN under physiological conditions 
(Anlezark et al. 1992). The enzyme has a theoretical pi of 5.5 (calculated using protein 
primary sequence) and is predicted, by homology to Frasel, to be a mixed a / p structure.
1.2 The Discovery of the Anti-Cancer Drug CB1954
The drug 5-(l-aziridinyl)-2,4-dinitrobenzamide (CB1954, formulated in the Chester Beatty 
Laboratories, London) is rare in its ability to selectively kill tumour cells. Its anti-tumour 
activity was unexpected for a mono functional alkylating agent, and had a therapeutic index 
(TI) of 70 against the Walker 256 carcinoma in rats (Connors et al. 1975). This large TI value 
can be compared to compounds used against cancers (cyclophosphamide TI = 22, cisplatin TI 
= 14). The TI is the experimental index of the safety and effectiveness of a particular 
compound, constituting the ratio between the toxic dose (numerator) and therapeutic dose 
(denominator). The cytotoxicity of CB1954 was found to be due to the formation of 
poorly-repaired DNA interstrand crosslinks (Roberts et al. 1986), which would have been 
expected for a difunctional alkylating agent. CB1954 could effectively eradicate the tumour 
cells and cure the Walker rat (Cobb et al. 1969).
Co-culturing of susceptible rat Walker cells with non-susceptible Chinese hamster V79 cells 
led to killing of both cell types after the application of CB 1954 (Knox et al. 1988), and it was 
hypothesised that activation of the drug by the Walker cells was leading to its cytotoxic 
effects. An enzyme, upregulated in tumour cells, designated NQO1 (sometimes referred to as 
DT-diaphorase) was purified from Walker cells, and found to aerobically reduce CB1954
using either NADH or NADPH (Knox et al. 1988). The product of CB1954 reduction, a 
4-hydroxylamino derivative, reacts with cellular thioesters to form the DNA reactive species 
(Knox et al. 1991). The conversion from nitro to hydroxlamine would require 4 electrons, and 
presumably proceed via a nitroso intermediate. Hope of using CB1954 to treat human 
tumours was lowered upon the discovery that the human equivalent of NQO1 had a lower 
activity against CB1954, with 500-5000 fold more drug needed to achieve a cytotoxic 
response commensurate with rat levels (Boland et al. 1991). To counter this, some studies are 
attempting to modulate CB1954 to obtain a drug optimised for human NQO1 (Knox et al. 
1993). Another CB1954-activating enzyme is present in human tumours (termed NQO2), but 
requires the exogenous cofactor dihydronicotinamide riboside for catalysis (Knox et al. 2000).
1.3 Gene Therapy Approach to Cancer Treatment
With the failure of human NQO1 to activate CB1954, it would be necessary to introduce a 
foreign enzyme into tumour cells to make them susceptible to the drug. This technique is 
known as GDEPT (Gene-Directed Enzyme Prodrug Therapy, see Figure 1.4), and a list of 
GDEPT candidates proposed for use with drugs other than CB1954 is provided in Table 1.1. 
In a typical GDEPT approach, the DNA coding for the desired foreign enzyme is targeted to 
the tumour cells and integrated into the host genome. If this targeting is achieved using a 
retroviral vector, it is known as VDEPT (Virus-Directed Enzyme Prodrug Therapy). The 
tumour cell then starts expressing the foreign enzyme, and upon administration of a relatively 
non-toxic prodrug, converts this to a toxic species, resulting in specific tumour cell killing. In 
some GDEPT approaches (Nettelbeck et al. 2000), enzyme expression is regulated by a 
tumour-specific promoter.
______Enzyme_____________Prodrug______________Drug_______ 
Cytosine Deaminase 5-Fluorocytosine 5-Fluorouracil 
Glucose Oxidase Glucose Hydrogen Peroxide 
(3-Glucosidase Amygdalin Cyanide 
Carboxypeptidase A Methotrexate-alanine Methotrexate 
Alkaline Phosphatase______Phenolmustard Phosphate___Phenolmustard________ 
Table 1.1. Various proposals for GDEPT systems in cancer therapy.
Early studies attempting to localise therapeutic enzymes to tumour cells used antibodies 
(ADEPT, Antibody-Directed Enzyme Prodrug Therapy). ADEPT has the limitation of only 
being able to use enzymes that do not require endogenous cofactors, and also has the potential 
to trigger an immune response. The advantages of G/V/ADEPT over conventional 
chemotherapy are enormous. Traditional anti-cancer agents (e.g. cisplatin) are 
anti-proliferatives, and unlike G/V7ADEPT, can cause damage to non-cancerous 
highly-proliferating cell types including bone marrow and gut epithelia. The damage to bone 
marrow is particularly significant, as this weakens the immune system of the patient 
undergoing treatment. Anti-proliferatives also lose their effectiveness against solid tumours, 
where most of the cells in the tumour mass are not dividing rapidly.
Aside from localising enzymes to tumour cells, prodrugs can be activated in other ways. The 
conversion to a toxic species can be triggered by therapeutic radiation (Wilson et al. 1996), 
low extracellular pH in tumour masses (Tietze et al. 1989), tumour hypoxia (Denny et al. 
\ 993) or upregulated endogenous enzymes (Traver et al. 1992). A summary of prodrug 
strategies is provided by Denny (2001).
1.4 The Use of NTR in a GDEPT System
Instead of using the Walker enzyme in a GDEPT approach, it was discovered that NTR can 
activate CB1954 more efficiently (Knox et al. 1992), with NTR possessing a kca, ~ 100-fold
delivery 
system
tumour cell non-transduced 
tumour cell
III
Figure 1.4. Schematic of GDEPT methodology. A gene encoding for the foreign protein is initially targeted 
specifically to tumour cells (i). This is most commonly achieved using an adenoviral vector. The foreign gene is 
then hopefully integrated into the host genome. At this stage, it is inevitable that some cells in the tumour may 
remain untransduced, and not contain the desirable gene. The gene is then transcribed & translated, and the 
transduced cells contain the foreign enzyme (ii). After successful expression of the gene, a relatively harmless 
prodrug (P) is introduced into circulation (iii), and is converted to a toxic drug (D) by the enzyme (iv). This will 
then lead to selective cell killing of the transduced tumour cells. Depending on the GDEPT system in use, the 
drug may diffuse over a limited distance, and kill non-transduced tumour cells (v), a process known as the 
"bystander effect" (Bridgewater et al. 1997).
higher than rat NQO1. Targeting of NTR to tumours would also allow the treatment of a 
wider variety of cancers than the use of an endogenous enzyme.
The kinetic advantage of NTR over rat NQO1 is offset slightly by the fact that NTR produces 
two products upon reduction of CB1954 (Knox et al. 1992, Figure 1.5). NTR generates both 
the toxic 4-hydroxylamine derivative, and a non-toxic 2-hydroxylamine derivative in 
equimolar quantities. There are three main advantages of using the NTR : CB1954 
combination in a GDEPT system. Firstly, untransfected cells can be killed by a "bystander 
effect", where the toxic product can diffuse into the surrounding environment over a limited 
distance (Bridgewater et al. 1997, Figure 1.4 part v). A second advantage would be the 
limitation of damage should any enzyme reach circulation from dead cells - the lack of 
NAD(P)H in the blood would prevent accidental activation of bloodstream prodrug. Finally, 
the NTR : CB1954 GDEPT system cell killing is independent of cell cycle stage, unlike that 
of many other treatments e.g. the thymidine kinase activation of ganciclovir (Moolten 1986).
1.5 Aims & Objectives
Although the NTR : CB1954 combination is usable and in clinical trials (Palmer et al. 2000), 
it would be advantageous to try to improve the catalytic efficiency of the system. A relatively 
high Km for CB1954 c.f. nitrofurazone (880 and 160 uM, respectively) and low potential 
maximum serum CB1954 concentration (~ 10 uM) mean that catalytic efficiency is far from 
optimal. It is the target of this study to obtain structural information of NTR and use this to 
design site-directed mutants of NTR with increased catalytic activity. If this design process 
proves successful, and mutants with an improved turnover of CB 1954 are obtained, it would
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NHOH
cellular H2N 
thioesters
NTR + 4-hydroxylamine 
NAD(P)H derivative DNA-reactive species
O NHOH
2-hydroxylamine 
derivative
Figure 1.5. Reaction of CB1954 with NTR. Unlike NQO1, which gives only the 4-hydroxlamine derivative, 
NTR gives two products upon CB1954 reduction. The 2-hydroxylamine has little to no cellular toxicity, but the 
4-hydroxlamine product reacts with cellular thioesters (e.g. acetyl CoenzymeA) to yield a DNA-reactive species. 
The reduction of CB1954 to a hydroxylamine requires 4 electrons, and is postulated to achieve this via a nitroso 
intermediate. It is not known whether the final 2 electrons come from enzymatic reduction or from solution 
reducing agents. Figure prepared using ISIS draw (MDL Information Systems).
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also be desirable to possess structural information on these enzymes. This may lead to an 
advantageous situation of "iterative design cycles".
1.6 Physiological Role of NTR, and Use In Other Applications
Although NTR has been studied for decades, no definite knowledge of its physiological role 
has arisen. Recent studies have linked nfsA with redox stress (Liochev et al. 1999), its 
expression induced by the transcriptional regulator SoxR under conditions of paraquat 
exposure. It has been postulated that NTR may also respond to redox stress, with the 
discovery that NTR transcription is increased by the activator protein MarA (Barbosa and 
Levy 2002). MarA is known to respond to environmental hazards including antibiotics, 
disinfectants, organic solvents and agents of oxidative stress (Alekshun et al. 1997). It can be 
seen from the studies involving nitroreductase-deficient nitrofurazone-resistant E. coli that 
NTR is not essential for cell growth (Whiteway et al. 1998). There is, of course, redundancy 
in E. coli nitroreductase activity, and effects of NTR knock-outs may not be observed until all 
nitroreductase enzymes are disabled.
Along with the use of NTR in GDEPT, the broad substrate specificity of nitroreductases lends 
their use to bioremediation. Nitroaromatics have a wide distribution in the environment due to 
their heavy use in several industrial processes (McCartney et al. 1986). The NTR homologue 
in E .cloacae (nfsl) has been proposed as an enzyme to clear TNT (2,4,6-trinitrotoluene) from 
the environment (Bryant et al. 1991b). TNT-contaminated soil resulting from the 
manufacture, usage and disposal of explosives is both hazardous and highly toxic (Whong and 
Edwards 1984). TNT undergoes three sequential two electron reductions to the compound 
2-amino-4-6-dinitrotoluene, which can then be further modified or conjugated, and
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metabolised by other enzymes (Nishino et al. 2000). A test study using transgenic tobacco 
plants showed promising results in eliminating TNT from soil samples (Hannink et al. 2001). 
As NTR has also been shown to reduce TNT (personal communication, Dr. Graham White, 
Department of Biosciences, University of Cardiff), an improved NTR enzyme generated by 
these studies may also have relevance to the field of bioremediation.
1.7 Introduction to Flavoproteins 
1.7.1 General Features of Flavoproteins
The diverse range of processes catalysed by flavoenzymes includes transfer of one or two 
electrons between redox centres, activation of oxygen, emission of light, and a wide variety of 
dehydrogenation reactions (Massey 1995). As a group of enzymes, flavoproteins are well 
characterised, mainly due to the accessible spectroscopic features of the flavin cofactor. 
Flavoproteins contain either FMN or FAD, and usually have a preference for one over the 
other. The protein : flavin cofactor interactions are normally non-covalent, although some 
enzymes modify the redox properties of the flavin via covalent linkage to the 6 or 8 position 
of the isoalloxazine ring (Mewies et al. 1998). This section will concentrate on the flavin 
cofactor as a redox centre.
The ubiquity of flavoproteins in redox reactions lies in their ability to transfer either one or 
two electrons. Oxidised flavin can accept one electron to form a semiquinone intermediate, 
and a further electron, in combination with two protons, to form reduced flavin (see Figure 
1.2). Some flavoproteins are unable to accept or donate more than one electron e.g. ETF 
(electron transfer flavoprotein), the reasons why have been well documented (Scrutton et al. 
1999). The transfer of electrons to and from the flavin can be split into a reductive
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half-reaction (where the nucleotide reduces the flavin), and an oxidative half-reaction (where 
the flavin uses this reducing power to reduce the enzyme substrate, and regenerate oxidised 
flavin). The redox activity of flavins is localised in the isoalloxazine ring, the rest of the 
cofactor not involved in catalysis. The N1-C10-C4A-N5 locus effectively acts as an "electron 
sink". The redox potential of the flavin two electron reduction is approximately -200 mV in 
solution, but varies between -400 mV and +60 mV in flavoproteins (Ghisla and Massey 
1989).
1.7.2 Flavoprotein Catalysis
The environment of the flavin cofactor is known to modulate its redox potential, and generally 
positive charge is thought to increase the redox potential, whereas negative charge or 
hydrophobic interactions are thought to decrease it (interactions occurring around the 
isoalloxazine ring, Massey 1995). This modulation of flavin redox potential is apparent in 
cases involving positively charged residues near the Nl atom, which serve to stabilise an 
anionic form of reduced flavin, which has a negative charge at this position (Figure 1.2, 
Ghisla and Massey 1989). Substrate binding to flavins may occur on either the re or si face of 
the isoalloxazine ring, and the other side of the cofactor is usually buried by the protein. 
Flavoproteins are known to have a wide variety of folds (Fraaije and Mattevi 2000), and often 
position the cofactor near another redox centre such as an iron-sulphur cluster (Enroth et al. 
2000) or heme (Narhi and Fulco 1986).
The role of flavoproteins in dehydrogenation reactions has raised questions as to the nature of 
catalysis. This area is controversial and several competing theories exist (Ghisla and Massey 
1989). The most popular theory involves direct hydride transfer between the substrate C(H)
and the flavin N5. This is supported by many crystal structures showing proximity between 
the N5 and C(H) (e.g. glutathione reductase, Pai and Schulz 1983). The reaction could also 
proceed via a radical mechanism. In a dehydrogenation reaction this would involve removal 
of a hydrogen atom from the substrate and the collapse of the subsequent radical pair to give a 
reduced flavin and oxidised product. The abstraction of the hydrogen atom would be the 
rate-limiting step, and this is used to validate the relevance of this particular theory on a case 
by case basis (Walker and Edmonson 1987). The final theory centres on the production of a 
carbanion by abstraction of a substrate proton from the C(H) group, as proposed by some 
authors for flavocytochrome b2 (Rao and Lederer 1998). This step would be catalysed by an 
active site base, and the carbanion would donate two electrons to the flavin, directly or via a 
covalent intermediate. This hypothesis is not as popular as the others mentioned above, and is 
favoured for "activated" substrates, such as the oxidation of acyl-CoA (Massey and Ghisla 
1983). Currently, the direct hydride transfer hypothesis is supported by the majority of the 
academic community. A full discussion of flavoprotein mechanisms is provided in Ghisla and 
Massey (1988) or Fraaije and Mattevi (2000).
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CHAPTER 2
INTRODUCTION TO 3a-HYDROXYSTEROID DEHYDROGENASE 
2.1. The AKR Superfamily
Oxidoreductase enzymes can be placed into three superfamilies: the long-chain alcohol 
dehydrogenases, short-chain dehydrogenases / reductases (SDR superfamily) and the 
aldo-keto reductases (AKR superfamily). The long-chain alcohol dehydrogenases and SDRs 
are structurally distinct, the former being zinc metalloproteins, and the latter possessing a 
Rosmann fold for NAD(P)(H) binding. The AKRs have some catalytic residues in common 
with the SDRs (see end of this section), but have a totally different protein fold. SDRs are 
multimeric, whereas AKRs are usually monomeric (with a few exceptions : Kavanagh et al. 
2002; Kozma et al. 2002), and form an ctgpg barrel with two additional a-helices (Rondeau et 
al. 1992). AKR enzymes bind NAD(P)H in an extended conformation, using loops at the 
C-terminal end of the barrel (Wilson et al. 1992). AKRs reduce and oxidize a wide variety of 
compounds (Table 2.1), some of which are potential therapeutic targets.
Enzyme
Human 3a-HSD type II 
Human aldose reductase
Human aldehyde reductase 
Rat aflatoxin reductase
G. echinata polyketide reductase 
Mouse vas deferens protein 
Bovine prostaglandin F synthase
AKR Identity
AKR1C3 
AKR1B1
AKR1A1 
AKR7
AKR4A3 
AKR1B7 
AKR1C7
Substrate
Steroids 
Glucose
Neurotransmitters 
Aflatoxins
Pro-antibiotics 
Androgens 
Prostaglandin D2
Therapeutic Target
Cancer 
Diabetes
Depression
-
Table 2. 1 . Diversity of the AKR superfamily.
AKRs can be found in mammals, amphibians, plants, yeast, protozoa and bacteria (Jez et al. 
1997). To avoid confusion, the naming of these enzymes is similar to that used for the
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cytochrome P450 family, with the prefix AKR followed by a number to indicate the subfamily, 
with further letters and numbers to identify subgroups (Jez et al 1996a). The subgroups are 
named with reference to human liver aldose reductase. All the AKR enzyme structures have 
the a8pg fold, and several groups of conserved residues have been shown to be important 
(Table 2.2).
__________Conserved Residues Function_______ 
D50, N167, Q190, S271, R276 Nucleotide cofactor binding 
D50, Y55, K84, H/E117* Active site geometry / catalysis 
G22, G45, D112, P119, G164, P186 (always conserved) I
G20, G62, LI 13, WHS, G158, El92 (usually present) ' Barrel formation________ 
Table 2.2. Conserved residues in the AKR superfamily. *H for carbonyl reduction, E for C=C reduction.
Positioning of the conserved active site residues with respect to the cofactor is shown in 
Figures 2.1 & 2.2. Mutagenesis studies and kinetic data suggest Y55 to be the general acid or 
base (Petrash et al. 1994). Three possible mechanisms for catalysis exist. Using carbonyl 
reduction as an example, in the first hypothesis proton donation from an active site acid is the 
first step, generating a carbocation, followed by hydride transfer from the nucleotide to yield 
the hydroxy product. A second mechanism would involve hydride transfer occurring first, 
generating an oxyanion, followed by proton donation from the active site acid. The third 
hypothesis follows a concerted model, with the two steps occurring concurrently. Solvent 
isotope effect measurements favour an oxyanion intermediate (Penning et al. 2001), and the 
geometry of the His-Tyr-Lys active site cluster can be likened to the catalytic triad and 
oxyanion hole of the serine proteases (Dodson and Wlodawer 1998). The SDR family of 
enzymes possess a Tyr-X-X-X-Lys motif at the active site, and the identity of these with the 
AKR conserved residues provides an example of convergent evolution. Some members of the 
AKR family retain the structural features mentioned above, but are not yet shown to possess
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Figure 2.1. Positioning of groups of conserved AKR residues. The figure was constructed using the AKR1C3 : 
NADP+ : acetate ternary complex (see Chapter 8). Nucleotide represented as stick model, coloured according to 
atom type : C, yellow; P, magenta; O, red; N, blue. Residues represented as stick model, coloured according to 
conservation type : nucleotide binding, blue; active site geometry & catalysis, red; barrel formation, green. 
Residues labelled using standard single letter code and sequence residue number. Protein Ca trace in dark grey. 
Figure prepared using MOLSCRIPT (Kraulis 1991) and RASTER 3D (Meritt and Bacon 1997).
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acetate
NADP+
Figure 2.2. Arrangement of AKR active site residues. The figure was constructed using the AKR1C3 : NADP+ : 
acetate ternary complex (see Chapter 8). Atoms coloured according to residue and atom type : NADP+ C, grey ; 
acetate C, green ; protein C, yellow ; O, red ; N, blue. Hydrogen bonding shown as dotted green lines. Figure 
prepared using MOLSCRIPT (Kraulis 1991) and RASTER 3D (Meritt and Bacon 1997).
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catalytic activity, e.g. frog p-crystallin (Tomarev et al. 1984) and the 0-subunit of the rat K+ 
shaker channel (McCormack and McCormack 1994).
2.2 Hydroxysteroid Dehydrogenases of the AKR Superfamily
In humans, there are four AKR 3a-hydroxysteroid dehydrogenases (HSDs), named AKR1C1- 
4. These enzymes share a high degree of homology (Table 2.3, Figure 2.3) and have 
functional plasticity, using 3a, 170 and 20cc-hydroxysteroids as substrates (Figure 2.4). 
AKR1C4 is expressed solely in the liver, but AKR1C1-3 have a wide tissue distribution 
(Penning et al. 2000). AKR1C1 is primarily a 20a-HSD and converts progesterone to the 
inactive steroid 20a-hydroxyprogesterone. AKR1C2 is distinguished from the other 3a-HSDs 
by its high affinity for bile acids and may be involved in bile acid transport. Most of the 
literature focuses on AKR1C2 involvement in 5a-dihydrotestosterone (5a-DHT) production 
and abnormal prostate growth (Gormley 1991). AKR1C3 expression is highest in the prostate 
and mammary gland, and has a largely reductive role, converting androgens to inactive 
metabolites (Penning et al. 2001). AKR1C3 also reduces estrone to the more active 
17p-estradiol, and AKR1C3 inhibitors have been proposed for the treatment of 
hormonally-dependent breast cancer (Penning et al. 2001). The 3a-HSD enzymes are also 
known to activate polycyclic aromatic hydrocarbon (PAH) proximate carcinogens, and have 
been shown to be overexpressed in lung carcinomas (Palackal et al. 2002). Some role for 
3a-HSDs may also exist in neurosteroid synthesis (Usami et al. 2002).
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1
MDSKYQCVKL
MDSKYQCVKL
MDSKQQCVKL
MDPKYQRVEL
--MkASCVLL
51
SAHLYNNEEQ
SAHVYNNEEQ
SAHLYNNEEQ
SAYLYNNEEQ
CAAIYGNEPE
101
ERSLKNLQLD
ERSLKNLQLD
ENSLKKAQLD
ESSLKKLQLD
RKTLADLQLE
151
AVEKCKDAGL
AMEKCKDAGL
AMEKCKDAGL
VMEKCKDAGL
ALEALVAKGL
201
RKLLDFCKSK
RKLLDFCKSK
SKLLDFCKSK
SKLLDFCKSK
NELIAHCQAR
251
RTPALIALRY
RTPALIALRY
RTPALIALRY
RTPALIALRY
RSPAQILLRW
301
NRNVRY ....
NRNVRY ....
DRNLHY ....
NRNYRY ....
NKNWRY IVPM
NDGHFMPVLG
NDGHFMPVLG
NDGHFMPVLG
NDGHFMPVLG
HTGQKMPLIG
VGLAIRSKIA
VGLAIRSKIA
VGLAIRSKIA
VGLAIRSKIA
IGEALKEDVG
YVDLYLIHFP
YVDLYLIHFP
YVDLYLIHSP
YVDLYLLHFP
YLDLYLMHWP
AKS IGVSNFN
AKSIGVSNFN
AKS IGVSNFN
AKSIGVSNFN
VQALGLSNFN
DIVLVAYSAL
DIVLVAYSAL
DIVLVAYSAL
DIVLVAHSAL
GLEVTAYSPL
QLQRGVWIA
QLQRGVWLA
QLQRGVWLA
QLQRGVWLA
QVQRKVICIP
LTLDIF. . . .
LTLDIF. . . .
FNSDSF. . . .
WMDFL. . . .
LTVDGKRVPR
FGTYAPAEVP
FGTYAPAEVP
FGTYAPPEVP
PGTYAPPEVP
LGTW.KSEPG
DG.SVKREDI
DG.SVKREDI
DG.SVKREDI
DG.SVKREDI
PGKAVPREEL
VSVKPGEEVI
VSVKPGEEVI
MSLKPGEELS
MALKPGETPL
YAFERGDNPF
RRQLEMILNK
HRLLEMILNK
RRQLEMILNK
CRQLEMILNK
SRQIDDILSV
GSHREEPWD
GSHREEPWD
GSQRDKRWVD
GTQRHKLWVD
GSS.DRAWRD
KSYNEQRIRQ
KSYNEQRIRQ
RSYNEQRIRQ
KSYNEQRIRE
KSITPSRILQ
.AGPPNYPFS
.AGPPNYPFS
.ASHPNYPYS
.MDHPDYPFS
DAGHPLYPFN
KSKALEATKL
KSKALEAVKL
RSKALEVSKL
RNRAVEVTKL
QVKA. .AVKY
FYTSKLWCNS
FYTSKLWSNS
FYTSKLWSTS
FYTSKLWCTF
FVTSKLWTK
PKDENGKILF
PKDENGKILF
PTDENGKVIF
PKDENGKVIF
PKNADGTICY
PGLKYKPVCN
PGLKYKPVCN
PGLKYKPVCN
PGLKYKPVCN
ASV..RPAVL
PNSPVLLEDP
PNSPVLLEDP
PNSPVLLEDP
PNSPVLLEDP
PDEPVLLEEP
NVQVFEFQLT
NVQWEFQLT
NVQVFEFQLT
NIQWEFQLT
NIKVFDFTFS
333
DEY
DEY
DEY
DEY
DPY
50
AIEAGFRHID
AIEAGFHHID
AIEAGFRHID
AIEAGFRHID
ALSVGYRHID
100
HRPELVRPAL
HRPELVRPAL
HRPELVRPAL
FQPQMVQPAL
HHPEDVEPAL
150
DTVDLG&TWE
DTVDLGATWE
DIVDLCTTWE
DTVDLSATWE
DSTHYKETWK
200
QVECHPYFNQ
QVECHPYFNQ
QVECHPYFNR
QVECHPYLNQ
QVECHPYIAQ
250
VLGALAKKHK
VLCaLAKKHK
VLCaiiAKKHK
VLGALAKKHK
WIALAEKYG
300
SEEMKAIDGL
SEEMKAIDGL
AEDMKAIDGL
SEDMKVLDGL
PEEMKQLNAL
Figure 2.3. Sequence alignment of AKR human HSD enzymes (AKRIC family) and human aldehyde reductase 
(AKR1 Al). Amino acids are represented by the standard single letter code, numbering is with respect to 
AKR1C3. Gaps in alignment indicated by full stops. Alignment produced using PILEUP feature of GCG 
package (GCG 1998).
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Figure 2.4. Steroid numbering system and positions for reduction / oxidation by the HSD enzymes, a), b) and c) 
the relative steroidal orientations for C3, C17 and C20 oxidoreduction. The C3 and C20 orientations are flipped 
relative to one another 180° around the vertical axis, whereas the C3 and C17 orientations are flipped 180° in 
both the horizontal and vertical axes. For enzymes possessing more than one type of HSD activity, some 
plasticity in steroid binding is required, d) the ring classification of steroids, e) standard steroid numbering 
system, a) to d) show alternative representations of the molecule testosterone, and e) shows cholesterol.
Protein % Identity to Residue (in steroid binding pocket) 
________ AKR1C3 _______________________________________
52 54 55 86 117 118 120 128 129 226 227 306 308 310
AKR1C3 100 ALYWHSMLSRWFSS 
AKR1C1 86 ALYWHFVVIPWLLI 
AKR1C2 88 AVYWHFVVIPWLLI 
AKR1C4 ____ 84 ALYWHFMPLLWVMF 
Table 2.3. Variability in AKR1C subfamily. Residues in bold are invariant.
2.3 HSDs and Prostaglandins
Prostaglandins are short-lived signalling molecules generated from the fatty acid arachidonate 
by cyclo-oxygenases, and are implicated in such diverse processes as inflammation, 
thrombosis, blood pressure regulation and cancer (Versteeg et al. 1999). The chemical 
structure of a variety of prostaglandins and related compounds is given in Figure 2.5. 
Synthesis of prostaglandins is dependent on the release of arachidonic acid from membranes 
by the action of phospholipase A2 / C, which is then converted to prostaglandin Fk by 
cyclo-oxygenases (see Section 2.4). Prostaglandins belong to a group of compounds known as 
the eicosanoid hormones, all of which are oxygenated 20 carbon fatty acids. Prostaglandins 
(PGs) have a cyclopentane ring, prostacyclins have two fused, five-membered rings, 
thromboxanes have a cyclohexane ring, and leukotrienes have three conjugated double bonds.
PGF2 has a variety of functions including muscle contraction and pain transmission (Shimizu 
and Wolfe 1990). PGF2 is derived from PGD2, and upon the cloning of PGF synthase from 
bovine lung, the enzyme was revealed to be part of the AKR superfamily (Watanabe et al. 
1988). In an attempt to clone the human counterpart of PGF synthase, it was discovered to be 
identical to the HSD enzyme AKR1C3 (Suzuki- Yamamoto et al. 1999). This raised important 
questions as to the primary physiological role of AKR1C3, the kcat/Kn, (the specificity 
nstant) for its "traditional" steroidal substrate 5p-androsetene-3,l 7-dione being -3.5 % ofco
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Arachidonic Acid
OH 
Prostaglandin H2
Prostaglandin D2 9a, 1113-Prostaglandin F2
Figure 2.5. Chemical structures of the prostaglandin precursor, arachidonic acid, and various prostaglandins. All 
contain 20 carbon atoms, and the stereospecificity of the OH substituents and certain C-C bonds is particularly 
important in prostaglandin function and recognition. Figure produced using ISIS draw (MDL Information 
Systems).
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that for PGD2 (Suzuki-Yamamoto et al. 1999). The association between AKR enzymes and 
PGs had also been seen with rat liver 3ct-HSD (AKR1C9), where PGs and arachidonic acid 
inhibited the oxidation of androsterone (Penning and Talalay 1983).
2.4 Cyclo-oxygenases and Nonsteroidal Anti-Inflammatory Drugs
As mentioned earlier, the primary synthesis of prostaglandins depends on cyclo-oxygenase 
(COX) activity. There are two enzyme isoforms (COX-1 and COX-2, 60 % amino acid 
identity), which show different modes of regulation. COX-1 is constitutively expressed, and is 
thought of as a "housekeeping" enzyme, involved in platelet aggregation and protection of the 
gastric mucosa (Oneill and Fordhutchinson 1993). COX-2 is induced by cytokines, oncogenes 
and growth factors, and is associated with inflammation (Dewitt and Smith 1995). The two 
isoforms also exhibit differential expression, COX-1 localised to the endoplasmic reticulum 
and plasma membrane, COX-2 localised to the nuclear envelope (Morita et al. 1995). COX-1 
and 2 are found in most, if not all mammalian tissues.
Both COX enzymes contain a heme cofactor and catalyse two reactions : a cyclo-oxygenase 
step that uses arachidonic acid and two O2 molecules to form PGG2; and a second peroxidase 
step that reduces PGG2 to PGH2 . Important active site residues have been identified from 
structures of COX-1 (Picot et al. 1994), COX-2 (Luong et al. 1996) and an arachidonic acid 
complex of COX-1 (Malkowski et al. 2000). The active site geometry is radically different to 
that of the AKRs, as would be expected given the sequence and cofactor differences. A 
comparison of the AKR, SDR and COX protein folds is provided in Figure 2.6. With their 
central role in inflammation and signalling, efforts have been made to inhibit the COX 
enzymes for therapeutic gain in pain relief and arthritis. As COX-1 is somewhat beneficial in
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Figure 2.6. Differing folds of the AKR, SDR and COX protein families. Left hand column view is at 90° to right 
hand column view. Diagram is coloured according to secondary structure : a-helices in red and p-strands in 
yellow, a) AKR pig aldose reductase (PDB code 1AH4, Urzhumtsev et al. 1997), b) SDR Drosophila 
lebanonesis alcohol dehydrogenase (PDB code IB 16, Benach et al. 1999), c) the COX-2 isoform from humans 
(PDB code 6COX, Kurumbail et al. 1996). The SDR and COX examples shown are dimeric, and the AKR 
example monomeric. Figure prepared using MOLSCRIPT (Kraulis 1991) and RASTER3D (Meritt and Bacon. 
1997).
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the prevention of gastric ulcers (Robert 1983), and COX-2 is labelled as the main protagonist 
due to its inducible expression, COX-2 specific inhibitors have also been identified (Prescott 
and Fitzpatrick 2000).
Nonsteroidal anti-inflammatory drugs (NSAIDs) have long been used in pain alleviation and 
the treatment of inflammation, the most well-documented of which is aspirin. The chemical 
structure of a selection of NSAIDs is given in Figure 2.7. In 1982, the Nobel prize was 
awarded to Bergstrom, Samuelson and Vane for the elucidation of the target of NSAID action 
- discovered to be the step of prostaglandin formation. The particular action of aspirin is to 
acetylate and inactivate COX-1 and COX-2 (Vane 1971). The effect of other NSAIDs is also 
to inhibit COX activity, and further COX : NSAID structures have been solved (Kurumbail et 
al. 1996; Loll et al 1996).
2.5 Cancers & The Protective Effect of NSAIDs
Colorectal cancer is the third most common of all cancer deaths, and the incidence of it is 
increasing (WHO 1997). Most colorectal cancers involve a progression of steps (see Figure 
2.8). The tumour mass initially forms an adenoma, eventually becoming metastatic 
whereupon it is classified as an adenocarcinoma. The individual steps in this process involve 
the mutation of several key "gate-keeper" genes including p53, Ki-ras, DNA mismatch repair 
enzymes and the adenomatous polyposis coli (APC) gene. Many studies have established that 
NSAIDs have a protective effect against colon cancer (Shiff and Rigas 1997), and sulindac 
was the first drug demonstrated to regress colonic polyps in familial adenomatous polyposis 
(Takayama et al. 1998). Celecoxib, a selective COX-2 inhibitor, is given as a cancer 
preventative agent to individuals known to possess a faulty APC gene (Tegeder et al. 2001).
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Figure 2.7. Chemical structures of various NSAIDs. Figure produced using ISIS draw (MDL Information 
Systems).
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Figure 2.8. Progression of colorectal cancer. Individual "gate-keeper" mutations in protective genes labelled by 
blue arrows, progressive stages labelled by black arrows. Figure adapted from Shiffand Rigas 1999.
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The anti-tumour activity of NSAIDs is not limited to colon cancer, with chemopreventative 
activity shown against both lung and breast cancer (Fosslien 2000), and NSAID-induced 
apoptosis of human myeloid leukaemia has been demonstrated in vitro (Klampfer et al. 1999). 
This is particularly relevant as tumours of myelopoietic bone marrow show a similar stepwise 
progression to those seen in the colon.
The majority of studies link the anti-oncogenic effect of NSAIDs with their ability to inhibit 
the COX enzymes (Vane 1971). Studies of colon cancer do indeed show increased levels of 
COX-2 and PGE2 (Shiff et al. 1997). Aside from this rinding, several other factors encourage 
the link between NSAID protection and COXs : 1) PGs are known to reduce apoptosis (PGE2 
induces Bcl-2), and overexpression of COX-2 in colon cells increases their life span (DuBois 
et al. 1996); 2) in APC knockout mice the COX-2 ";" mice develop fewer tumours than 
COX-2 '/+ mice, which have fewer still than COX-2 +/+ individuals (Oshima et al. 1996); 3) 
COX-2 induces angiogenesis (Tsujii et al. 1998); 4) free arachidonic acid has been shown to 
promote apoptosis (Surette et al. 1996), and NSAID inhibition of COX would elevate cellular 
levels ; and 5) inflammation is a known risk factor for several types of cancer (Prescott et al. 
2000).
There is, however, a growing body of evidence that the chemoprotective effects of NSAIDs 
are independent of COX activity. The most prominent of these was the realisation that much 
higher doses of NSAIDs were required to show an anti-oncogenic effect than that needed to 
inhibit PG synthesis by COX (Flower et al. 1980). Other studies also showed that NSAIDs 
could inhibit tumour formation in COX-deficient cell lines (Hanif et al. 1996; Zhang ct al. 
1999). Some NSAIDs are not COX inhibitors (e.g. sulindac sulphide), yet induce the cellular
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apoptotic response (Thompson et al. 1997). These COX-independent activities of NSAIDs 
have been suggested to elicit their effects via the transcription factors NF-KB and AP-1 
(Tegeder et al. 2001), but as the proven chemoprotective NSAID indomethacin is unable to 
bind these, some doubts remain. To complicate the situation further, some NSAIDs 
(indomethacin included) can activate the peroxisome proliferator-activated receptor y 
(PPARy), and others such as salicylate cannot (Schoonjans et al. 1996). Loss of PPARy 
function is associated with some human colon cancers (Sarraf et al. 1999). PPARy is known to 
form complexes with retinoid X receptors (RXR), and have an influence over cellular 
proliferation and differentiation (Clay et al 2000). Evidence for PPARy being an effector of 
NSAID-induced chemoprotection is given by Wick (Wick et al. 2002). The interplay of 
COX-dependent and independent effects and the different NSAID types in cancer prevention 
is obviously highly complex, and may involve a combination of a variety of the proposed 
pathways.
2.6 AKR1C3 as a Candidate for NSAID Effects
The HL60 cell line (derived from human myeloid leukaemia) is a well-studied system used to 
investigate cellular differentiation. The sensitivity of HL60 cell cultures to the differentiation 
agent all-trans retinoic acid (ATRA) was increased with the addition of indomethacin and the 
steroid hormone dexamethasone (Bunce et al. 1994). These, and other compounds that 
increased differentiation, were all found to be inhibitors of 3a-HSD enzymes (Bunce et al. 
1996). It was concluded that inhibition of a 3a-HSD was leading to the differentiation effects, 
and this 3a-HSD was shown to be AKR1C3 (Bunce et al. 1994). Figure 2.9 details the 
proposed mechanism by which NSAIDs and other inhibitory compounds effect AKR1C3
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Figure 2.9. Proposed mechanism for AKR1C3 involvement in NSAID chemoprotection. Inhibition of AKR1C3 
reductase activity by NSAIDs leads to an increase in cellular levels of prostaglandin D2 . Non-enzymatic 
conversion of prostaglandin D2 to prostaglandin J occurs, and this can activate PPARy In tandem with 
differentiation agents like all-trans retenoic acid. Downstream events of PPARy activation (such as cadherin-E 
expression, Ohta et al. 2002) then lead to the desired chemoprotective effects, including differentiation of 
tumour cells. The scenario between this proposed COX-independent mechanism, and other COX-independent 
mechanisms remains complex however, an example being the direct binding of PPARy by some NSAIDs (see 
main body of text).
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activity and promote differentiation (personal communication, C.M. Bunce, School of 
Biosciences, University of Birmingham).
2.7 Aims of the Project
It is the purpose of this study to obtain structural information on AKR1C3 and use this to 
examine the functional plasticity between the AKR1C1-4 subfamily members. If possible, it 
would be desirable to look at NSAID binding and relate this to the COX studies, with an 
eventual target of acquiring enough information to allow the design of AKRlC3-specific 
NSAIDs. Such compounds would hopefully be useful in differentiation therapy, treating some 
hormonally-dependent cancers, and assist mechanistic studies on the enzyme. Furthermore, 
AKRlC3-specific NSAIDs could also provide a means for determining what extent of the 
chemoprotective activity of NSAIDs may be attributed to AKR1C3 inhibition.
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CHAPTER 3
INTRODUCTION TO X-RAY CRYSTALLOGRAPHY 
3.1 Foreword
In tandem with mechanistic studies on proteins, it is desirable to find out about the precise 
distribution of the amino acids in the protein structure and use this information to explain how 
that protein functions. Since the small size of proteins limits studies using longer wavelength 
light (microscopy of large complexes excluded), a wavelength appropriate to the features of 
the molecule studied would need to be used. Due to the distance between atoms being on the 
Angstrom scale, x-ray wavelengths (0.1 to 100 A) are used for visualising protein structure.
With proteins as small as they are, a single protein molecule would not be able to scatter a 
detectable amount of x-rays. It had been previously observed that many different types of 
crystals diffracted x-rays well (the idea being that their extraordinary external appearance 
reflected some internal regularity being a correct assumption). This led to the hypothesis that 
a protein crystal would prove similarly useful. Protein crystals were known to exist, with 
haemoglobin crystallizing directly from earthworm blood (studies by Hunefeld in 1840), and 
excelsin storage protein from brazil nuts also able to crystallize (studies by Hartig in 1855). 
Studies on early crystalline samples proved disappointing as the proteins were treated in the 
same manner as small molecules, and the drying out process destroyed the crystal order. 
However, in 1934, Bernal & Crowfoot (Bernal et al. 1934), kept their protein crystal hydrated 
whilst collecting data and the first protein crystal diffraction pattern was observed. From this 
starting point, it took many years before the diffraction patterns could be analysed and used in 
structure determination.
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3.2 Theory of Diffraction
With a crystal consisting of repeating units arranged in an essentially infinite array (truncated 
by an exhaustion of supply or poisoning of the crystal growth faces), it can be thought of as a 
series of regular lattice planes that dissect the unit cell. The unit cell is defined as the smallest 
portion of the crystal that can recreate the crystal itself when translational symmetry is applied 
in three dimensions. The interplay of crystal lattice planes, x-rays and the resultant diffraction 
pattern is explained by Bragg's Law, a pictorial description of which is given in Figure 3.1.
The diffraction pattern consists of an array of reflections arising from the fulfillment of 
Bragg's Law, with their position relative to the scattering angle 20 (as this increases so does 
the resolution, as the spacing between the planes d decreases), and the intensity of the 
diffraction spot is proportional to the electron density of the scattering atoms of that particular 
Bragg plane. The crystal and its contents are said to be in real space, and the diffraction 
pattern in reciprocal space. It is useful to separate the two this way since the real space 
electron density is derived from the reciprocal space diffraction pattern. As Bragg's Law is 
rearranged to sinG = rik/2 x 1/d, it can be seen that d is inversely proportional to sinG. A 
decrease in d would lead to an increase in 6 (seen from the existence of high resolution spots 
at larger scattering angles), and also the shortening of distance between lattice points in 
reciprocal space when dealing with larger unit cells in real space. In describing vectors in the 
unit cell, real space uses a, b, c and reciprocal space uses a*, b*, c*.
Reconstruction of the diffracted x-rays and visualization of the structure of the crystal 
contents remains elusive, as information on the phases of the diffracted x-rays is lost. The 
phase of a scattered x-ray wave determines its periodicity with respect to the direct beam, and
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Figure 3.1. Pictorial representation of Bragg's Law. For diffraction to be obtained, the diffracted x-rays have to 
reinforce each other, i.e. be in phase. The incoming x-rays (beams 1 and 2) strike the crystal lattice planes at 
points O and C, at an angle of 6. The planes are spaced apart by a distance d. If the diffracted x-rays are to 
emerge in phase (the extra distance travelled by x-ray 2 c.f. x-ray 1 must be equivalent to an integral number of 
wavelengths [nX], i.e. AC = CB = dsinO). Hence, Bragg's Law nA,=2dsin6, with the diffracted x-ray leaving the 
crystal at an angle of 9 to the lattice planes, and an angle of 29 to the direct beam.
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this information is needed for every diffraction spot. In very small unit cells (mainly those of 
small molecules or very small proteins / peptides), statistical methods exist for the estimation 
of the phase values, and the structure of the cell contents can be phased de-novo using 
so-called direct methods. With the larger cell volumes found in protein crystallography, some 
method has to be employed to estimate the phase values from experimental observations (see 
section 3.3).
The diffracted x-ray contains contributions from all atoms in the unit cell, and may be 
described as a structure factor Fhki. Since this structure factor is a series (containing 
contributions from atom A, atom B. . . . . .atom N), a fourier transform can be applied to it,
generating another series that essentially describes the electron density of the unit cell. The 
equation connecting the structure factor (Fhki, reciprocal space) and the electron density in the 
unit cell (p [x,y,z], real space) is represented in Equation 3.1:
p (x,y,z) = 1 E Z S Fuk. e-2*i(hx+ky+lz-(x'M/)
h k I
Equation 3. 1 . Equation linking real and reciprocal space, x, y, and z are points in the unit cell (p the value of the 
electron density at a particular point), h, k and 1 are indices of the reflection hkl, V is the volume of the unit cell 
and i is V-l . The phase contribution a of reflection hkl is represented by a' (a=27ta').
Crystals are not perfect and are subject to disorder. This disorder limits the effective 
resolution of structural studies, with the diffraction of many protein crystals only observable 
to a medium resolution (around 2 A). Crystals show varying resolution limits, and a fair 
correlation can be observed between effective resolution and crystal solvent content, with 
resolution decreasing as the solvent content increases. This correlation acts merely as a guide, 
however, and crystals of high solvent have been shown to diffract to high resolution and vice
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versa. Disorder of the crystal lattice is termed mosaicity and high values indicate increased 
disorder, with a greater number of partial and a lower number of full reflections on an 
oscillation image for the same relative oscillation range.
3.3 Phasing Protein Structures
3.3.1 Overview of Techniques Used
To estimate phases of the diffracted x-rays using experimental methods, two techniques are 
used that alter the intensities of the spots in the diffraction pattern, and a third technique 
compares the collected data with that from a previously determined homologue. In 
isomorphous replacement, the intensity difference is achieved by the inclusion of a heavy 
atom in the protein crystal (an atom at least as heavy as those in the first row of the transition 
elements, third row transition elements are most commonly used), but with anomalous 
scattering the intensity differences come from interactions of the heavy atom with the x-rays 
at a particular wavelength. A third technique for estimating phases, molecular replacement, 
can be utilised when the structure of a homologous protein to the one studied is known, no 
intensity differences are measured.
3.3.2 Single or Multiple Isomorphous Replacement
With this technique, measurable changes in diffraction spot intensity are made by the 
introduction of a heavy atom into the crystal lattice, binding to the protein in an ordered 
manner and altering the unit cell dimensions as little as possible (being isomorphous with the 
"native" crystal form). This is traditionally achieved by long periods of soaking the crystal in 
a mother liquor solution, supplemented with a low concentration of heavy atom compound 
e.g. I Ig and Pt salts. These may react covalently (Hg bonding to cysteine S), ionically (PtCl.f
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interacting with histidine NIT1") or hydrophobically (I binding to hydrophobic patches) with 
the protein. An excellent review of heavy atom derivitisation of protein crystals is provided in 
(Blundell and Johnson 1976). Heavy atoms are required due to their large number of 
electrons, which make a larger and more measurable intensity change in the diffraction 
pattern.
To estimate phases using the intensity differences achieved upon heavy atom derivitisation of 
the protein crystal, it is convenient to represent the structure factors of the reflections as 
vectors on an Argand diagram, with the real axis horizontal, and the imaginary axis vertical. 
The intensity is represented as the length of the vector, and its phase as the angle between the 
vector and the real axis. The protein (Fp) and the heavy atom (FH) structure factors combine to 
give an additive contribution (FPH). Computationally the phasing comes from finding the 
position of the simple heavy atom substructure by looking at the difference between FPH and 
FP . An assumption is made that FPH - FP = FH . This is shown diagrammatically in Figure 3.2.
It can be seen that this single derivative provides two potential solutions for the phase angle. 
If the two are sufficiently close, such that their average gives a good estimate of the true 
solution, then the structure may be solved with this single derivative (known as SIR, single 
isomorphous replacement). More commonly, other derivatives are needed to remove this 
phase ambiguity (MR, multiple isomorphous replacement). Further derivatives must bind at 
different sites to previously obtained derivatives, to ensure that the ambiguity can be resolved.
The actual information in positioning the heavy atom in the unit cell to allow use of the 
aforementioned procedure comes from a calculation known as a Patterson function. The
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Figure 3.2. Geometric representation of MIR phasing. Having found the positions of the heavy atoms in the unit 
cell, the phases for the protein : heavy atom structure factors can be calculated. A) Argand style diagram 
representing structure factors as vectors. The magnitude of the structure factor is represented by the vector 
length, and the phase is represented by the angle made with the real axis (the vector has 2 perpendicular 
components, one along the real axis, and one along the imaginary axis), b) Individual structure factors (Fl to F3) 
can be added into a single contribution (F4). Part (c) shows that because the diffractive contributions from atoms 
are additive, FPH = FP + FH. In part (d) the known quantities |FHP| and |FP (calculated from measured spot 
intensities), the calculated |FH | and phase angle of FH (from the heavy atom substructure) are used to solve the 
equation FP = FPH - FH - This construction provides two equally valid solutions for the phase angle of FP 
(represented as dotted green lines, angles al and a2). Part (e) repeats construction (d), using a different 
derivative. Information from (d) and (e) indicate the true solution of the phase angle in (f). In practice, MIR 
solutions are calculated numerically rather than geometrically, by obtaining a solution to the equation F2m> ~ F2 P 
+ F2H-t-2[ l ,F ll cos(aP
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Patterson function is computed from data without the use of phases (it uses |FPH-FP| 2). and 
gives a contour map showing vectors between atoms. A difference Patterson map (calculated 
using the difference between FP and FPH) shows vectors between heavy atoms of the 
derivative, which due to the small number of heavy atoms present allows us to reconstruct 
their substructure (the atomic placement of the heavy atoms with respect to a fixed point, the 
origin). This search for heavy atoms can be simplified using knowledge of the crystal 
symmetry and looking for vectors between related atoms in areas of the map known as Marker 
sections.
3.3.3 Anomalous Scattering
Friedel discovered that reflections that come from the lattice planes hkl and -h-k-1 are of 
equal intensity, and are known as Friedel pairs. However, the inclusion of certain atoms in the 
crystal lattice (either by soaking, inclusion from the start of crystal growth or as a natural 
component of the protein e.g. metalloproteins), at certain x-ray wavelengths can absorb the 
x-rays and re-emit them out of phase. As a result of this, the Friedel pairs are no longer 
equivalent and this is known as anomalous dispersion. The wavelength at which this 
phenomenon is maximal is called the absorption edge of the atom (Figure 3.3). The 
anomalous dispersion of atoms can be used in phasing and anomalous scatterers most 
commonly used are Hg, Fe and Se. Selenium offers a distinct advantage, since it can be 
incorporated into the protein with 100 % occupancy as a selenomethionine derivative (see 
Chapter 5).
The anomalous scattering contribution of an atom can be described as a vector, having two 
perpendicular contributions. The vector is represented in the Argand diagram format, on a
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Figure 3.3. X-ray absorption profile of Selenium. The peak (i), inflection point (ii) and remote (iii) energies are 
shown in section (a). The imaginary component f (maximum agreeing with i) and real component f (minimum 
agreeing with ii) of the anomalous scattering are given in section (b). Figure adapted from Walsh et al. 1999.
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Figure 3.4. Geometric representation of MAD phasing, (a) structure factors for FHP at A,l (no anomalous 
scattering) and FHp at \2 (anomalous scattering). The effect is seen as 2 components, one real (AFr) and the other 
imaginary (Afj). Due to the anomalous scattering, there is a breakdown in Friedel's Law (part (b)). FnpM+ and 
FHI>A,I- are equivalent, but FHpA2+ and FHpA2- are not. After location of the anomalous scatterers using Patterson 
methods, and knowledge of AFr and Afj from standard tables, a construction like that in part (c) can be used to 
estimate phases for F^Xl. The construction is a solution to F^K = PHpA2+ - AFr+ - Afj+. At this point the 
phase has two solutions (green dotted lines 1 + 2), but can be solved unambiguously using the Friedel pair of this 
reflection, and a construction reflecting FHpA2- across the real axis (parts (d) and (e)). The two phase solutions 
(green dotted lines 3+4) are obtained, with the true phase, 3, agreeing with phase 1 obtained in part (c).
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horizontal axis (real axis) and a vertical axis (imaginary axis). It is because of these two 
contributions that Fkh] is no longer the same as F.h .k-i (Figure 3.4). At the x-ray absorption 
maximum of the anomalous scattering atom, the imaginary contribution is at a maximum. At 
the inflection point of the absorption edge, the real component reaches its minimum value. An 
absorption profile of selenium is shown in Figure 3.3. Using this peak, inflection point, and a 
third, remote wavelength where the anomalous contribution is negligible, the intensity 
differences can be maximised and used in phasing (MAD, multiwavelength anomalous 
dispersion, Figure 3.4).
Occasionally the peak wavelength contains sufficient anomalous signal to locate the scatterer 
with the use of just this one dataset (SAD, singlewavelength anomalous dispersion). However, 
like SIR, this gives two possible solutions to the phase determination and is referred to as the 
hand problem. Electron density maps are calculated for both possibilities (in practice using 
both enantiomers of the anomalous scattering atom positions), and the most interpretable map 
used. Density modification (where the protein electron density and solvent electron density 
boundaries are "flattened out", giving a clearer map and improved phases) is especially useful 
in making the correct solution stand out.
3.3.4 Advances In Anomalous Scattering
The MAD technique is very popular since a single crystal is often sufficient, and avoids all 
problems of non-isomorphism (all the data from a single crystal, no unit cell changes as 
observed in the soaking of crystals needed in SIR/MIR). MAD requires the use of tunable 
wavelength x-rays, obtainable at synchrotrons (see section 3.6). With synchrotron beamtime 
at a premium, it is a distinct advantage to use SAD rather than MAD. Several excellent
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examples of the use of SAD are provided in Dauter et al. 2002. It is becoming possible to use 
SAD phasing on Cu K« home sources, with an excellent anomalous contribution from atoms 
such as Iodine (Evans et al. 2002). Anomalous scattering can also be used in combination 
with isomorphous replacement (M/SIRAS, multiple/single isomorphous replacement 
anomalous scattering) to further reduce phase ambiguity.
Determination of anomalous scattering positions becomes more complex as the number of 
scatterers increases, but the successful use of programs such as Shake & Bake (Weeks and 
Miller 1999) allow the location of larger numbers of heavy atom sites. This employs a direct 
methods procedure to locate the anomalous scattering substructure.
3.3.5 Molecular Replacement
If the protein being studied has reasonable homology to a protein whose structure has 
previously been determined (this is very case dependent, but the usual limit of success 
requires > 30 % sequence identity), then the structure can be solved without the need for 
derivitisation or anomalous scattering experiments. The phases from the known homologue 
are used in calculations estimating the phases of the unknown structure dataset.
If the structure is isomorphous (same unit cell, same protein, most commonly encountered 
when attempting substrate or inhibitor soaks on a crystal, or when dealing with site-directed 
mutants), then the phases from the known structure are sufficient to phase that of the 
unknown. Typically, a few cycles of rigid-body refinement will be used to allow for slight 
crystal non-isomorphism (changes of less than 2 % in cell axes). If the known structure 
(hereafter referred to as the search model) is non-isomorphous with the unknown x-ray data.
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then a six-dimensional search must be undertaken - the orientation of the search model in the 
unknown structure unit cell must be established. Newer molecular replacement programs 
(Kissinger et al. \ 999) are able to search in all six dimensions simultaneously, but the search 
is more traditionally split into a 3D rotation step and a 3D translation step, executed in that 
order.
The Patterson map, as discussed earlier, gives an identical set of vectors wherever the search 
model is positioned. It is only dependent on the model orientation. In the rotation function 
step, Patterson maps of the unknown data (using Fp2) and those computed from a set of 
orientations of the search model are compared. If the unknown structure contains more than 
one molecule per ASU (as described in section 3.4), several correct solutions are obtained. 
The solutions are ranked on their agreement with the data, and the top rotation trials used in a 
subsequent translation step search. Here the search models are positioned in the unit cell in 
discrete translational steps, and their calculated structure factor amplitudes compared with 
those from the unknown structure diffraction data.
The separation of the 6D search into two 3D searches lowers computational time 
considerably. Positioned search molecules are then analysed with regard to their crystal 
packing interactions. Electron density maps are calculated to verify that a correct solution has 
been found. In molecular replacement searches, a truncated or poly-alanine search model is 
often preferred to reduce existing phase bias in the initial model.
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3.4 Crystal Symmetry
The unit cell can be translated in steps equivalent to the length of cell axes to recreate the 
entire crystal. The asymmetric unit (ASU) is defined as the smallest part of the crystal that can 
recreate the unit cell using a series of rotations and translations. Any symmetry between 
multiple protein copies in the ASU is designated non-crystallographic symmetry (NCS). The 
symmetry of the unit cell and the relationship between the asymmetric units that comprise it 
fall into seven crystal systems. These are (in order of increasing symmetry) triclinic, 
monoclinic, orthorhombic, tetragonal, rhombohedral, hexagonal and cubic. These crystal 
systems may have further lattice symmetry known as point groups. A full description of these 
symmetry elements (hereafter referred to as spacegroups) can be found in Stout and Jensen 
(1968).
3.5 Model Building & Refinement
With a set of phases and a subsequently calculated electron density map, the protein model 
can then be built. If molecular replacement was used to phase the structure, model building is 
a simple case of replacing the non-conserved residues between the model and the target, and 
looking for any shifts in the protein structure. With other cases, knowledge of the protein 
primary sequence is used, possibly with other biochemical data to identify where the residues 
fit into the electron density. With some derivatives (especially selenomethionine), it is easy to 
associate the protein sequence with the located heavy atom positions. Several aids to building 
exist. With high resolution data (usually 1.2 A or better, cases with very accurate phases will 
tolerate up to 2.5 A), programs such as ArpWarp (Morris et al. 2002) can trace the 
polypeptide automatically, provided that the initial phase estimates are sufficiently accurate.
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With noisier, low-resolution maps, programs can build a skeleton of "bones" between peaks 
in the electron density as a guide (Kleywegt and Jones 1994).
The built model is then refined to ensure a good fit to the collected diffraction data. The 
refinement protocol may use different targets to ensure a better fit (e.g. conjugent gradient or 
maximum liklihood targets - Murshudov et al. 1997), and use information from the phase 
estimates or a target just using the structure factor amplitudes alone. Refinement using 
experimental phase information is more accurate and faster than refinement against 
amplitudes alone. Restraints are used in refinement (geometry libraries), which can be 
weighted according to the resolution of the structure - high resolution structures are refined 
with more "freedom". The residual index (Rfactor) is used to measure convergence:
obsl
Equation 3.2. Definition of the residual index (Rfactor, represented above by R, Fobs relates to observed i.e. 
measured amplitudes, and Fcalc to amplitudes calculated from the model)
It is considered best practice to exclude around 5 % of the data from this refinement to avoid 
over-fitting of the structure (the 5 % is a random selection taken over the resolution range, and 
is not used in refinement of the structure, but is included in a cross-validation calculation 
known as Rfree). Values of Rfree obtained at the end of model refinement are highly 
dependent on the resolution of the data, the quality and completeness of the data, but most 
importantly, the accuracy of the final model. The model must also have good geometry, 
usually compared to values derived from small molecule structures (Engh and I luber 1991), 
and make biochemical sense.
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3.6 Production of X-rays
X-rays (in laboratory use) are produced by accelerating electrons towards a metal target, 
usually Cu or Mo. The incoming electron displaces a lower orbital electron in the metal atom, 
which is replaced by a higher orbital electron, emitting the excess energy as an x-ray. Older 
laboratory sources use a sealed tube, whilst newer sources prefer a rotating anode target which 
can dissipate the heat produced more efficiently and give more powerful x-rays. The electrons 
are produced using a large charge difference between a cathode filament and the target anode. 
The x-rays are then filtered to give a monochromatic wavelength, and focussed on the crystal 
sample.
Higher energy x-rays are produced in particle accelerators, where electrons circulate at near to 
the speed of light. The electrons are guided using magnetisation, and emit highly parallel, 
high intensity x-rays at a tangent. The resulting x-ray beam (synchrotron radiation) is far more 
powerful than that from home sources, and datasets may be collected in minutes as opposed to 
days. The data are usually of a far higher quality and there is also the capability of tuning the 
precise x-ray wavelength used, ideal for the MAD & SAD phasing techniques. A diagram of 
the ESRF (European Synchrotron Radiation Facility) is provided in Figure 3.5.
3.7 Protein Crystallization
Crystallization of macromolecules is often viewed as an enigma by those who do not practice 
it, and almost always so by those that do. Many indicators to the ability of a protein to 
crystallize exist, most importantly purity (both bulk sample purity and also sample micro 
heterogeneity) and lack of polydispersity in light scattering (Ferredamare et al. 1994). It does 
however remain largely a case of empirical trial and error.
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Figure 3.5. The ESRF, Grenoble, France. Steep overhead view given in inset. The circular storage ring of the 
electrons can clearly be seen. The strip extending into the storage ring is the linear accelerator (linac), used to 
initially boost the electrons up to speed before circulation.
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a) protein drop glass coverslip b)
vacuum 
grease
reservoir 
solution
Typical Hanging Drop Tray 
(24 experiments)
Vapour Diffusion (hanging drop)
Figure 3.6. Vapour-diffusion method for protein crystallization. Section (a) provides a schematic of a 
vapour-diffusion experiment, the hydrated protein drop losing water to the reservoir solution over a period of 
time. The drop has a typical volume of 5-10 ul, and the reservoir solution 0.5-1 ml. Section (b) shows a VOX 
plate (Hampton Research, Laguna NigueK CA), used to house such experiments.
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The sample to be crystallized is usually filtered to remove both proteolytic bacteria and any 
aggregate that may hinder crystal growth. It is then concentrated to approximately 10 mg/ml, 
or even higher dependent on solubility.
The most popular method for protein crystallization is the vapour diffusion experiment 
(Figure 3.6), which can be either hanging drop (suspended from a glass coverslip), sitting 
drop (sat on a pillar) or sandwich drop (lying between two glass coverslips). The protein 
solution is mixed with a crystallization solution which contains a pH buffer, a precipitant and 
possibly extra salt or additives (see McPherson 1999). The mixed drop is then placed in a 
sealed environment and equilibrates slowly with the crystallization solution, usually losing 
water over time. The resultant concentrating of the protein and precipitant then forces 
molecules out of solution, hopefully into a crystalline phase. A protein solubility curve (also 
called a phase diagram) is shown in Figure 3.7.
The protein moves into the supersaturation zone, leading to a crystal nucleus. This is defined 
as a stable, regular array of protein molecules. As protein molecules add to this growing 
lattice, the solution protein concentration decreases, and the equilibrium lies in the metastable 
zone. It is desirable to avoid phase separation, but in some cases protein crystal growth in this 
region can be seen to occur.
Other techniques for crystal growth include dialysis (where the protein is slowly equilibrated 
against a crystallization solution in a capillary or dialysis button) or batch method (the mixing 
of the protein and crystallization solutions, often under oil, results in direct crystal growth). 
A shift in temperature can also alter protein solubility and lead to direct crystallization.
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Figure 3.7. A typical protein solubility diagram. The protein & precipitant concentrations typically start off low 
(at a point in the bottom left of the diagram) and increase as the drop dehydrates. Example 1 would lead to a 
clear drop upon equilibration, example 2 to a protein precipitate, and example 3 to a shower of microcrystals. 
Example 4 shows an idealised case, where nucleation is achieved upon touching the nucleation zone, and then a 
few single crystals grow to a large size in the metastable zone.
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With initial crysallisation trials, it is commonplace to use a set of standard crystallization 
solutions that have proved successful in crystallizing other proteins (Jancarik and Kim 1991). 
This approach remains moderately successful. If some crystalline material is observed in one 
or more of the set conditions, these can then be altered in an attempt to optimise crystal 
growth. An alternative starting point may be to use knowledge of the protein pi in a series of 
systematic solubility studies (Ries-Kautt 2001). It is assumed that neutral precipitants 
(polyethylene glycol [PEG], alcohols) will have most success with a neutral protein (pH at the 
pi), and charged precipitants (ammonium sulphate, other salts) will give a result away from 
the pi, where the protein has a strong charge. Both scenarios lead to crystallization when the 
uncharged protein is not stable in a hydrophilic solution.
Many other techniques may be used to assist the macromolecular crystallographer in growing 
diffraction-quality crystals. Seeding artificially inserts a foreign nucleus into the protein drop 
and initiates crystal growth. The seed may be of a previously grown crystal, or be epitaxial - 
from a related protein or just another growth surface e.g. clothes fibre. An excellent source of 
information covering all details of protein crystallization is given by McPherson (1999).
3.8 Sample Mounting, Data Collection & Processing
As mentioned earlier (section 3.1), protein crystals need to remain hydrated during data 
collection or they lose their internal order. A room temperature dataset can be collected by 
taking the crystal and sealing it in a glass capillary with beeswax, leaving a small buffer 
region of mother liquor to keep the crystal hydrated. A disadvantage of this technique is that 
radiation damage to the crystal at room temperature is higher than at lower temperatures
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(primary damage from the direct beam is unavoidable, but secondary damage from free 
radicals can spread throughout the lattice). This will eventually affect the electron density 
map and the effective resolution of the data. To prevent or minimise such damage, most data 
is collected at 100 K. The crystal is transferred to a solution containing a cryoprotectant 
(unless the mother liquor will already freeze without forming ice), and flash frozen in a loop, 
bathed in a cone of dry nitrogen gas. Crystals become essentially immortal on home x-ray 
sources and last far longer at synchrotrons. However, some crystals are too fragile to survive 
such soaking, and many suffer with increased mosaicity (lattice disorder). See Figure 3.8 for 
an explanation of both styles of crystal mounting.
The diffraction pattern itself was traditionally collected on x-ray sensitive film, but modern 
techniques use an image plate system, multiwire area detector or CCD (charge-coupled 
device). Image plate detectors use a phosphor that is stimulated by x-rays, which is then 
recorded after further laser stimulation using a photocell. Multiwire area detectors have a 
series of wire grids that produce a signal when x-rays polarise gas molecules in their vicinity. 
CCDs are different in that they have no "dead time", responding directly to the x-rays that 
strike them. They do, however, use phosphors, which transfer light to a fibre optical array, the 
signal of which is amplified and read. Image plates remain the most popular detector type at 
home sources due to the cheaper cost, greater dynamic range and lack of urgency, whilst 
CCDs are more popular at synchrotrons with their high spatial resolution and rapid read out 
time. CCDs are prone to zingers (spots from background cosmic radiation), and so use on a 
home source with long exposures would be problematic, requiring use of a fine <j> slicing 
approach where data is collected in smaller segments.
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beeswax seal
glass capillary
protein crystal
b)
mother liquor
Figure 3.8. Sample mounting for data collection. Section (a) shows a schematic of a typical room temperature 
crystal mount. The crystal is held by surface tension against the wall of the capillary, and is kept hydrated by a 
small buffer region of mother liquor. Beeswax is used to seal both ends of the capillary. Section (b) shows a 
cryo-mounted crystal (of 3a-hydroxysteroid dehydrogenase, see Chapter 8) flash-frozen in a loop, held in a 
stream of dry gaseous nitrogen at 100 K. The loop itself is usually made from a low-diffracting material such as 
rayon or mylar. Crystal size approximately 40 x 40 x 300 um.
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The mounted crystal is placed on a goniometer head, on the spindle axis, which usually 
rotates parallel to the face of the detector (perpendicular to the x-ray source), and allows a 
section of the cell volume to be sampled. A beamstop prevents the direct x-ray beam from 
hitting the detector. The exact rotation range to be sampled depends on the crystal alignment 
and spacegroup symmetry.
Each spot in the diffraction data set is assigned a value of hkl, and the intensity of the spot 
measured via integration. The square root of this intensity is proportional to the amplitude of 
the structure factor it represents. From the positioning of the spots relative to one another and 
the direct beam, and the distance of the detector relative to the crystal, unit cell axes and 
angles are calculated and a putative spacegroup assigned. The true spacegroup may only 
become apparent after data reduction or phasing, and is sometimes ambiguous even upon final 
refinement of a structure. The intensities are scaled relative to one another, and data reduction 
commenced (symmetry-related reflections are merged and the dataset is reduced to the 
asymmetric unit, where a set of unique reflections correspond to a section of the reciprocal 
unit cell). The finalised dataset is then given a Rfree set (a random 5 % of the data tagged as a 
cross-validation set, these data are not included in refinement) and used in refinement of the 
protein structure of interest.
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CHAPTER 4
OBTAINING CRYSTALS OF NITROREDUCTASE
4.1 Introduction
It is generally agreed that the single most important determinant in obtaining protein crystals 
is a high level of protein purity and homogeneity. At the outset of this investigation large 
quantities of active NTR, purified to > 95 % purity (as assayed by SDS-PAGE) were desired. 
Upon achieving this, the protein stock could be utilised in a series of crystallization trials to 
screen for a set of conditions that would yield large, reproducible crystals suitable for 
diffraction studies.
4.2 Materials & Methods 
4.2.1 General Procedures
Unless stated otherwise, all chemicals and reagents were purchased from Sigma-Aldrich 
(Poole, UK). The spectrophotometer used in all O.D. determinations was a Kontron Uvikon 
923 model (Bio-Tek Kontron Instruments, Milton Keynes, UK).
4.2.1.1 LB Media
Luria-Bertani (LB) media was made to the following recipe : 10 g tryptone digest (from 
casein), 10 g NaCl and 5 g yeast extract, made up to a final volume of 1 litre with de-ionised 
water and autoclaved. "Half-strength" LB for selenomethionine derivative starter culture 
media was made using 50 % v/v LB and 50 % v/v sterile water.
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4.2.1.2 SDS-PAGE
All gels were made using the Biorad mini-protean apparatus (Biorad, Hemel Hempstead, 
UK). The resolving gel was made using 3.3 ml of 30 % w/v acrylamide stock solution, 2.5 ml 
of 4 X lower Tris (1.5 M Tris, pH 8.8, 0.4 % w/v SDS), 4 ml water, 150 ul of 10 % w/v 
(NHOiSiOg and 6 ul of TEMED. The gel was levelled with the use of a few drops of 
water-saturated n-butanol. The stacking gel was made using 0.5 ml of 30 % w/v acrylamide 
stock solution, 1.25 ml of 4 X upper Tris (0.5 M Tris, pH 6.8, 0.4 % w/v SDS), 3.2 ml water, 
20 ul 10 % w/v (NH4)2S2O8 and 6 ul TEMED. The finished gels were ran at 100 V in a buffer 
containing 12 g of Tris base, 66 g L-glycine and 22.5 ml 10 % w/v SDS, made up to a final 
volume of 2.25 litres. Gel samples were loaded in 20 ul aliquots, after heating for 3 minutes at 
100°C in the presence of 5 ul gel loading buffer (0.2 M Tris, pH 6.8, 0.52 M DTT, 0.35 M 
SDS, 50 % w/v glycerol and 3.7 mM BPB). All gels were stained and destained using a 
solution containing 40 % v/v methanol, 10 % v/v glacial acetic acid, 50 % v/v water and the 
presence/absence of 2.5 g Coomassie Brilliant Blue, respectively. After reaching the desired 
level of staining, gels were dried using a Biorad 583 gel-drier and vacuum pump.
4.2.1.3 Dialysis Tubing
All dialysis tubing was boiled for 10 minutes in a litre of water containing 0.1 mM EDTA, 
0.1 % v/v p-mercaptoethanol and 10-20 mg of NaHCOs. Boiled tubing was rinsed with, and 
kept in, sterile water at 4°C.
4.2.1.4 Protein Concentration Determination
For rapid protein concentration determination during the purification protocol, a solution with 
an absorbance of 1.0 was estimated to have a protein concentration of 0.5 mg/ml. For more
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sensitive measurements, the Bradford protein assay (Bradford 1976) was preferred, with 
calibration against a set of BSA standards of known concentration.
4.2.2 Protein Expression 
4.2.2.1 Transformation of Cells
The plasmid DNA construct pJG6Alb used for NTR over-expression was a generous gift 
from Dr Peter Searle (Institute of Cancer Studies, University of Birmingham). The plasmid is 
a derivative of pETl Ic (Novagen, Madison, WI), with a NTR insert that was originally 
amplified from E. coli DH5a using PCR. The DNA sequence was found to be identical to that 
previously reported (Anlezark et al. 1992). The plasmid was added to a 100 ul aliquot of 
competent BL21 cells (Phillips et al. 1984), which were then gently mixed and left on ice for 
30 minutes. The cells were subjected to a heat shock step at 42°C for 90 seconds and then 
mixed with 1 ml sterile LB media and left at 37°C for 1 hour before being plated out onto LB 
agar plates containing ampicillin (hereafter referred to as +amp, and unless stated otherwise at 
a concentration of 100 ug/ml).
4.2.2.2 Bacterial Growth & Protein Induction
Successful transformants, determined by growth on a +amp plate, were picked effusing a 
sterile loop and placed into conical flasks containing 50 ml LB media +amp and left to shake 
overnight at 37°C. Five ml of this starter culture was used to inoculate 500 ml of LB +amp 
and left to shake at 37°C until the OD at 560 nm reached -0.8. Expression of NTR was 
induced by the addition of 5 ml of 100 mg/ml IPTG. The cells were then grown for a further 
4-6 hours and harvested by centrifugation at 8000 X g for 10 minutes. Pelleted cells were 
frozen at -20"C to facilitate cell wall weakening and aid lysis.
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4.2.3 Preparation of a Crude Extract
The cells and all cell suspensions were kept on ice during the preparation of the extract. A 
volume of 4 ml of lysis buffer (10 mM KH2PO4, pH 7.0, 10 uM FMN, 10 ug/ml PMSF) was 
added per gram of dry cell weight. The cells were brought gently into suspension using a 
rubber teat placed over the end of a glass rod. The cellular suspension was then broken open 
using 2 cycles of sonification (Heat Systems XL2020 sonicator [Heat Systems, Farmingdale, 
NY], level 5 strength, 4X15 second bursts), and DNAse (1 ug/ml) and RNAse (1 ug/ml) 
added to hydrolyse polynucleotides for reduced sample viscosity. The lysed cells were 
centrifuged at 8000 X g for 10 minutes and the supernatant collected. Ammonium sulphate 
was added to the supernatant until a final concentration of 0.5 M was reached, upon which the 
solution was centrifuged at 10,000 X g for 10 minutes. The resultant supernatant was filtered 
through a 0.45 urn filter and used as the starting material for the purification procedure.
4.2.4 Purification of the Crude Extract
The extract was applied onto a column of phenyl sepharose media (approx. 50 ml in volume), 
pre-equilibrated with 20 mM KH2PO4, pH 7.0, 0.5 M (NH4)SO4 and 10 uM FMN. The 
column was then washed with this equilibration buffer until the OD at 280 nm of the eluate 
was close to zero. Fractions were eluted with a stepwise gradient using a buffer containing 
10 mM Tris, pH 7.6 and 10 uM FMN. NTR fractions were pooled and dialysed against the 
elution buffer at 4°C overnight.
Dialysed protein was loaded onto a column (approx. 40 ml in volume) of Q-sepharose 
(Pharmacia, Milton Keynes, UK), pre-equilibrated with 20 mM Tris, pH 7.6. Protein fractions 
were eluted using a linear salt gradient from 0.1 to 0.4 M NaCl, made with a gradient maker
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and two solutions of 20 mM Tris, pH 7.6 (75 ml each). NTR fractions were pooled and 
dialysed against 10 mM KH2PO4, pH 7.0, 10 uM FMN at 4°C overnight.
The dialysed NTR was applied to a small column (approx. 10 ml in volume) of 
hydroxylapatite equilibrated in 10 mM KH2PO4, pH 7.0, 10 uM FMN. NTR was found not to 
bind the column and pass-through fractions were collected and pooled.
4.2.5 Crystallization Sample Preparation
Purified NTR was dialysed at 4°C for 4 hours against a buffer containing 5 mM Tris, pH 7.0 
and 10 uM FMN. This dialysed sample was concentrated to a volume of approximately 
2-5 ml using an AMICON concentrator (Millipore, Watertown, MA), and then concentrated 
further to a protein content of-20 mg/ml using a CENTRICON 10,000 Mwt cut-off spin filter 
(Millipore) spun at 5000 X g. The final protein stock was stored at 4°C after the addition of 
0.01 % w/v sodium azide.
4.2.6 Crystallization
4.2.6.1 Coverslip Preparation
Glass coverslips were immersed in a bath of Aquasil siliconising solution (Pierce, Rockford, 
IL), washed briefly in a bath of methanol and then allowed to dry for several minutes in a 
heating cabinet at 60°C.
4.2.6.2 Initial Sparse Matrix Sampling & General Crystal Tray Preparation
For initial crystallization trials, a vapour diffusion experiment was preferred, using Hampton 
Research sparse matrix screens I and II (Hampton Research, Laguna Nigucl, CA). VOX
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plates (Hampton Research) were used to house 600 ul of reservoir solution per well, with 4 
trays of 24 wells each providing a basis to screen 96 conditions, 1 to 48 from each screen. 
Wells were greased with Dow Corning high vacuum silicon grease to provide a tight seal for 
the vapour-diffusion experiment. The protein sample (volume of 5ul, at 10 mg/ml) was mixed 
with 5 ul of the reservoir solution on a pre-siliconised coverslip, inverted and placed over the 
well to give a hanging-drop equilibration experiment.
4.2.6.3 Incomplete Factorial Screening
To facilitate controlled screening of any promising crystallization conditions, an incomplete 
factorial sampling technique was used to explore experimental variables. This method is fully 
described by Carter and Carter (1979).
4.3 Results & Discussion
4.3.1 Protein Expression & Purification
The NTR construct expressed well in the BL21 cells, giving an average of 30 mg of purified 
protein per litre of LB culture. A bright yellow band could be observed upon loading the 
crude extract onto the phenyl sepharose column. The yellow nature of the protein solution was 
subsequently witnessed in all further purification steps and was often used as a crude guide to 
the NTR content of the samples. The lengthy washing step of the phenyl sepharose column 
allowed a large proportion of contaminating proteins to be removed from the lysate solution 
(results not shown). Elution of protein from the column and subsequent SDS-PAGE analysis 
of the fractions obtained showed a clear, major band at the expected NTR Mwt. of 24,000 Da 
(Figure 4.1). From the OD 280 nm measurements and gel lane observations, it was decided to 
pool fractions that possessed at least half the OD 280 nm value of that of the most
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1 8 9 10
77kDa TJi^ffl^to Mf
21 KDa
24kDa
NTR 
Dimer?
NTR
UP*1* ••f »•• ^^P
Gel from Q-sepharose column. Lane 1 = size markers,
Lanes 2-10 = fractions from NaCl gradient wash
(Increasing salt concentration left to right).
1 8 10
48kDa
24kDa
Gel from hydroxylapatite column. Lane 1 = size markers,
Lanes 2-9 = run through fractions, lane 10 = 0.2 M
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Figure 4.1. SDS-PAGE gels from NTR purification steps. Size markers identical on all three gels.
64
concentrated fraction. After running this pooled sample on the Q-sepharose column, two 
yellow bands were seen when eluting with the salt gradient. This was attributed to both the 
NTR enzyme and a band of free FMN, which originated from FMN added to the running 
buffers, and can presumably interact with the positively charged matrix via its negatively 
charged phosphate group. From conductivity measurements both of the gradient starter 
solutions and the eluted protein fractions in conjunction with SDS-PAGE, it could be seen 
that NTR eluted at a conductivity of 10 mMHO, commensurate with a value of-200 mM 
NaCl. Fractions with half-maximal OD 280 nm were pooled, and from SDS-PAGE analysis 
of the eluant (Figure 4.1), it can be seen that this purification step removes many of the 
contaminating proteins of higher MWt. The purity of these pooled fractions was deemed not 
quite ideal, and indeed crystallization trials using protein obtained after just these two column 
steps yielded no appreciable results. Several other chromatography columns were tried in an 
attempt to increase the purity of the sample (e.g. trisacryl blue - affinity matrix for 
nucleotide-binding proteins), but had little effect.
Application of the pooled protein to a hydroxylapatite column proved advantageous. It could 
be clearly seen that NTR in the loaded sample passed straight through without binding to the 
matrix. Other bound proteins could be eluted using a buffer comprised of 0.2 M NaH2PO4, 
pH 7.0, and these were ran on a SDS-PAGE gel alongside the NTR fractions (Figure 4.1). The 
NTR run-through shows improved purity, and the fraction from the phosphate wash shows the 
contaminants bound by the column. The second band, at a MWt. of-48,000 Da in the NTR 
fractions has been attributed to a dimeric form of the enzyme, even though reducing 
SDS-PAGE was used. All of the "run-through" NTR fractions were pooled and their purity 
was found to be of sufficient quality for use in crystallographic studies.
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4.3.2 Crystallization
From the sparse matrix trials, several conditions were observed that gave crystalline needles, 
but one well (0.2 M sodium acetate, pH 4.6 and 8 % w/v PEG 4000) gave promising 
nucleated flat plates, approximately 0.4 mm in the longest dimension (Figure 4.2). Initial 
incomplete factorial sampling was not found to improve the crystals significantly to a point 
where they could be used in diffraction experiments. It was decided to investigate the effects 
of additives, and after an exhaustive screening process (48 small molecule compounds 
investigated), the inclusion of 15 mM nicotinic acid yielded large, single crystals (up to a size 
of 1 x 0.5 x 0.4 mm, Figure 4.3). The success of nicotinic acid was assumed to be related to its 
similarity to the nicotinamide headgroup of NAD(P)H. All crystals obtained had a yellow 
colour and were found to be sensitive to mechanical disruption, favouring the chance that they 
were protein crystals. From observation of the crystals alone, it was obvious that two forms 
could be grown in the same drop - one square and plate-like, and the other elongated and 
lozenge-shaped (Figure 4.3). Typical "final" conditions for producing these crystals were : 10- 
15 mg/ml protein equilibrated against a reservoir solution containing 0.2 M sodium acetate, 
pH 4.6, 8-12 % w/v PEG 4000 and 15 mM nicotinic acid. In the interests of cryo-protection 
for sample mounting and data collection, it was discovered that the crystals could be grown 
with 25 % v/v ethylene glycol incorporated into the reservoir solution, allowing direct 
freezing of crystals in mother liquor and eliminating any need for post-growth soaking.
4.4 Summary
NTR was over-expressed successfully and a purification protocol established that resulted in a 
NTR solution of > 95 % purity. Purified NTR was used in a series of crystallization trials,
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Figure 4.2. Crystals from initial sparse matrix screening experiments. Crystals grown using vapour diffusion 
experiments and Hampton Research Crystal Screen I solution 37 (0.2 M sodium acetate, pH 4.6, 8 % w/v PEG 
4000).
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Figure 4.3. Single NTR crystals from optimised growth conditions: a) tetragonal form; b) monoclinic form. 
Crystals grow from identical conditions of 100 mM sodium acetate, pH 4.6, 8-12 % w/v PEG 4000, 15 mM 
nicotinic acid and 25 % v/v ethylene glycol. Protein used at a concentration of 12 mg/ml, 3 u,l protein + 3 u.1 
reservoir solution drops, equilibrated over a reservoir solution of 600 ul Crystals appear within 1-2 days and 
reach maximum size after a period of a week. The difference in shape between the two isoforms can be easily 
seen.
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culminating in the growth of single crystals of a suitable size for X-ray diffraction studies. 
Multiple crystal forms of NTR were observed. Owing to an increase in the power of phasing 
programs in the past few years (e.g. DM Multi, Cowtan 1994), multiple crystal forms are now 
seen as advantageous and no longer such a detriment to structure determination via their lack 
of isomorphism. It will also be of use to attempt to phase and solve all forms, reducing bias 
and error with several independent determinations of the NTR structure.
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CHAPTER 5
SOLVING THE STRUCTURE OF NTR
5.1 Introduction
Having obtained protein crystals (Chapter 4), the first step was to test their diffraction 
qualities, and if suitable, propose a method for estimating the phases of the diffracted X-rays. 
With a successful derivative (as judged by the criteria provided in Chapter 3), map calculation 
and model building can be commenced, hopefully leading to a situation where most of the 
protein of interest can be visualised in the electron density map.
5.2 Materials & Methods
5.2.1 Native Crystal & General Data Collection
5.2.1.1 General Data Collection
Crystals were taken direct from the growth drop using a Hampton cryo-loop and flash-cooled 
to 100 K in a stream of nitrogen gas using an Oxford cryostream apparatus (Oxford 
Cryosystems, Oxford, UK). Unless stated otherwise, all diffraction data were indexed using 
DENZO, and integrated and scaled using SCALEPACK (Otwinowski et al. 1997). All 
subsequent data manipulations were accomplished using the CCP4 suite of programs (CCP4 
1994).
5.2.1.2 Native Crystal Data Collection
Initial diffraction images of the native crystals were collected at: i) the Synchrotron Radiation 
Source (SRS), Daresbury on beamline 9.6 and ii) on the in-home RAXIS system. Data
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collection for the published monoclinic and native tetragonal crystal forms were collected at 
the European Synchrotron Radiation Facility (ESRF), Grenoble, France on beamline ID 14-1.
5.2.2 Preparation of a Selenomethionine Derivative 
5.2.2.1 Selenomethionyl Protein Preparation
The pJG6Alb plasmid was used to transform the methionine auxotroph strain B834 D3 and 
grow a starter culture in 50 ml "half-strength" LB +amp. Ten ml of this starter culture were 
used to inoculate 500 ml of pre-warmed modified M9 minimal media (containing 0.4 % w/v 
glucose, 42 mM Na2HPO4, 22 mM KH2PO4, 20 mM NlLjCl, 8 mM NaCl, 4 mM 
nicotinamide, 8 uM thiamine, 10 uM biotin, 6 mM uracil, 2 mM guanosine, 5 mM adenine, 
5 mM thymine, 2 mM MgSO4, 0.1 mM CaCl2 , 10 uM FeSO4, 40 mg/ml selenomethionine, 
100 jig/ml ampicillin, 0.4 mM H3BO3 , 30 uM CoCl2 , 10 uM CuSO4 and 80 uM MnCl2). The 
culture was left to shake at 37°C until an OD 595 nm of 0.55 was reached. NTR expression 
was then induced by the addition of 1 mM IPTG. Subsequent steps are the same as those for 
the native protein protocol, with the exception that all buffers contained 10 mM DTT to 
prevent oxidation of the selenomethionine residues.
5.2.2.2 Crystallization of the derivative
Crystals were grown using the same protocol as that provided for the native protein, except 
that 10 mM DTT was added to the protein crystallization stock.
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5.2.3 Data Collection Using Derivative Crystals
5.2.3.1 Crystal Characterisation
From crystal appearance alone, it was presumed that two crystal isoforms had grown using the 
same conditions. This was confirmed during initial diffraction experiments, with the 
square-shaped crystals belonging to the tetragonal P4 } 2\2 spacegroup, and the lozenge-shaped 
crystals belonging to the monoclinic P2i spacegroup. Upon crystallizing and obtaining 
diffraction images of the selenomethionine derivatives, it was apparent that the tetragonal 
crystals were isomorphous with the native tetragonal form, but the monoclinic crystals had 
been "replaced" by a third, orthorhombic P2i2]2i crystal form that looked identical in 
appearance to the monoclinic form. Images of the crystal forms are shown in Figure 5.1.
5.2.3.2 MAD data collection on Orthorhombic SeMet NTR
Data were collected at the ESRF on beamline ID 14-4. Crystals of a poorer quality were used 
for a fluorescence spectrum taken using a RonTec detector and multi-channel analyser to 
obtain the optimal wavelengths at which to collect the peak and inflection point datasets. A 
crystal of higher quality was used for data collection. The order of the three wavelengths 
collected was peak (pk - 0.9795 A), inflection point (ip - 0.9793 A) and remote (rm - 
0.9393 A), in order to salvage the experiment should radiation damage occur (i.e. use the pk 
dataset for SAD phasing). Complete datasets were collected at all three wavelengths.
5.2.3.3 SAD data collection on Tetragonal SeMet NTR
Following the MAD data collection on the orthorhombic form, it was decided to collect some 
data on the tetragonal selenomethionyl NTR crystal form. In contrast to the orthorhombic 
phasing, and in tandem with some radiation damage experiments (collaboration with Drs
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Figure 5.1. Observation of different crystal morphologies grown using optimised conditions. Photos a) to e) 
tetragonal crystals, note the square / half-square appearance and shortest physical dimension (c axis). Crystals all 
roughly on same scale, longest dimension is 400 jam. Photo f) monoclinic crystals, note the plate / rod 
appearance and tendency to cluster from nucleation. Longest dimension is around 800 urn.
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Raimond Ravelli and Scan McSweeney, ESRF, Grenoble, France), a SAD experiment was 
chosen in order to compare the phases obtained with those from a more traditional MAD 
experiment. Data were collected (at the pk wavelength of 0.979 A) at the ESRF on beamline 
ID 14-4. From the fluorescence spectrum of the crystals it was apparent that the 
selenomethionine residues were partially oxidised (results not shown). This would be 
deleterious as the mixed oxidation state of the residues would severely lower the anomalous 
signal from the experiment. It could be seen that the crystals could be returned to a fully 
reduced state by the addition of 1 u.1 p-mercaptoethanol to the reservoir solution in the well, 
and allowing vapour diffusion of the reductant to occur over a period of time. As a large 
crystal was used for this process (400 x 400 x 100 jam), sufficiently sized pieces could be 
broken off for monitoring of the oxidation state using the Rontec detector. After 6 hours the 
crystal could be shown to be fully reduced, and was deemed usable for data collection.
5.2.4 Phasing
5.2.4.1 Phasing of Selenomethionyl Crystals
5.2.4.1.1 MAD Phasing of Orthorhombic Crystals
The three scaled wavelengths (pk, ip and rm) were read into SOLVE (Terwilliger and 
Berendzen 1999), and the number of anomalous scatterers set to 16, even though 20 were 
expected (4 monomers from a Vm calculation, 5 Met per monomer). It was preferred not to 
count the N-terminal methionine, assuming that flexibility of the protein chain would result in 
the residue not having a defined orientation, or that the residue had possibly been cleaved off 
during protein production. A resolution cutoff of 30-2.5 A was used in phasing calculations.
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5.2.4.1.2 SAD Phasing of Tetragonal Crystals
The scaled data were entered into the CNS suite heavy-search protocol (Grosse-Kunstleve and 
Brunger 1999), with an expected 8 scatterers and a resolution cutoff of 15-3 A used in phasing 
calculations.
5.2.4.2 MR Phasing of Monoclinic Crystals
The scaled data were entered into the CNS suite molecular replacement protocol (Brunger 
1990), using the fastdirect option for the rotation function search. The solved orthorhombic 
NTR co-ordinates were used as the search model (just the AB dimer). A resolution cutoffof 
15-4 A was applied in both the rotation and translation functions. An initial search was used 
to locate one dimer, which was then fixed and used in locating the second dimer.
5.2.5 Model Building
5.2.5.1 Initial Model Building With the MAD Data
Located selenium sites were used to initially place methionine residues. The electron density 
was of sufficient quality to trace the polypeptide chain using knowledge of the protein 
primary sequence. All model building was done using the molecular graphics package 
TURBO-FRODO (Roussel et al. 1991).
5.2.5.2 Further Model Building With Other Crystal Forms
The located selenium sites from the SAD phasing results were used as a guide to move a 
pre-built dimer from the refined orthorhombic structure determination into the tetragonal form 
unit cell (based on interatomic vectors between the heavy atom positions matching vectors 
calculated from the Met positions of the dimer). For the monoclinic molecular replacement
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solution, the fit of the rigid-body refined model was good enough, large scale model 
movement was not required.
5.2.6 Refinement Protocols
Each of the three structures was refined using the CNS suite of programs (Brunger et al. 
1998). A maximum likelihood target was used with cycles of rigid body refinement, simulated 
annealing, powell minimization and individual B-factor refinement, interspersed with manual 
rebuilding in TURBO-FRODO (Roussel and Cambillau 1991) using 2mF0-DFc 
SIGMAA-weighted (Read 1986) electron density maps as a guide. The experimental phases 
from the MAD and SAD datasets were included when refining the orthorhombic and 
tetragonal structures, respectively. Non-crystallographic symmetry constraints or restraints 
were not applied at any time.
5.3 Results & Discussion 
5.3.1 Data Collection 
5.3.1.1 Native Crystals
The first native crystal form to be used in a diffraction experiment was the tetragonal isoform. 
Due to a long c axis of-260 A, crystal mounting (and subsequent mechanical disruption) led 
to disorder along this axis and "smearing" of the diffraction image (Figure 5.2). With fine 
phi-slicing and a detector with excellent spatial resolution, it would have been possible to 
collect to the crystal diffraction limit of ~1 A. In practice, with both the native and derivative 
tetragonal crystals, a diffraction limit of ~1.7 A could be collected. Full data collection 
statistics for the native dataset used to refine the tetragonal NTR structure are shown in Table 
5.1.
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2.4 A
** ^^ *
b) 2.4 A-
Figure 5.2. The figure highlights some of the problems facing tetragonal crystal form data collection. Data 
collected from a sample of tetragonal crystals, beamline ID14-1, ESRF. Images from a 0.5° oscillation, X-ray 
exposure identical for both diffraction patterns, a) "good" diffraction image with resolvable c-axis spots (close up 
on right), b) "poor" diffraction image with smeared, non-resolvable c-axis spots (close up on right). Resolution 
indicated in corner of main images.
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1.8 A
Figure 5.3. Example diffraction pattern from monoclinic crystal form, collected at beamline 
ID 14-1, ESRF. Diffraction pattern from a 1° oscillation. Resolution indicated in corner of image.
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Native protein crystallization also yields a monoclinic crystal form. This has far smaller 
lattice parameters than the tetragonal form (longest axis, c -120 A), and diffracts to -1.6 - 
1.7 A resolution. The crystals are very plate-like and this can lead to anisotropy regarding 
exposure levels during data collection. Full data collection statistics for the monoclinic dataset 
used in MR and monoclinic form refinement are shown in Table 5.1. A typical diffraction 
image from these crystals is shown in Figure 5.3.
5.3.1.2 MAD Data Collection
From the fluorescence spectra results (data not shown), the wavelengths used in data 
collection were pk = 0.9785 A, ip = 0.9793 A and rm = 0.9393 A. No significant loss in 
diffraction spot intensity was observed during the data collection. Full statistics for all three 
wavelength datasets are shown in Table 5.1.
5.3.1.3 SAD Data Collection
Following the six hour equilibration with p-mercaptoethanol (see section 5.2.3.3), the 
diffraction pattern of the crystal looked unaffected by this procedure. A single pk dataset was 
collected using a wavelength of 0.979 A. Full statistics for this dataset are shown in Table 5.1.
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5.3.2 Phasing 
5.3.2.1 MAD Phasing
The program SOLVE (Terwilliger and Berendzen 1999) was used to find 16 Se sites (from a 
requested 16), with an overall Z-score value of 59.8 (breakdown of individual Z-score values 
in Table 5.2), and a mean figure of merit (FOM) of 0.75. The sites (Table 5.3) had an average 
height above sigma of 20.6, with no site possessing a value less than 14. The selenium 
positions showed non-crystallographic symmetry (NCS) commensurate with the expected 4 
protein monomers per ASU.
Criteria
Pattersons
Cross- Validation
NatFourier CCxlOO
Mean FOM x 100
Correction for Z-scores
Overall Z-score value
VALUE
12.0
176
44.4
54.8
Z-SCORE
8.20
39.4
18.2
11.0
-17.0
59.8
After running SOLVE with NOBAYES keyword to obtain 
"traditional" phasing statistics :
Phasing Power 1.11
Table 5.2. Scoring results from MAD Phasing using SOLVE (Terwilliger and Berendzen 1999). Value column 
indicates score given to that criteria by SOLVE (on an arbitrary scale), Z-score column alters this value to put all 
criteria on the same scale. For structures incorporating this amount of heavy atoms, overall Z-scores above 20 
are significant.
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Site
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
X
0.693
0.854
0.985
0.621
0.083
0.454
0.341
0.155
0.947
0.140
0.524
0.070
0.284
0.227
0.588
0.778
Y
0.646
0.829
0.764
0.629
0.662
0.293
0.086
0.684
0.510
0.191
0.209
0.175
0.378
0.086
0.233
0.539
Z
0.161
0.139
0.215
0.147
0.181
0.241
0.069
0.181
0.087
0.188
0.176
0.180
0.194
0.164
0.177
0.171
Occupancy
0.959
0.760
0.688
0.860
0.745
0.664
0.794
0.855
1.060
0.789
0.399
0.900
0.885
0.821
0.773
0.987
B factor (A2)
23.218
15.000
15.035
43.271
15.000
31.358
15.000
24.193
31.956
15.000
15.000
26.191
21.895
25.982
22.141
49.429
Peak Height
24.82
24.45
21.77
14.39
22.87
16.48
25.24
17.38
22.35
25.63
21.92
21.19
22.06
18.58
15.04
17.08
Table 5.3. Heavy atom (Se) positions from MAD phasing. Co-ordinates expressed as fractions of cell axes.
5.3.2.2 SAD Phasing
The heavy atom search protocol in the CNS package (Grosse-Kunstleve and Brunger 1999) 
found 8 sites (from a requested 8), with an average height above sigma of 15.8 and no site 
possessing a value less than 9. The mean FOM was 0.52, and the correct hand for the sites 
was determined using the MAD selenium positions as a guide (comparing interatomic vectors 
from both possible hands of the SAD heavy atoms with those obtained from the MAD heavy 
atoms). The sites showed a clear relation to those obtained from the MAD phasing, and NCS 
was observed accounting for the expected 2 monomers per ASU.
5.3.2.3 MR Phasing
The cross-rotation list of peaks (top 10 trials, based on rotation function Rfactor) is shown in 
Table 5.4, with 4 very clear solutions, of which there are 2 pairs related by 180° in Theta3. 
Following a translation search to place the first dimer, a monitor value of 0.4 and a packing
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value of 0.3 can be seen for the correct solution. Upon fixing this dimer and placing the 
second dimer, a final monitor value of 0.75 and packing value of 0.6 are observed.
Trial Number
1
2
4
9
18
20
25
26
27
35
Thetal
179.211
183.742
182.348
176.413
180.605
182.348
185.136
184.755
183.316
178.501
Theta2
68.365
65.577
60.000
58.941
57.212
57.212
68.365
73.941
51.635
65.577
Theta3
92.000
270.954
99.319
282.472
90.606
265.377
103.501
279.402
273.316
290.137
RF-function
0.2303
0.2273
0.2249
0.2187
0.0998
0.0954
0.0826
0.0823
0.0815
0.0717
Table 5.4. Top peaks for monoclinic form cross-rotation search. Rotation angle given in Eulerian format.
5.3.3 Model Building
Upon determination of the selenium atom substructure from the MAD orthorhombic dataset, 
it was apparent that the 16 sites corresponded to four monomers in the ASU. These monomers 
were assigned chain identities A-D. No density modification or NCS averaging was necessary 
to improve the map as the electron density was of excellent quality and sufficient to start 
tracing the polypeptide backbone. Initial unrefined electron density for the orthorhombic form 
is shown in Figure 5.4. It was decided to build one monomer completely and then use this and 
the selenium sites to replicate all four monomers.
Building of all secondary structure elements and loops proceeded without trouble, and 
problems were only encountered when trying to establish the presence or absence of the 
N-terminal methionine, which was built in some monomers and left out in others. The flavin 
cofactor and nicotinic acid ligand (denoted NIC in figures) could also be seen in these starting
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a) b)
d)
Figure 5.4. Initial electron density map calculated from MAD phases, with an overlay of structural elements 
from the final refined orthorhombic co-ordinates. Map is 2mFo-DFc, contoured at la, 2.4 A resolution. Regions 
of structure are: a) B44-47, b) B94-95, c) FMN & NIC from monomer A and d) B144 and W51. Note the 
excellent quality of the initial phases and subsequent electron density, where most residues, the cofactor and 
water molecules can be visualised. Figure prepared using BOBSCRIPT (Esnouf 1997) and RASTER3D (Meritt 
and Bacon 1997).
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maps (Figure 5.4). Electron density from initial maps calculated from the SAD derived phases 
would have been more difficult to interpret de-novo, but significant improvement can be seen 
upon density modification and NCS averaging (data not shown). However, it was sufficiently 
easy to use the orthorhombic traced polypeptide chain in both the tetragonal and monoclinic 
model building steps.
5.3.4 Refinement
The progress of refinement for the orthorhombic structure can be seen in Table 5.5. Final 
refinement statistics for all three crystal forms are shown in Table 5.6. Refined electron 
density for the structures can be seen in Figures 5.5 to 5.7.
Refinement Step
Initial 2° structure fitting
Side chain build
Minimisation and B-factor
Cofactor Fitting
1 ^ round water picking
2nd round water picking
Optimise weighting
Thorough model examination
Final model
Rfactor (%)
43.5
31.6
27.8
26.0
23.6
22.0
20.9
20.6
19.8
Rfree (%)
43.5
35.2
31.0
28.4
26.5
25.1
24.5
24.4
24.2
Table 5.5. Refinement progress of the orthorhombic NTR structure determination. 
Rfree from a random 5 % of reflections, not used in refinement.
5.4 Summary
Having obtained 2 crystal forms for both native and derivative NTR protein crystals, MAD, 
SAD and MR were used to obtain phase information. Solution of the orthorhombic form by 
MAD provided the basis for solving the other two crystal forms. SAD phasing of the 
selenomethionine tetragonal form allowed selenium site comparison with the MAD results,
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Orthorhombic Tetragonal Monoclinic
Refinement
Data Set
Resolution (A)
No. of Non-hydrogen 
Atoms
No. Water Molecules
R factor3
R b Kfree
Average B factor
(protein atoms only)
RMSD Bond Angles0
RMSD Bond Lengths'1
Copies in ASU
RM
2.4
7515
643
19.8%
24.2 %
21.0 A2
1.88°
0.018 A
4
Native
1.7
4038
586
18.2%
20.4 %
16.9 A2
1.57°
0.015 A
2
Native
1.8
7027
139
22.6 %
23.8 %
44.9 A2
1.12°
0.006 A
4
a R factor = 1^1 |F0 | - |FC| |/Xhkl |F0|.
bR factor based on 5 % of the data withheld from refinement
CRMSD bond angles and dbond lengths are the root mean square deviations from ideal values
Table 5.6. Final refinement statistics for all three NTR structure determinations.
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a) -u. b)
c) .x
-» "T1 I~!*-. I ~^"""^"^»
^^f^M^s^ t"
Figure 5.5. Refined electron density and co-ordinates from the orthorhombic NTR structure determination. Map 
is 2mFo-DFc, SIGMAA-weighted, contoured at Id, 2.4 A resolution . Regions shown are : a) B138-139, b) B48- 
50 and c) A198 & Al 1. Figure prepared using BOBSCRIPT (Esnouf 1997) and RASTERSD (Meritt and Bacon 
1997).
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a)
I"«B5*3I
b)
0
Figure 5.6. Refined electron density and co-ordinates for the tetragonal NTR structure determination. Map is 
2mFo-DFc, SIGMAA-weighted, contoured at ICT, 1.7 A resolution. Regions shown are : a) B36, W6 & W67, b) 
A84-85 and c) A165 and B138. Figure prepared using BOBSCRIPT (Esnouf 1997) and RASTER3D (Meritt and 
Bacon 1997).
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a) b)
c)
Figure 5.7. Refined electron density and co-ordinates from the monoclinic NTR structure determination. Map is 
2mFo-DFc, SIGMAA-weighted, contoured at ICT, 1.8 A resolution. Regions shown are : a) A10, W21 and W58, 
b) Al49-151 and c) A214-216. Figure prepared using BOBSCRIPT (Esnouf 1997) and RASTERSD (Meritt and 
Bacon 1997).
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and the tetragonal structure was refined against a higher resolution native dataset. Finally, MR 
with the orthorhombic form co-ordinates as a model was used to solve the native monoclinic 
crystal form. A tabulated form of these results is given in Table 5.7.
Crystal Form___Protein Used Cell Phasing Refinement
Orthorhombic SeMet 
P2,2,2,
Monoclinic 
P2i
58 x 120 x 144 A MAD Maximum likelihood
(Solve) with experimental 
phases
Tetragonal SeMet (for SAD) 57x57x262 A SAD Maximum likelihood 
P4i2i2 Native (to refine) (CNS) with experimental
phases
Native 72 x 58 x 117 A MR Maximum likelihood 
p=103° (CNS)_______________
Table 5.7. Summary of Chapter 5 - Solving the Structure of NTR.
90
CHAPTER 6
STRUCTURAL ANALYSIS OF NTR
6.1 Introduction
Following the refinement of the three crystal forms of NTR (Chapter 5), we can now start to 
look at the general fold of the protein and analyse how its various secondary structure 
elements interact. After the general topology has been investigated, we can look at specific 
residues in the active site and start to identify key steps in the catalytic process. It will also be 
of use to study differences between the three crystal forms, and also compare our structures to 
those of previously determined NTR homologues.
6.2 Results
6.2.1 Secondary Structure Assignments
Using the A chain monomer of the refined tetragonal NTR structure as a representative of the 
different monomers in the three crystal forms, secondary structure assignment was calculated 
with PROCHECK (Laskowski et al. 1993). The 10 a-helices were designated A to K (with I 
excluded to avoid confusion with 1). The 5 [3-strands were designated 1 to 5 inclusive. The 
occurrence and placement of these secondary structure elements in the NTR primary sequence 
is shown in Figure 6.la. Loops are named with respect to the secondary structure elements 
that proceed and follow them e.g. B-l is the loop between helix B and strand 1.
6.2.2 Topology & Description of the Protein Fold 
6.2.2.1 General Topology
The main body of the monomer consists of a large hydrophobic core (residues 2-91 and 131- 
217), with a small two-helix domain (helices E and F, residues 92-130) protruding from this.
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a)
B 1
1 MDIISYALKRHSTKAFDASKKLTPEQAEQIKTLLQYSPSSTNSQPWHFIV 50
C D 2 . E
51 ASTEEGKARV^SAAGNYVFHERKMLIlASHVVVFCAKT^^lDDVWLKLVV^ 100
F G
101 QEDADGRFATPEAKAANDKGRKFFADMHRKDLHDDAEWMAKQVYLNVGNF 150
a H 4
151 LLGVAALGLDAVPIEGFDAAILDAEFGLKEKGYTSLVWPVGHHSVEDFN 200
K 5
201 ATLPKSRLPQNITLTEV 217
b)
Figure 6.1. (a) Secondary structure assignments for NTR. The a-helices are represented by rectangles and the 
p-strands by arrows, (b) TOPS (Westhead et al. 1999) topology diagram for the NTR dimer. Circles represent
a-helices and triangles represent P-strands (downward = into plane of diagram, upward = out of plane of
diagram). Connections drawn from edge to centre represent loops that project out of the plane of the diagram,
connections drawn from centre of edge represent loops that project into the plane of the diagram. All secondary
structure elements were assigned according to PROCHECK. (Laskowski et al. 1993) analysis.
Two orthogonal views of the NTR dimer and this domain structure can be seen in Figure 6.2. 
Each monomer is comprised of a central twisted P-sheet, flanked on both sides by a-helices. 
Each P-sheet contains four anti-parallel strands from one monomer and a fifth parallel strand 
contributed by the five C-terminal residues of the other monomer. Helices B and G contact 
one face of the P-sheet, whilst helices C, D and H lie on the other. The general fold of the 
protein, built up one secondary structure element at a time can be seen in Figure 6.3. The 
active site contains one tightly bound FMN cofactor, and a molecule of the nicotinic acid 
ligand used to crystallize the protein. Each active site is comprised of residues from both 
monomers and lies in a solvent-exposed channel at the dimer interface, with the two separate 
FMN N5 atoms 26.4 A apart. Each channel is lined by helix F, and three loops (B-l, C-D and 
3-H).
6.2.2.2 The dimer interface
A full description of specific monomer : monomer residue contacts is provided in Table 6.1. 
The dimer interface is extensive and has a buried surface area of 3,686 A2 per monomer, as 
calculated by AREAIMOL (CCP4 1994). The two N-termini are positioned close together, 
with the D2 side-chains only 3.1 A apart. The A helices sit between the grooves formed by the 
G helices, which run parallel together at an angle of approximately 25° to the 
non-crystallographic axis of symmetry. Helix A also contacts helix B of the opposing 
monomer. The N-terminus (helices A & B and loop A-B) contacts the C-terminus (helices J & 
K, loop J-K, strand 5), as the chain feeds into the other monomer and completes the P-sheet. 
The C-terminus also makes contacts to helix E of the opposing monomer.
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a)
b)
Figure 6.2. Parallel stereo diagram of NTR Fold: (a) view looking down the non-crystallographic 2-fold axis; (b) 
view of dimer rotated approximately 90° from (a) about the horizontal axis. For one monomer, with the 
backbone coloured light grey, the a-helices (red) are labeled A to K and p-strands (yellow) are labeled 1 to 5. 
The FMN cofactor and nicotinic acid ligand are represented in stick form and are coloured by atom type (C, 
yellow; N, blue; O, red; P, mauve). The diagram was generated using MOLSCRIPT (Kraulis 1991) and 
RASTER 3D (Meritt and Bacon 1997).
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N10
11 12
13 14
15
Figure 6.3. Schematic trace of protein, starting at the N-terminus (1) and ending at the C-terminus (15).
Secondary structure elements are added to the diagram sequentially. Figure prepared using MOLSCRIPT
(Kraulis 1991) and RASTER 3D (Meritt and Bacon 1997).
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Helix A : Helix B B-l Loop : G-3-H Loops
14 : L33 hydrophobic P38 : L151 hydrophobic 
L8 : Y36 hydrophobic S40 : El65 hydrogen bond
N-terminus : C-terminus
K31 : L214 hydrophobic Helix A : Helix G 
K31 : E216 salt bridge 13 : L157 hydrophobic 
Q35 : L208c hydrogen bond 13 : A 156 hydrophobic 
Y36 : K205 hydrophobic
S37c : R207 hydrogen bond Helix D : Helix F 
Q44 : L208c hydrogen bond Y68 : F124 hydrophobic 
H47 : T215 hydrogen bond
F48n : T213 hydrogen bond Helix E : C-terminus 
F48c : T215n hydrogen bond W94 : L208 hydrophobic 
V50 : L214 hydrophobic L97 :1212 hydrophobic 
V50n : T215c hydrogen bond Q101 : L208 hydrophobic 
A51 : V217 hydrophobic D105 : S206 hydrogen bond 
S52n : V217c hydrogen bond Rl 07 : N200 hydrogen bond
Helix G : Helix G Rl 07 : P204c hydrogen bond 
Y144 : K141 hydrophobic
L145 : G148 hydrophobic Helix G : 3-H Loop 
L145 : V147 hydrophobic_________W138 : El65 hydrogen bond____
Table 6.1. Monomer : monomer contacts in the NTR dimer. Backbone nitrogens are denoted by n and carbonyls 
by c, other contacts involve the residue side-chain. Amino acids labelled using standard single letter code.
6.2.3 The Active Site, FMN & Ligand Binding 
6.2.3.1 FMN Binding
The FMN cofactor is located in a pocket comprised of residues from both monomers, as 
shown in Figure 6.4. The flavin cofactors are tightly bound to the enzyme, and are 
well-defined in the electron density (see Figure 6.5) with an average B factor of 11.5 A2 for 
the tetragonal structure form (the protein has an average B factor of 16.9 A2). The FMN 
shows a "butterfly" conformation, observed in many other flavoenzymes (Barber et al. 1992), 
with an angle between the planes of the two outer rings of approximately 15°.
The phosphoribityl tail and dimethylbenzoid parts of the flavin are buried in the protein fold, 
but the re face of the isoallozaxine ring is solvent exposed at its polar end. The si face of the
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Figure 6.5. Parallel stereo diagram of FMN and NIC refined electron density from the tetragonal crystal form. 
Map is 2mFo-Dfc, resolution 1.7 A, SIGMAA-weighted and contoured at la. Diagram coloured by atom type 
(C, grey; N, blue; O, red; P, magenta). Nl of NIC and N5 of FMN labelled in blue. Note the position of NIC C4 
(directly opposite Nl on the ring of NIC) over N5 of the flavin. Diagram prepared using BOBSCRIPT (Esnouf 
1997) and RASTER 3D (Meritt and Bacon 1997).
98
FMN is largely buried and contacts (3-strand 3 and some of the loop A-B. Hydrophobic 
contacts to the non-polar dimethylbenzoid ring of the flavin are provided by the G helices 
from both monomers of the NTR dimer.
All water molecules mentioned hereafter are numbered with respect to the tetragonal NTR 
crystal structure. Hydrogen bonding contacts to the FMN are exclusively from one of the 
monomers only. Asparagine 71 forms two polar contacts with the flavin, N71-ND2 to FMN 
O4, and N71-OD1 to FMN N3. The FMN O4 also hydrogen bonds to the backbone nitrogen 
of G166, and the FMN N3 to a water molecule W4. The backbone nitrogen of El 65 hydrogen 
bonds to atom N5 of the cofactor. The FMN O2 makes two hydrogen bonds to the protein, the 
NZ atoms of lysines 14 and 74, and one to a water molecule W551. The ribityl tail hydrogen 
bonds to an array of ordered waters, FMN O2* with W74, FMN O4* with W37, and FMN 
O5* with W86, and only once to the protein - FMN O3* with atom OG of SI 2. Serine 12 also 
forms two hydrogen bonds to the phosphate group of FMN, O2P with S12-OG, and O1P with 
the S12 backbone nitrogen. The phosphate also has several other hydrogen bonds or potential 
salt bridges with the protein, atom O2P with NH1 of RIO, and atom O3P with the NH2 of 
R207 and atom NZ of K205. A diagram of these contacts is provided in Figure 6.6.
6.2.3.2 Nicotinic Acid Ligand Binding
Although the majority of contacts to the FMN cofactor are provided by just one of the 
monomers, the opposing monomer contributes several residues that form the binding pocket 
for the nicotinic acid (NIC) ligand. The NIC ligand has excellent electron density in all three 
crystal forms (tetragonal example in Figure 6.5) and sits sandwiched between the flavin 
cofactor and F124, approximately 3.5 A from both. The ligand also appears to be
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N71
<SV Y*'*"\
> 1 .1 .x
R10
R207
K74
"•• \JK•• v y^
K14
v T K205
Figure 6.6. Schematic of hydrogen bond and salt bridge contacts between FMN cofactor and protein side chains 
or bound water molecules. Protein side chain carbons are represented in grey, and FMN carbons in yellow. 
Oxygen atoms (both of protein, cofactor and water molecules) are coloured red, and nitrogen atoms blue. 
Hydrogen bonds and/or potential salt bridges are shown by dotted green lines. Loop 3-H consists of residues 
162-167 between p-strand 3 and a-helix H. Figure prepared using MOLSCRIPT (Kraulis 1991) and RASTER 
3D (Meritt and Bacon 1997).
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well-ordered, with an average B-factor of 18.6 A2 . Apart from the Van der Waals contacts 
between the FMN isoalloxazine and nicotinic acid rings, the cofactor has a further contact to 
the ligand, with the carbonyl group O7 of the ligand hydrogen bonding to the FMN ribityl 
O2*. The nicotinic acid only makes one contact to the protein, NIC O7 hydrogen bonding to 
the backbone nitrogen of T41. The other carbonyl oxygen of the ligand makes two short 
hydrogen bonds to ordered waters W551 (2.8 A) and W542 (2.6 A), and a possible longer 
interaction to W303 (3.4 A).
A diagram of all of the active site residues (omitting F124 for clarity, see section 6.3.5 for a 
detailed description of the role of this residue in ligand binding) is provided in Figure 6.7, 
showing the residues that interact with both the FMN cofactor and NIC ligand. Other active 
site residues that line the binding pocket, but make no strong interactions with either cofactor 
or ligand, include Q142, Y144 and W138 which cap the dimethylbenzoid moiety of the FMN. 
Tyrosine 68 and F70 from helix D are on the edge of the binding pocket, with F70 bent away 
from the nicotinic acid ligand and Y68 at the top of the active site channel, 3.8 A from F124.
6.2.4 Comparison Between Crystal Forms 
6.2.4.1 Crystal Packing Arrangements
A view of the packing arrangements down each of the crystallographic axes of all three 
crystal forms is provided in Figure 6.8. Detailed close-up schematics of the contact points 
between the symmetry related molecules can be seen in Figures 6.9 to 6.11. Each contact 
point may incorporate several residues and a full description of these contacts is given in 
Table 6.2.
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Y68
F70
K74
^ v ..^ * 
mjf^•"•r vn.V162 v
K14
b)
K14
Figure 6.7. Active site residues, bound water molecules, FMN cofactor & nicotinic acid (NIC) ligand. Diagram
coloured by atom type (FMN & NIC C, yellow; Protein C, grey; O, red; N, blue; P, mauve). Residues from other
monomer of the dimer indicated by a prime. Parts (a) and (b) are related by approximately 90°. All residues are
labeled in (a), but only a selection are labeled in (b) to improve clarity. In this diagram the side-chains of
residues 69, 72 and 73 have been omitted as they point away from the binding pocket of the enzyme. Figure
prepared using MOLSCRIPT (Kraulis 1991) and RASTER 3D (Meritt and Bacon 1997).
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Monoclinic a Monoclinic b
Orthorhombic a Orthorhombic b
Monoclinic c
Orthorhombic c
Tetragonal a Tetragonal b Tetragonal c
Figure 6.8. Crystal packing between symmetry neighbours. Diagram shows all three NTR spacegroups, and the 
close crystal packing between symmetry equivalents. Colours represent particular sections of the crystal, and are 
equivalent within a set of diagrams for a particular spacegroup. Lettering a, b and c refer to crystal unit cell axes. 
Diagram prepared using Turbo (Roussel et d. 1991).
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Figure 6.9. Crystal contacts of tetragonal crystal form. NTR is shown as a Ca model, with crystal contact 
residues represented in ball-and-stick fashion and coloured by atom type (C=grey, N=blue, O=red). The 
reference molecule (X,Y,Z) is coloured red in all diagrams and symmetry related molecules are coloured green 
or blue. Crystal axes are given (x=red, y=green, z=blue). The different contact areas are labeled a to h, and are 
described in more detail in Table 6.2. Contacts labeled e in the diagram come from 2 molecules related by a one 
unit cell translation along the y axis. Diagram produced using MOLSCRIPT (Kraulis 1991) and RASTER 3D 
(Meritt and Bacon 1997).
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Figure 6.10. Crystal contacts of orthorhombic crystal form. NTR is shown as a Ca model, with crystal contact 
residues represented in ball-and-stick fashion and coloured by atom type (C=grey, N=blue, O=red). The 
reference molecule (X,Y,Z) is coloured red in all diagrams and symmetry related molecules are coloured green. 
Crystal axes are given (x=red, y=green, z=blue). The different contact areas are labeled a to e, and are described 
in more detail in Fable 6.2. Diagram produced using MOLSCRIPT (Kraulis 1991) and RASTER 3D (Meritt and 
Bacon 1997).
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Figure 6.11. Crystal contacts of monoclinic crystal form. NTR is shown as a Ca model, with crystal contact 
residues represented in ball-and-stick fashion and coloured by atom type (C=grey, N=blue, O=red). The 
reference molecule (X,Y,Z) is coloured red in all diagrams and symmetry related molecules coloured green. 
Dimer: dimer contacts within the asymmetric unit are shown at the top of the diagram. Crystal axes are given 
(x red, y=green, z=blue). The different contact areas are labeled a to d, and are described in more detail in 
Table 6.2. Diagram produced using MOLSCRIPT (Kraulis 1991) and RASTER 3D (Meritt and Bacon 1997).
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Tetragonal Form
Contact (a) A20-A104, A202-B5
Contact (b) B36-A25, A5-A28, A5-A31, A8-A24, A8-A25, A9-A28
Contact (c)B24-B 197
Contact (d)B 19-A109
Contact (e) B130-A62, B130-B67, B131-A62, B133-A175
Contact (f)B67-B 130
Contact (g) B72-A73, B72-A76, B73-A77, B76-A73
Contact (h)B54-A197
Orthorhombic Form
Contact (a) B19-C55, B19-C59, B21-C55, B21-C175, B23-C54, B24-C58, B54-C174
Contact (b) A24-A8, A24-B32, A28-A5, A28-A9, A31-A5
Contact (c) C5-D202, C9-D202, C2-D204
Contact (d) C18-A54, C19-A62, C73-A18, C73-A54, C77-A54, C196-A73, C197-A72
C197-A77 
Contact (e) B91-C133, B170-D171, B174-D67, B174-D168, B174-D171, B179-D132
B179-D170, B180-C127, B180-D68, B180-D131, B181-C131, B182-C131 
Monoclinic Form 
Contact (a) B18-C54, B19-C62, B21-C55, B73-C18, B73-C77, B77-C54, B196-C72
B196-C73, B197-C73, B197-C77
Contact (b) A24-A8, A24-B32, A28-A5, A28-A9, A31-A5 
Contact (c) B5-A202 
Contact (d) B122-A133, B126-A133_______________________________
Table 6.2. Residues in crystal contacts (see Figures 6.9 to 6.11). Contacts were defined as residues within 3.5 A 
of each other, and calculated using the CCP4 program CONTACT (CCP4 1994). Residues from the reference 
molecule (X,Y,Z) are given first (identified by chain), followed by those from the symmetry related molecule. 
Upper-case letters refer to the protein chain of the asymmetric unit. Contact (a) for the monoclinic crystal form 
lists dimer : dimer contacts in the asymmetric unit, no direct contacts are observed between dimers in the 
orthorhombic form.
6.2.4.2 Conformation Differences
All three forms give near identical Ca traces and show a small rmsd based on Ccc positions 
(Table 6.3). The main point of backbone conformation variation in the structures occurs loop 
C-D (residues 64-72), which is solvent exposed (and so more prone to flexibility) and 
contains residues that form crystal contacts in all 3 of the different spacegroups. The other 
major deviation in backbone conformation occurs in the tetragonal structure, at loop F-G 
(residues B126-135), which is again involved in crystal contacts, which are unique to the 
tetragonal form.
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8
The side-chain conformations between the three forms show the greatest variation in areas of 
solvent exposed residues, as would be expected, and conformation difference around the 
active site is effectively limited to residue F70, which is discussed in detail in section 6.3.5. 
Some smaller conformation differences can be seen in R107 and K207 in the orthorhombic 
structure. These residues contact the FMN phosphate group, and the differences may be 
attributed to a lower comparative resolution, and lower accuracy in fitting residues to the 
electron density.
6.3 Discussion
6.3.1 Active Site Residues & Implications for Catalysis
NTR has previously been proposed to adopt a "ping-pong" mechanism (see chapter 1), where 
the flavin is reduced by NAD(P)H, the nucleotide leaves and then allows the substrate to bind 
and become reduced, oxidizing the FMN cofactor in the process. A full discussion of flavin 
oxidation and reduction is provided in Chapter 1. The structures presented here support this 
hypothesis and provide little allowance of the ternary complex alternative, there being scant 
extra space in the active site to bind nucleotide and substrate at the same time.
We can assume that the nicotinic acid ligand binding is indicative of how NAD(P)H would 
bind the protein (due to the structural similarity of nicotinic acid to the nicotinamide 
headgroup), and that the redox reactions must occur at the re face of the FMN, as the si face is 
occluded by contacts to the protein. With the NIC ligand representing the nicotinamide ring of 
the nucleotides, the remainder of the NAD(P)H would point out of the active site, toward a 
solvent pocket of the crystal, and give some explanation as to why NTR has no direct 
preference for NADH or NADPH (with no protein contacts to the nicotinamide ribose). With
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the NIC ligand positioned in this orientation, the C4 is 3.4 A away from the flavin N5. This 
C4 atom of NIC corresponds to the C4 atom of the nucleotide cofactors that is responsible for 
hydride transfer in redox reactions. Atoms N5 and Nl of the flavin are known to be the two 
positions on the isoalloxazine ring system that accept reducing equivalents during reactions of 
FMN with reductants. The geometry of flavin:nucleotide reactions was studied in depth by 
Fraaije and Mattevi (2000), who looked at the distances and angles involved in a variety of 
flavoproteins. Their average value of 3.5 A between the position of attack (site of electron 
transfer) and the flavin N5 compares favourably to the 3.4 A found using our structures (our 
equivalent being atom C4 of NIC), and the angle between N10, N5 and the site of attack 
ranged between 96 to 117°, commensurate with our value of 101.6°. These measurements 
confirm the validity of NIC as a nucleotide substrate analogue in our structures, and the 
possibility that the reactions of NTR with substrates proceed via hydride transfer.
Fraaije & Mattevi found other aspects of flavoprotein: ligand interactions to be conserved, one 
of which was the stereochemistry of the hydrogen bond donor to N5 (donor-N5-N10 angle 
was between 116-170°). The hydrogen bond donor in NTR is the backbone nitrogen atom of 
Glul65, with a Glul65N-N5-N10 angle of 153.6°. This precise geometry arrangement is 
thought to increase the oxidative power of the FMN co factor, the hydrogen bond stabilising a 
protonated FMN N5 (Fraaije and Mattevi 2000). A diagram of the protein:FMN:NIC 
geometry is provided in Figure 6.12.
In the reductive half of the ping-pong reaction, a proton must be transferred to the flavin, 
along with a hydride ion from the nucleotide. The proton may come from any of the residues 
contacting the isoalloxazine ring as mentioned in section 6.2.3.1 (e.g. both the protonatable
110
_^**^^w
1164 NIC
FMN
Figure 6.12. Geometry of the protein : flavin : nicotinamide interactions. Atoms coloured according to atom type 
: C, yellow; N, blue; O, red. Straight lines (in dotted form, green) have been drawn between the centres of atoms 
El65 N, FMN N5, FMN NIO and NIC C4 (all shown with a larger atom radius above for clarity). The NIC C4 is 
3.4 A from the FMN N5, placed ideally for hydride transfer. Figure was prepared using MOLSCRIPT (Kraulis 
1991) and RASTER 3D (Meritt and Bacon 1997
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lysine residues near Nl - K14 & K74), or a bound water molecule. Upon reduction of the 
flavin, tautomerisation can occur and form a negative charge on atom Nl, which could be 
stabilized by K14 which lies 3.4 A away. Stabilisation of this negative charge, and the 
environment around the flavin Nl position has long been proposed to affect the flavin redox 
potential, favouring cofactor reduction (Ghisla and Massey 1989; Massey 1995).
The oxidative half of the ping-pong reaction concerns reducing the substrate and reoxidizing 
the flavin, presumably obeying a substrate binding orientation similar to that seen in the first 
half of the reaction. This raises the problem that if substrates bind with the aromatic ring in 
exactly the same position as NIC, the atoms that would accept the hydride (e.g. NO2 groups, 
quinone carbonyls) would be further away from N5, but if substrates bind with the acceptor 
atom in the equivalent C4 position, the ring stacking interactions would differ. It is possible to 
model CB1954 with its ring over the NIC ring, but the N of the NO2 group forms a flatter 
angle with the N5-N10 axis of-90°. If the ring of any aromatic substrates bound like that of 
NIC, then the broad substrate specificity of NTR is partly explained. The protein shows few 
contacts to NIC (mainly hydrophobic stacking between NIC, FMN and F124), and so a range 
of substrates could bind, and some like CB1954 could presumably bind in multiple 
orientations. This would also explain the occurrence of two products upon reduction of 
CB1954.
6.3.2 Comparison to Unliganded Structures
Shortly after solving the three nicotinic acid liganded forms presented in this work, 
co-ordinates for 2 unliganded nitroreductases, one from E .coli (Parkinson et al. 2000) and 
one from E .cloacae (Haynes et al. 2002) were deposited in the RCSB Protein Data Bank
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(Berman et al. 2000). This allows a direct comparison between liganded and unliganded NTR. 
and the use of the E. cloacae structure (and also that of the V.fischeri FRase homologue) to 
reaffirm assumptions made regarding the unliganded state.
In general, changes in the structure attributed to ligand binding are concentrated around the 
FMN cofactor and helices E and F. In the unliganded structures, helices E and F have high B 
values and are not well-ordered, the B values for this domain being two to three times that of 
the average for the protein. Binding of the NIC substrate analogue has increased the order of 
these domains in our structures, with the B values for this domain being close to those for the 
protein as a whole. The reason for these changes may lie in helix F contacting the NIC ligand 
(mainly through F124), and changes in mobility may be important in regulating ligand 
binding and catalysis.
Some amino acid side-chain conformation differences can be seen between the liganded and 
unliganded structures. In the active site, F124, which sandwiches NIC against the FMN, 
rotates away from the FMN in the liganded structures to allow NTR to bind the ligand (Figure 
6.13). A smaller effect is seen on the neighbouring residue F123. Another residue F70 shows 
more variability, but moves away from the active site when NIC binds (Figure 6.13). The 
F124 acts to clamp ligands to the cofactor (explaining the enzyme preference for aromatic 
substrates), whereas F70 may be more involved in access to the active site or contacts to 
larger ligands.
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Figure 6.13. Amino acid side-chain shifts upon binding of NIC ligand. The ten NTR NIC monomers are shown
in red, the two unliganded E. coli monomers from IdsT.pdb (Parkinson et al. 2000) are shown in blue, and the
two V. fischeri unliganded monomers from 1 vfr.pdb (Koike et a\. 1998) are shown in green. FMN and NIC
coloured by atom type (C, yellow; N, blue; O, red; P, magenta). Notably, F124 can be seen to shift upon the
binding of NIC, rotating away from the active site. The bound NIC is sandwiched between the F124 side-chain
and the FMN isoalloxazine ring. The F70 side-chain is generally mobile and seen here in many orientations, as
opposed to the two distinct populations observed with F124. Diagram prepared using MOLSCRIPT (Kraulis
1991) and RASTER 3D (Meritt and Bacon 1997).
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6.3.3 Comparison to Nitroreductase Homologues
The fold of NTR is very similar to that of the nitroreductase from E. cloacae and the flavin 
reductase FRase from V. fischeri, the rmsd based on Cot positions being 0.28-0.36 A and 0.99- 
1.05 A, respectively (see Table 6.3). The E. cloacae enzyme sequence is 88 % identical to 
NTR and shows no significant deviations in the fold, and the only residue difference at the 
active site is the substitution of F123 by Y122, which remains in a similar conformation. 
Comparison of NTR with FRase shows more variation, and although the secondary structure 
elements superimpose well, several loop differences can be seen. Loop E-F in FRase (same 
secondary structure notation as NTR) has one amino acid less than the corresponding loop in 
NTR and adopts a different conformation. A large difference can be seen in loop F-G, a 
smaller difference in loop H-4, and the N-terminus has an extension, with a short loop leading 
into helix A. NTR shows a lower sequence homology to NADH oxidase of T. thermophillus, 
but is structurally similar (21 % identity, rmsd based on Ca of 1.52 A). Remarkably, NTR and 
nfsA (see Chapter 1, PDB code 1F5V) share little homology (15 % similarity) but are 
structurally similar (rmsd based on Ca of 1.59 A). A major difference exists in the E + F 
a-helix region, with the nfsA active site being more solvent exposed. The central (3-sheet and 
other secondary structure features are largely super-imposable. The structural similarity 
between the two proteins raises the prospect of a distant ancestor with a related function.
Shortly after this work on the NIC liganded form of NTR was published (Levering et al. 
2001), two liganded and one reduced structures of the E. cloacae nitroreductase were 
published (Haynes et al. 2002). The acetate complex is discussed with reference to the NTR 
acetate structure determination in Chapter 7. The other inhibitor bound structure, a benzoate 
complex, shows the same amino acid shifts and binding orientation as the NIC-NTR
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structures. This is expected as benzoate and nicotinic acid differ only by a single atom, a C to 
N substitution. The reduced FMN complex of the E. cloacae nitroreductase is more 
interesting, and shows an increased FMN butterfly angle of 25°. No significant amino acid 
shifts were observed upon FMN reduction (the largest being a 0.15 A movement of PI 63). It 
is therefore tempting to attribute the different behaviour of reduced and oxidised FMN in 
binding substrates (see Chapter 7) to purely electronic effects, or to small steric effects of the 
newly introduced hydrogen atoms. The butterfly angle seen in the oxidised and reduced 
nitroreductase structures may favour reduction of the flavin, and explain why no semiquinone 
intermediate is formed during catalysis (Zenno et al. 1996a). The preference of NTR for this 
bent, "butterfly" FMN would not favour the formation of a planar semiquinone species.
There are several amino acid differences in the active site when comparing FRase and NTR. 
Loop 3-H at the si face of the flavin has 2 substitutions, V162 for T162 and P163 for T163, 
possibly playing some role in subtly altering the polarity of the FMN environment. Lysine 74, 
which hydrogen bonds to atom FMN O2 in NTR, is replaced by an ordered water molecule 
bound to the shorter residue H76 in FRase. At the re face of the FMN, T41 is replaced by 143. 
F123 and Y68 at the extremity of the substrate binding pocket are replaced by K123 and H70, 
respectively. Mutation of F123 to K may allow the binding of the larger FMN substrate to the 
active site. Mutations of NTR that are known to increase FRase activity are discussed in 
(Zenno et al. 1996b). The active sites of NTR and FRase match well and provide a basis for 
modelling other nitroreductase homologues with potentially lower sequence identity with a 
high degree of confidence.
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6.3.4 Crystal Packing Discussion
When analysing the crystal packing interactions present in the three different spacegroups, it 
can be seen that the tetragonal form is the most distinct, with the monoclinic and 
orthorhombic forms sharing a few similar characteristics. The similarity between the 
monoclinic and orthorhombic forms is also apparent when looking at the unit cell axes (the 
orthorhombic c axis being approximately a doubling of the monoclinic a axis), and the 
conversion between the two forms upon a substitution from methionine to seleno-methionine 
is also an important factor. Looking at the contact diagrams supplied in Figures 6.9 to 6.11, it 
can be inferred that the (b) + (c) contact regions of the two forms look identical, and that the 
inter-asymmetric unit monoclinic contacts (a) are approximate to the (d) contact point of the 
orthorhombic form. Super-imposition of the NTR dimers involved in the (b) + (c) contacts of 
the two forms shows that the two interactions are not identical - it is possible to overlap one of 
the dimers with its equivalent from the other spacegroup, but the other dimer involved (across 
the contact point) will not superimpose as well. This could be attributed to slight 
non-isomorphism in cell axes between the two forms, but it can be seen that the exact contacts 
are not completely interchangeable (see Table 6.2), and the differences are more likely to be 
real. The orthorhombic (d) contact is also subtly different to the monoclinic (a) contact, most 
clearly seen in contact differences involving residues 72 and 197.
Other contacting regions in the monoclinic and orthorhombic spacegroups appear to be 
different, with the (a) and (e) contacts unique to the orthorhombic form, and the (d) contact 
unique to the monoclinic form. The spacegroup "switch" between the two forms has to be 
attributed to the change between the use of methionine and seleno-methionine. One possible 
explanation for this switch is the non-equivalence of the monoclinic (d) contact (involving
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residue HI33) in the orthorhombic form. Here chain C HI33 hydrogen bonds to chain B D91 
(in contact point (e)), the significance of this difference being that D91 is next to methionine 
90 in the primary sequence, and the increase in volume upon substituting sulphur for selenium 
may change the local environment, favouring one contact type over the other. Also the contact 
B El80 : D Y68 in the orthorhombic form (again in contact point (e)) is packing near C 
Ml27, which may also result in local conformation changes and preferences.
The tetragonal form is different again, and shares few contact similarities with the other two 
forms, presumably as a result of its markedly different solvent content (43 %, 5 % lower than 
the monoclinic form, 7 % lower than the orthorhombic form). The tetragonal and the 
monoclinic or orthorhombic forms growing from the same drop is most likely a result of local 
differences in protein supersaturation.
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CHAPTER 7
LIGAND COMPLEXES & MUTANT ENZYMES 
7.1 Introduction
7.1.1 Mutant Nitroreductases
Following the structural determination of the native enzyme in complex with a substrate 
analogue, it was possible to identify residues that may play a role in the recognition of the 
CB1954 substrate. As both nicotinate and CB1954 (presumably) bind over the isoalloxazine 
of the FMN, and both have a six-membered ring, it was assumed that the binding modes of 
the two compounds would be similar. From observation of those residues closest to nicotinate, 
several residues were selected as candidates for mutation in an attempt to find a mutant or 
combination of mutants with increased catalytic activity towards CB1954. Residues deemed 
essential to FMN cofactor binding (part active site analysis, part sequence alignment-based) 
were omitted from selection. The final list of candidates was as follows :- S40, T41, Y68, 
F70, N71, G120, F124, E165 and G166.
7.1.2 Crystal Soaking
Enzymes that utilise a ping-pong mechanism present difficulties with regard to determining a 
ligand-bound structure - a compound that binds the protein without being turned over or 
released is required, and this may be complicated by the two different binding steps. Although 
no major conformational differences occur between the reduced and oxidized enzyme state 
(Section 7.4.1), the electrostatics and shape of the cofactor change, affecting ligand binding. 
These factors are less of a problem when dealing with inhibitors as opposed to substrates. 
Two crystal soaks were attempted, both with oxidized crystals of NTR. The first soak used the 
inhibitor (and buffer) acetate, which binds in the active site if no nicotinate is present in
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crystal growth. The second soak used the antibiotic substrate nitrofurazone, chosen because of 
the presence of a nitro- group, and also due to the paucity of mechanistic detail on its 
activation by NTR.
7.2 Materials and Methods
7.2.1 Preparation and Assay of Mutant Nitro red uctases
All mutagenesis was the work of Dr. Jane Grove and Dr. Peter Searle (Institute for Cancer 
Studies, University of Birmingham). Studies on the kinetics of the mutants were the work of 
Paul Race (School of Biosciences, University of Birmingham).
The full basis of this work is described in detail in Grove et al. (2003). A pUC19-based 
plasmid (pJG12Bl) was used as a template for PCR-based site-directed mutagenesis. Mutant 
libraries for each position were obtained with the use of partially overlapping PCR products 
that span the 5' and 3' ends of the NTR gene, with NNN (all 4 mixed deoxyneucleotides) at 
the desired codon. After PCR amplification, the products were digested and cloned into a 
derivative of the bacteriophage lambda vector XNM1151 (AJG3J1). After packing of the DNA 
into phage, the phage particles were used to infect the nitroreductase-deficient E. coli strain 
UT5600 (Elish et al. 1988). All lysogens were replica plated onto a series of agar plates 
containing a range of CB1954 concentrations (0-400 uM). Clones more sensitive to CB1954 
than the wild-type NTR were amplified by PCR, then sequenced.
7.2.2 Crystallization
For the eventual goal of crystallization, selected mutant phage-infected UT5600 cultures were
handled in the same manner as the wild-type enzyme (both in over-expression of NTR and
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purification of the enzyme). Crystallization conditions were similar to those reported for the 
wild-type, with careful screening to compensate for any difference in protein concentration 
between batches.
7.2.3 Ligand Soaks
All crystal soaks contained 10 % w/v PEG 4000 and 25 % v/v ethylene glycol. The acetate 
inhibitor soak was buffered by 100 mM sodium acetate, pH 4.6, all other soaks (including 
"holo" structures, with no ligand bound over the flavin) were buffered using 50 mM sodium 
citrate, pH 4.6. The nitrofurazone soak contained 15 mM nitrofurazone, solubilised in DMSO 
(final concentration 15 % v/v). Soaking times for all were approximately 10 minutes.
7.2.4 Data Collection
All crystals were flash cooled to 100 K in a cryostream prior to data collection. Diffraction 
data were collected at the ESRF using beamline ID 14-1 (nitrofurazone substrate soak, acetate 
inhibitor soak, F124K mutant, N71 mutant - holo and NIC-bound forms) and beamline 
ID14-4 (T41L mutant, F124N mutant, N71S/F124K double mutant - holo and NIC-bound 
forms). All data were indexed, integrated and scaled using MOSFLM (Leslie 1992) and 
SCALA (Evans 1993).
7.2.5 Refinement Protocol
Initial refinement steps used the CNS suite of programs (Brunger et al. 1998), as described in 
Chapter 5. For both forms of the double mutant, N71S NIC-bound form and T41L structure 
determinations, data were of high resolution and TLS refinement was included in REFMAC 
runs (Winn et al. 2001).
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7.3 Results
7.3.1 Mutant Screening Results
(Work by Jane Grove, Institute for Cancer Studies, University of Birmingham). The proposed 
amino acid positions for mutation were fruitful - mutations that conferred an increased 
sensitivity to CB1954 were observed at positions S40, T41, Y68, F70, N71, G120 and F124; 
none were obtained at positions El65 and G166. A histogram showing the various mutations 
and their relative activities in comparison to the wild-type enzyme is provided in Figure 7.1. 
From this preliminary characterisation of the activities of the mutant enzymes, structural 
studies were instigated on the N71S, F124K, F124N and T41L single mutants, along with a 
N71S F124K double mutant. Kinetic data on these particular enzymes is provided in Table 
7.1.
7.3.2 Crystallization
The N71S, F124K and N71S/F124K (double) mutants gave large single crystals characteristic 
of the tetragonal NTR crystal form. The T41L enzyme yielded very poor crystal clusters 
which showed no response to screening experiments. Small single crystals were cut from the 
mass of monoclinic form crystals. The F124N mutant also yielded a crystalline mass rather 
than single crystals, and an orthorhombic NTR crystal form was finally used. For the ligand 
soaks, wild-type NTR crystals were grown as documented in Chapter 4.
7.3.3 Data Collection
Data were collected for both NIC-bound and holo forms of the N71S mutant and N71S/F124 
double mutant. Data for a NIC-bound form were collected for the F124K, F124N and T41L 
single mutants. A tetragonal NTR dataset was collected for the acetate soak, and a monoclinic
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WT S40 T41 Y68 F70 N71
Arnino acid substitution
G120 F124
Figure 7.1. Work by Dr. Jane Grove (Institute of Cancer Studies, Birmingham). Relative sensitivity to the 
prodrug CB1954 by bacterial colonies with mutant nitroreductase. The wild-type enzyme has an arbitrary 
sensitivity score of 4, mutant enzymes with a score greater than 4 show increased toxicity to bacterial colonies at 
lower concentrations of prodrug. Assay involves replica plating of bacteria (infected with a phage, vector carries 
random amino acid at designated position in NTR sequence) onto plates containing 0 - 200 ^M CB1954. 
Colonies that show inhibited growth at lower CB1954 concentrations than required to kill bacteria expressing the 
wild-type enzyme are picked off and sequenced.
Mutation
Wild-type enzyme 
N7 1 S single mutant 
F124K single mutant 
N71S / F124K double mutant
F124N single mutant 
T41L single mutant
KM for CB1954
(uM)
880 ±56 
180 ±25 
400 ±13 
180±16
280 ±21 
1000 ±86
Kca, for CB 1954 
(min' 1 )
140 ±11 
150 ±14 
140 ±4 
170 ±12
180 ±21 
400 ±43
kcat/ KM for 
CB 1954 (min- VM-')
0.2 ±0.02 
0.8 ±0.2 
0.4 ±0.03 
0.9 ±0.1
0.6 ±0.1 
0.4 ± 0.03
Table 7.1. Work by Paul Race (School of Biosciences, University of Birmingham, Birmingham). Kinetic 
parameters (apparent) for NTR enzymes. All calculations used a fixed NADH concentration of 60 uM.
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dataset for the nitrofurazone soak. Full data collection statistics are listed in Table 7.2 (native 
soaks) and Table 7.3 (mutant enzymes).
7.3.4 Phasing and Model Building
Datasets for all mutant enzymes or native soaks yielded interpretable electron density maps 
when using the corresponding native crystal form to phase the structure. Final refinement 
statistics for the structures are listed in Table 7.4 (native soaks) and Table 7.5 (mutant 
enzymes).
7.3.5 Structural Features
7.3.5.1 F124K Mutations
Electron density for K124 in the F124K single mutant and both the NIC and holo forms of the 
N71S/F124K double mutant is provided in Figure 7.2. This mutation was the most ambiguous 
of all the mutations to model, with partial disorder in all of the conformations observed. It 
cannot be discounted in some of the models (single mutant B chain and double mutant holo 
form A chain especially) that the position of the NZ atom of the introduced lysine is modelled 
incorrectly, taking the place of an ordered water molecule.
7.3.5.2 N71S Mutations
Electron density for S71 in both the NIC and holo forms of the single and double mutants is 
provided in Figure 7.3. Density for the mutated residue in all of the forms was excellent. A 
bound water molecule between S71 and the FMN cofactor could clearly be modelled in all 
chains apart from chain B of the single mutant holo form.
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Nitroftirazone Acetate
Refinement
Resolution (A) 1.7
No. of Non-hydrogen 7831 
Atoms
No. Water Molecules 907
R factor3
R b 
Kfree
14.4%
16.6%
Average B factor 12.33 A2
RMSD Bond Angles0 1 .25°
RMSD Bond Lengths'1 0.008 A
a R factor = Ihld |I-o - |FC | |/2hki|Fo|.
1.7
4035
653
17.3%
19.5%
12.77 A2
1.17°
0.010 A
bR factor based on 5 % of the data withheld from refinement
CRMSD bond angles and dbond lengths are the root mean square deviations from
ideal values
Table 7.4. Final refinement statistics for all NTR ligand:complex determinations.
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Figure 7.2. Refined electron density for K124 in mutant enzymes. Colouring is by atom type (C, yellow; O, red; 
N, blue), a) + b) F124K single mutant, c) + d) F124K N7IS double mutant NIC form, e) + f) F124K N71S 
double mutant holo form, all have chain A on the top and chain B on the bottom. Residue labelling in first panel 
only, omitted from the others. All figures are shown in the same orientation. Maps are 2mFo-Dfc, 
SIGMAA-weighted, contoured at la. The resolution range of data included in map calculation varies for each 
structure, see Table 7.3. Figure prepared using BOBSCR1PT (Esnouf 1997) and RASTER 3D (Meritt and Bacon 
1997).
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d)
Figure 7.3. Refined electron density for S71 in mutant enzymes. Colouring as Figure 7.2. a) + b) N71S single 
mutant holo form, c) + d) single mutant NIC form, e) + f) F124K N71S double mutant NIC form, g) + h) double 
mutant holo form, all show chain A first, then chain B. Residue labelling in first panel only, omitted from the 
others. All figures are shown in the same orientation. Maps are 2mFo-Dfc, SIGMAA-weighted, contoured at ICT. 
The resolution range of data included in map calculation varies for each structure, see Table 7.3. Figure prepared 
using BOBSCRIPT (Esnouf 1997) and RASTER 3D (Meritt and Bacon 1997).
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Figure 7.4. Refined electron density for T41L and F124N single mutants. Colouring as Figure 7.2. a) to d) T41L, 
e) to h) F124N, all chains shown in order A-D. Residue labelling in first panel only, omitted from the others. All 
figures from same structure are shown in the same orientation. Maps are 2mFo-Dfc, SIGMAA-weighted, 
contoured at ICT. The resolution range of data included in map calculation varies for each structure, see Table 7.3. 
Figure prepared using BOBSCRIPT (Esnouf 1997) and RASTER 3D (Meritt and Bacon 1997).
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7.3.5.3 Other Single Mutants
Electron density for the T41L and F124N mutants is provided in Figure 7.4. Density for L41 
was excellent, and the residue was modelled in the same conformation in all four chains. 
Diffraction data for the F124N mutant may be twinned (observation from cumulative intensity 
analysis, data not shown). However, electron density for N124 was good in all four chains, 
leading to the inclusion of this data in this investigation.
7.3.5.4 Native Ligand Soaks
Clear electron density for the respective bound molecule was observed in the active site of the 
nitrofurazone and acetate complexes (Figure 7.5). In both cases only one molecule is bound 
per active site. Nitrofurazone adopts a planar conformation, with the aliphatic moiety stacking 
over the two polar rings of the FMN, and the nitrofuran ring projects into a loop formed by 
residues 68 to 71. This orientation was unexpected as it places the nitrogroup away from the 
site of hydride transfer. Nitrofurazone is bound with good occupancy, with an average B 
factor of 19.4 A2 (c.f. the overall average B factor of 12.3 A2).
Nitrofurazone makes 7 hydrogen bonds to the protein, FMN and ordered waters (Figure 7.5). 
Atom N4 of nitrofurazone hydrogen bonds to El 65 OE1, atom O4 with the T41 backbone 
nitrogen and the FMN O2*, atom Ol with the F70 backbone nitrogen and a water molecule, 
and atom O2 with N71 ND2. There are extensive Van der Waals contacts between the 
nitrofurazone aliphatic region (C5, N2, N3, C6, N4 and O4) and the isoalloxazine ring.
Changes in active site residue conformations exist between the NTR:nitrofurazone complex 
and the NTR:NIC structure. The F124 sidechain of the nitrofurazone complex more closely
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b)
Figure 7.5. Binding of nitrofurazone and acetate to NTR. a) to c) coloured by atom type: protein C, grey; other 
C, yellow; O, red; N, blue; P, magenta. Refined electron density maps of a) nitrofurazone and b) acetate, 
2mFo-DFc, SIGMAA-weighted, contoured at ICT, resolution 1.7 A. c) contacts of nitrofurazone to the protein, 
FNfN and water molecules, hydrogen bonds displayed as dotted green lines, d) shift of active site residues when 
binding the two ligands, nitrofurazone structure in red, acetate structure in green. Figures produced using 
MOLSCRIPT (Kraulis 1991), BOBSCRIPT (Esnouf 1997) and RASTER 3D (Meritt and Bacon 1997).
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resembles the orientation observed in the non-liganded NTR structure (Parkinson et al. 2000). 
F70 has its mobility reduced due to the binding of the nitrofuran ring in the pocket formed by 
residues 68 to 71. The contact between nitrofurazone and El65 causes the glutamate 
sidechain to orient itself closer to S40 (2.3 A), the electron density between the two residues 
is continuous (Figure 7.6a). A comparison between the nitrofurazone complex and the NIC 
complex is presented in Figure 7.6b.
Upon elucidation of the NTR:acetate structure, it was apparent that acetate binds NTR in an 
orientation analogous to the carboxamide moiety of nitrofurazone (Figure 7.5). The bound 
acetate has good occupancy, with an average B factor of 24.5 A2 (overall average B factor of 
12.8 A2). Although it would be possible to model the acetate molecule with the methyl carbon 
in the same position as the nitrofurazone N3 atom (with the acetate oxygens occupying the 
nitrofurazone N4 and O4 positions), it was decided to model the methyl carbon pointing 
directly into the ring of F124. This positions one acetate oxygen into a hydrogen bond with 
the T41 backbone nitrogen, and the other facing bulk solvent.
7.4 Discussion 
7.4.1 Ligand Soaks
The role of the antimicrobial agent nitrofurazone in the discovery of NTR is detailed in 
Chapter 1. Nitrofurazone and the related compound nitrofurantoin remain important in 
treating burns victims and genitourinary infections (Asnis 1975), proving effective against 
organisms that have developed resistance to other treatments. Although nitrofurans have been 
used in such a manner for many years, the mode of their activation into a toxic species by 
nitroreductases has never been fully investigated.
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S40
b)
E165
S40
Figure 7.6. Changes observed upon binding nitrofurazone. a) Electron density of contact between El 65 and S40, 
2mFo-DFc style, SIGMAA-weighted, contoured at ICT, resolution 1.7 A. The electron density map shows 
continuous density between the two sidechains. Diagram coloured identical to Figure 7.2. b) Residue shifts upon 
binding nitrofurazone. The NTR : NIC complex (Lovering et al. 2001) is in green, the holo NTR structure 
(Parkinson ct al. 2000) in blue, and the nitrofurazone complex in red. The nitrofurazone complex F124 is similar 
to the holo form, and F70 more resembles the NIC form. HI 65 of the nitrofurazone structure moves closer to the 
flavin, pushing S40 away slightly. The conformation of the loop formed by residues 64 to 71 is different between 
all 3 structures, but the nitrofurazone complex is different from the other two. Diagram produced using 
MOLSCRIPT (Kraulis 1991), BOBSCRIPT (Esnouf 1997) and RASTER 3D (Meritt and Bacon 1997).
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One hypothesis is that the nitrogroup of nitrofurazone is reduced by nitroreductase to a 
nitroso-compound (2 electron reduction), and then reduced by a further 2 electrons to a toxic 
hydroxylamine product (Haynes et al. 2002). The final two-electron reduction may be 
enzymatic or non-enzymatic (reduced directly by NAD(P)H). Another possibility is that 
nitrofurazone is reduced at the aliphatic end of the molecule, resulting in the liberation of 
formamide (Guay 2001).
Mutations of NTR that affect the reduction of nitrofurazone (Whiteway et al. 1998) are of no 
use in analyzing amino acid residues important for catalytic activity, simply being 
interpretable as mutations that affect protein folding or FMN binding. With the crystal 
structure of the NTR:nitrofurazone complex, and the acetamide portion of the drug bound 
over the flavin, reduction away from the nitro group remains a possibility. Unfortunately, 
attempts to obtain a nitrofurantoin complex failed, leaving the chance that the nitrofurazone 
complex is something of an artefact of crystallization.
The question of nitrofurazone activation by NTR was answered by the use of HPLC and mass 
spectrometry of the reaction products (personal communication, Paul Race). It confirmed the 
presence of a nitroso intermediate, and upon anaerobic analysis under nitrogen, the 4 electron 
reduction hydroxylamine product. This indicated that the orientation of nitrofurazone 
observed in the crystal structure is that of a non-productive complex. The distance between 
the nitro group and the flavin N5 is 7.7 A, with no real possibility of tunneling electrons 
between the two.
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The observation of this non-productive complex can be rationalized in terms of active site 
changes upon reduction of NTR. The crystal structure with nitrofurazone was obtained with 
an oxidized enzyme (i.e. is a dead-end complex), and presumably nitrofurazone binds 
differently to the reduced enzyme. No large structural changes are observed upon reduction of 
the homologous enzyme from E. cloacae (Haynes et al. 2002), with the greatest change being 
a shift in the butterfly angle of the flavin from 16° to 25°. It was also noted that this reduced 
enzyme no longer bound acetate, in contrast to the oxidized form. As nitrofurazone binds to 
the oxidized NTR with the acetate-like acetamide group over the flavin, the reduction of the 
enzyme may favour binding of the nitrogroup over this region instead.
Multiple binding modes for ligands between an oxidized and reduced enzyme have been 
observed in another flavoprotein, PETN reductase (Barna et al. 2001). This scenario may be 
prevalent in relatively non-specific flavoenzymes, although its purpose remains unclear. This 
substrate "flipping" may be due to the distribution of charge on the flavin, changing with the 
two electron reduction.
7.4.2 Mutant Enzymes
Conformational diagrams (with descriptions of contacts formed between the mutated residue 
and other aspects of the active site) and comparisons to the wild-type structure are provided in 
Figures 7.7 to 7.9. A summary of the kinetic parameters of the mutant enzymes (personal 
communication, Paul Race) is provided in Table 7.1.
The mutation of N71 to serine yielded two distinct groups of structures, one with a bound 
water molecule between the serine and the FMN, and one without. The absence of a water
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Figure 7.8. Contacts of S71 residue, a) to c) colouring as Figure 7.2. a) N71S mutants with no water bound near 
flavin, b) N71S mutants with water adjacent and K74 facing away from flavin, c) N71S mutants with water 
adjacent and K.74 facing towards flavin. Hydrogen bonds shown as dotted green lines, d) to f) coloured 
according to structure : native enzyme, grey; N71S mutant with water adjacent, red; N71S mutant with no water 
adjacent, blue. Residue labelling in first panel only, omitted from the others for clarity. All figures are shown in 
the same orientation. Figure prepared using MOLSCRIPT (Kraulis 1991) and RASTER 3D (Meritt and Bacon 
1997).
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a) b)
W138
c) d)
G166
e) g)
Figure 7.9. Contacts of other single mutants, a) T41L, coloured as Figure 7.2, hydrogen bonds as green dotted 
lines, VDW contacts as blue dotted lines, b) comparison of T41L structure (red) with native enzyme (grey), c) -+ 
d) contacts formed by N124 in the F124N mutant, c) chain A and d) chain D. Colouring as above, e) to g) 
comparison of F124N structure (chain A red, chain D blue) to native enzyme (grey). Residue labelling in first 
panel only, omitted from the others for clarity. All figures from same structure are shown in the same orientation. 
Figure prepared using MOLSCRIPT (Kraulis 1991) and RASTER 3D (Meritt and Bacon 1997).
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molecule in chain B of the single mutant holo form cannot be attributed to low resolution data 
(2.4 A) as the water molecule is observed in chain A. The water molecule sits 2.8 A from the 
S71 OG, 2.9 A from the FMN N3, and 2.6 A from K74 NZ (measurements from the A chain, 
double mutant holo form), forming a hydrogen bonding network (Figure 7.8). In comparing 
the 7 mutant chains that have the water molecule bound, chain A of the single mutant holo 
form, and to a lesser extent, chain A of the double mutant NIC form, have the end of K74 
rotating away from the FMN. In the former case this is quite extreme, and instead of hydrogen 
bonding to the FMN O2, K74 NZ now contacts G166 O (2.8 A). Why differences are 
observed between these different forms remains unclear. Small movements can also be seen 
in the 1164 sidechain, which although can be in multiple orientations (see chain B of the 
double mutant holo form, Figure 7.8), prefers to orient itself away from the cofactor, possibly 
as a result of the introduced water molecule (although the converse is not observed in the 
chain with the water molecule absent). The N71S mutation also causes general movement of 
the main chain loop in this region (Figure 7.8). The lack of recovery of a N71G mutant may 
indicate that increased flexibility in this area is detrimental to enzyme activity.
A reason for the improved catalytic activity of the N71S mutant (at least with regards to 
CB1954 turnover) must exist. An attractive proposition is that this mutation increases the 
polarity of the isoalloxazine environment (chiefly via hydrogen bonding from the introduced 
water molecule), favouring reduction of the FMN cofactor. The wild-type asparagine residue 
is too far away to form hydrogen bonds to the FMN (ND2 : FMN O4 - 3.8 A, OD1 : FMN 
N3 = 3.8 A), and there is no space for an intervening water molecule. Other mutations at this 
position (D, Q, T) support this theory somewhat, although the preference of Q over E suggests 
that charge too close to the cofactor is not tolerated. The lack of an improved enzyme with
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histidine at position 71 may be due to detrimental charge repulsion with the neighbouring K74 
residue.
Any modulation of the enzyme redox potential will have two effects - one on the relative rate 
of reduction by nucleotide, and an opposite effect on the relative rate of oxidation by 
substrate. The redox potential of NTR is -210 ± 5 mV (personal communication. Dr Simon 
Daff, Department of Chemistry, University of Edinburgh), that of the NAD+/NADH couple 
-320 mV and CB1954 -385 mV. There exists the potential to lower the redox potential of 
NTR toward that of NAD+/NADH, sacrificing the rate of the reductive half-reaction of the 
ping-pong mechanism to facilitate a more favourable oxidative half-reaction. The actuality 
may be more complex, however, with any residue mutation also likely to have unrelated 
effects, e.g. substrate fit to active site. It would be advantageous to have accurately measured 
redox potentials for all of the mutant enzymes.
The mutation of F124 to lysine gave a greater conformational variability than the N71S 
mutant (Figure 7.7), presumably due to the increased number of torsion angles possible in a 
lysine sidechain. No distinct pattern emerges in the analysis of the six forms, other than that 
when NIC is not present K124 is free to extend further toward the flavin. When NIC is 
present the sidechain moves away to accommodate the ligand. With NIC being a fairly small 
molecule, K124 may have to move even further when binding bulkier substrates such as 
CB1954. The mutation of F124 to lysine has a minimal effect on other residues in the active 
site (Figure 7.7), merely causing slight movement of the neighbouring F123 sidechain. In the 
variety of conformations observed K124 makes mainly VDW contacts to the NIC ligand 
(where present) and active site residues (T41 and Ml 27). In the double mutant holo structure
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chain A, the lysine NZ makes a hydrogen bond (2.6 A) to a water molecule occupying the 
space where NIC would bind.
Although the conformation of K124 is variable, the Ca - Cs atoms of the sidechain are 
usually in the same position as the C atoms of the F124 sidechain (Figure 7.7), indicating a 
potential preference of the active site in positioning aliphatic sidechains at this residue. The 
lack of any large scale movement of residues in the active site, or definite position of the 
K124 NZ makes it difficult to analyse how this mutant possesses an increased activity for 
CB1954 reduction compared to the wild-type enzyme. This may become apparent in an 
enzyme : substrate complex structure.
The introduction of a positive charge at position 124 may increase the activity of NTR by 
favourable interactions with the negatively charged substrate groups. Indeed F124H also 
shows increased activity, F124R presumably not obtained from the mutant screening 
procedure due to unfavourable steric clashes upon introduction of such a large sidechain, 
leading to a lower enzyme activity. This hypothesis may have some promise as no F124D or 
F124E mutants were recovered. The only other F124 mutation not recovered was F124P, 
understandable in that a proline residue could act as a "helix-breaker" in helix F. With such a 
wide variety of mutations at F124, it would be prudent to say that not all mutations may lead 
to an improved NTR for precisely the same reasons. The best candidates at this position all 
possess some flexibility (M, H. K ; N less so), and are usually polar. The error bars involved 
in such a scoring protocol (Figure 7.1) can mean that the wild-type enzyme, W124, Y124 and 
1124 can be grouped together. It would not be unreasonable to suggest that (for CB1954 
reduction) bulky hydrophobic residues at this position hinder turnover. This may be due to
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substrate access, or unfavourable interactions with the polar substituents on the aromatic ring 
of the substrate. The mutation of F124 to lysine is flexible enough to accommodate a range of 
binding orientations of CB1954. The prevalence of K124 over G124 suggests that interaction 
of some sort is preferred.
No reason can be given for chain D of the F124N mutant occupying a different conformation 
to the other three chains (Figure 7.9), other than that position 124 is near to the protein surface 
and may be influenced by subtleties in crystal packing. Using chain A as an example, N124 
makes two hydrogen bonds to separate water molecules, both 3 A away (Figure 7.9). Chain D 
of F124N is different from chains A-C, atom ND hydrogen bonding to G120 O (2.9 A). Both 
conformations show the polar interactions possible upon mutation from phenylalanine. As 
N124 does not alter any of the surrounding residues (although an alternate conformation of 
T41 is observed, this can also be seen in some high resolution wild-type studies, unpublished 
data), it must increase NTR activity by interaction with substrate.
The mutation of T41 to leucine is intriguing as the KM and kcat for CB1954 are increased 
compared with the wild-type enzyme. The T41L mutant is also the only mutant investigated 
that alters the ratio of the 2 / 4-hydroxylamine products of CB 1954 reduction (personal 
communication, Paul Race), from 1 : 1 to 1 : 3, yielding more of the desired toxic product. 
The leucine residue makes Van der Waals contacts with NIC. F124 and W138 (Figure 7.9). 
The backbone conformation of this mutant L41 residue remains identical to T41 of the 
wild-type enzyme, forming a hydrogen bond between the backbone nitrogen and the NIC 
oxygen. The mutation does not affect any other active site residues, and presumably the 
increased activity is due to a direct interaction with substrate. Analysis of other mutations
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recovered at position 41 does not yield any clear result (G, I, N and S). Presumably S41 
behaves similarly to T41, and G41 allows more possible orientations of substrate binding but 
has less substrate interaction. With L/I/N 41 it appears that medium-sized flexible, uncharged 
residues are preferred, making the inclusion of G and S, but the omission of A puzzling. This 
may be an artefact of the mutant screening procedure.
To understand why L41 may change the 2 / 4-hydroxylamine ratio, CB1954 was modelled 
into the active site, its central ring superimposed with that of NIC (Figure 7.10). The 2 
possible "right" orientations have the 4-nitro group at position A (3.5 A from the nitro N atom 
to the flavin N5 for hydride transfer), and the 2 "wrong" orientations switch the 4-nitro group 
for the 2-nitro group (which would lead to formation of the non-toxic product). The modelling 
serves only to act as a guide, as the ring systems of CB1954 and NIC may not bind to NTR 
identically. Table 7.6 describes the environment of the protein near the substituents of the 
ring.
Position (pocket) Description_________________________________ 
A OverFMNN5, clash with S40, near T41 
B Clash with E165, near S40 
C Very close to F124, near Y68 and G166 
D NearF124andN71 
E Projecting into solvent
______F______NearT41__________________________________ Table 7.6. Environment of protein near modelled CB1954 (also see Figure 7.10)
Positions A and F are closest to residue 41. Position A is occupied by a nitrogroup in all four 
of the modelled orientations, position F is occupied by a H atom or aziridine group in the 
"right" models and a H atom or CONH2 group in the "wrong" models. Although both sets 
allow a hydrogen atom substituent at position F, in justification of the T41L mutant producing
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Q120
FI.III /**"• K14
e) f)
Figure 7.10. Modelling of CB1954 into active site of NTR. Diagram coloured according to atom type : protein C, 
grey; FMN and ligand C, yellow; O, red; N, blue; P, magenta, a) + b) two orthogonal views of active site, with 
the ring of NIC (acid group removed) used to model CB1954 upon, c) to f) possible orientations when placing a 
nitrogroup of the ligand over N5 of the FMN. c) + d) illustrate the two "right" orientations, where the desired 
4-hydroxylamine would be produced, e) + f) illustrate the two "wrong" orientations, where the non-toxic 
2-hydroxylamine would be produced. Protein environment of the ring substituents labelled as A to F. Figure 
prepared using MOLSCRIPT (Kraulis 1991) and RASTER 3D (Meritt and Bacon 1997).
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more of the 4- than the 2-hydroxylamine, the hydrophobic leucine would interact more 
favourably with an aziridine group than a CONH2 group.
The improvement of NTR by mutation becomes a complex issue when considering multiple 
mutants. The combination of single mutants may be additive or multiplactive, or indeed they 
may negate one another. There is also no indication that mutant enzymes will behave 
identically in E. coli and tumour cells.
7.4.3 Other Mutants - No Structural Data
Mutation at serine 40 recovered A, T and G mutations, indicating the need for a small residue 
at this position, large residues presumably clashing with bound substrate. Mutation at tyrosine 
68 recovered a range of mutants (G, N, A, H, S, W, C, Q, D), the omission of a phenylalanine 
mutant a possible artefact of the screening protocol. Small residues at position 68 score well, 
indicating a possible role in accessibility to the active site or removing steric hindrance. 
Mutations recovered at position 70 (P, A, V, S, I, L, E, C, Q, G, T, D) show a similar lack of 
cohesion, other than the preference for a smaller residue (no W, Y or R). Mutations at glycine 
120 (A, T, S) indicate the importance of a small side chain near the entrance to the active site.
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CHAPTER 8
THE STRUCTURE OF AKR1C3
8.1 Introduction
From the starting point of a pure and homogenous source of AKR1C3. it was desired to obtain 
well-diffracting protein crystals to lead to eventual use in structure-based drug design and 
binding-mode studies. It would therefore be advantageous to have high resolution data and 
crystals amenable to soaking in substrates and inhibitors (good mechanical stability, solvent 
channels in close proximity to the enzyme active site). Derivitisation for phasing purposes 
would not be necessary due to the high sequence similarity of previously solved homologues 
(Hoog et al. 1994; Bennett et al. 1996; Nahoum et al. 2001), but the structure / function 
differences between family members would have to be addressed with respect to the small 
number of amino acid residue changes between enzyme subtypes.
8.2 Materials & Methods 
8.2.1 Sample Preparation
Purified HSD was a generous gift from Dr Jon Ride (School of Biosciences, University of 
Birmingham). The protein was supplied at a concentration of 20 mg/ml in a buffer containing 
10 mM KH2PO4, pH 7.0, 1 mM DTT, 1 mM EDTA and 2 mM NADP+.
8.2.2 Crystallization
Using a starting point of sparse matrix screening (solutions 1-96 from screening kits I and II 
from Molecular Dimensions), a series of hanging-drop vapour diffusion trials were set up, 
using 3 \i\ of protein stock mixed with 3 \*\ of reservoir solution, equilibrated against 1 ml of 
reservoir solution in VOX plates. From the analysis of crystallization conditions for
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homologues of HSD (Zhu et al. 2001), salt concentration appeared to be critical in obtaining 
different crystal forms, and was treated as the most important factor in subsequent fine 
screening optimization of the growth conditions. Final crystallization conditions were 
100 mM sodium citrate, pH 6.0, 0.4 or 0.8 M ammonium acetate, 25 % w/v PEG 4000 and 
2.5 % v/v MPD, and are discussed in more detail in section 8.3.1
8.2.3 Inhibitor Soaking
Crystals were soaked in a buffer containing 100 mM sodium citrate, pH 6.0, 0.8 M NaCl, 
25 % w/v PEG 4000, 10 % v/v ethylene glycol, 5 % v/v DMSO and 5 mM indomethacin or 
flufenamic acid for a period of 2 hours. Crystals could be flash-cooled direct from this 
solution.
8.2.4 Cryoprotection
For the binary complex structures (NADP+ and acetate bound), crystals were soaked for 2 
minutes in a buffer identical to the reservoir solution but supplemented with an extra 12 % v/v 
MPD. This was performed in a single step, with the crystals then being transferred directly to 
the cryo-stream at 100 K.
8.2.5 Data Collection
Data for 1) the low-salt P3221 crystal form, 2) the indomethacinrNADP complex P2\2\2] form 
and 3) the flufenamic acidiNADP complex P2\2\2i form were collected at the ESRF on 
beamline ID 14-2. Data for the high salt P2\2\2\ crystal form were collected at the ESRF on 
beamline ID 14-1.
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8.2.6 MR Phasing
The protein chain (all atoms) of the human type III 3a-hydroxysteroid dehydrogenase 
(AKR1C2) complexed with NADP+ and ursodeoxycholate (PDB entry 1IHI. Jin et al. 2001) 
was used as the search model for molecular replacement. Data for the P3221 crystal form were 
entered into the CNS suite molecular replacement package (Brunger 1990). The fastdirect 
option and a resolution cutoff of 15-4 A were used. The P2|2|2i crystal form was solved in a 
similar manner, with the refined P3221 form of AKR1C3 used as the search model.
8.2.7 Refinement Protocol (all 4 structures)
All models were built using the molecular graphics program TURBO-FRODO (Roussel et al. 
1991). Initial refinement steps were analogous to those described for the NTR protocol (see 
Chapter 5), followed by several rounds of TLS refinement using REFMAC5 (Winn et al. 
2001). Due to the high resolution of the P2\2\2\ form data, individual anisotropic B-factors 
were refined, as opposed to isotropic B-factors for the other three structures. Geometric 
restraint files for the NSAID inhibitors were generated interactively using CCP4i sketcher 
(CCP4 1994).
8.3 Results
8.3.1 Crystallization
Poor crystals were identified growing in the well from MDL Crystal Screen I solution 2 
(0.1 M sodium acetate, pH 4.6, 0.2M ammonium acetate, 30 % w/v PEG 4000). From 
optimisation of this initial "hit", two conditions giving different crystal morphologies were 
identified, differing only in the concentration of ammonium acetate present (0.4 M gave 
diamond-shaped crystals, 0.8 M cuboids). Typical refined conditions for crystal growth were
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100 mM sodium citrate, pH 6.0, 0.4 or 0.8 M ammonium acetate, 25 % w/v PEG 4000 and 
2.5 % v/v MPD. The two optimised crystal forms and initial crystalline results can be seen in 
Figure 8.1. The crystals grew over a period of 2-3 days and reached maximum dimensions 
within a week (-0.4 x 0.3 x 0.3 mm for the diamond-like crystals, -0.6 x 0.2 x 0.2 mm for the 
cuboids).
8.3.2 Data Collection & Phasing
Upon diffraction analysis of the crystals, it was apparent that the two crystal morphologies 
corresponded to two distinct spacegroups, both possessing one monomer per ASU (Vm 
calculations, results not shown). The diamond-shaped, low salt crystals belonging to the 
trigonal spacegroup P3221 and diffracting to -2.1 A resolution, and the cuboids belonging to 
the orthorhombic spacegroup P2\2\2\ and diffracting to ~1.1 A resolution. Full data collection 
statistics for both forms and the inhibitor soaks are shown in Table 8.1. The P3221 form 
possesses a large c axis of-250 A, subject to disorder and responsible for the choice of the 
P2i2|2i form for the inhibitor soaking. Typical diffraction images for both spacegroups are 
shown in Figure 8.2.
The list of peaks obtained from the cross-rotation function in the first step to solve the P3221 
form are shown in Table 8.2, with a clear solution as the top peak. The translation function 
was used to determine the P3i or P32 screw-axis ambiguity, with top solutions of monitor = 
0.3 and packing = 0.5 for P3i, and monitor = 0.6 and packing = 0.5 for P32 . The molecular 
replacement step solving the P2i2|2| form with the refined P3221 structure gave a clear 
solution in the cross-rotation function, and a top translation function answer with monitor = 
0.7 and packing = 0.6.
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a)
100 (im 200 urn
^Jp-sJ*"^
C)
400
Figure 8.1. AKR1C3 crystallization photographs: a) Initial crystalline results using MDL screen 1 solution 2; b) 
Round crystals, possibly obtained by too fast an equilibration between protein drop and reservoir solution; c) 
Diamond-like P3 221 crystal form, low salt (0.4M ammonium acetate); d) Cuboid-like P2 1 2 1 2, crystal form, high 
salt (0.8M ammonium acetate).
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3
a) 2.6 A 2.4 A
b) 1.8A 1.6A
Figure 8.2. Diffraction patterns of AK.RIC3 crystals, a) P3221 crystal form, 0.5° oscillation, ESRF Beamline 
IDI4-2. b) P2|2,2| crystal form, 1° oscillation, ESRF beamline ID14-1. Note the larger spacing between spots on 
the smaller cell P2 ( 2|2| form, and the long reciprocal c-axis spot arrangement of the P3 221 form (smaller spacing 
between diffraction spots). Resolution given at corner and edge of diagram.
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Trial Number
1
6
7
9
10
Thetal
267.711
329.828
252.674
275.275
269.966
Theta2
56.250
47.135
47.135
67.500
45.573
Theta3
257.035
243.387
263.351
241.681
256.643
RF value
0.1056
0.0364
0.0349
0.0336
0.0331
Table 8.2. Rotation function peak list for cross rotation step in molecular replacement with P3 221 crystal form. 
Theta angles are defined in CNS (Brunger et al. 1990), RF value represents scoring of rotation function step, 
comparing the vectors of the diffraction data with those generated from the placement of the trial model. Peaks 
shown are the top five scoring solutions.
8.3.3 Model Building & Refinement
Initial electron density from the molecular replacement-determined phases was excellent, 
allowing residue changes to be made from the search model to our sequence (P3a21 form, 
Figure 8.3), and showing clear density for NADP+ in all 4 structures. In the inhibitor-soaked 
structures, electron density corresponding to indomethacin or flufenamic acid was visible 
adjacent to the nucleotide. Refinement of all four structures was straightforward owing to the 
high resolution X-ray data and high sequence similarity to the MR search model. Final 
refinement statistics for all four structures are shown in Table 8.3. Refined electron density 
for the individual structure determinations can be seen in Figures 8.4, 8.7 and 8.8.
8.3.4 Structural Features
8.3.4.1 Protein Fold & Secondary Structure Assignments
From structural analyses of related AKR family members (Hoog et al. 1994; Bennett et al. 
1996; Jin et al. 2001), it was presumed that AKR1C3 would fold in a similar manner, that of a 
TIM a8pg barrel (named after triose phosphate isomerase, Banner et al. 1976). The a8px fold 
was indeed observed with AKR1C3, in tandem with several other features common to the 
AKR family of proteins. A schematic of the secondary structure assignments (as designated
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Figure 8.3. Lack of pre-existing model bias in AK.R1C3 molecular replacement results. Electron density map is 
2mFo-DFc, SIGMAA-weighted, 1.5 A resolution. Map calculated from phases of correctly placed HHI.pdb (Jin 
et al. 2001) molecular replacement solution, and amplitudes from P3221 crystal form dataset. The residue shown 
is that of S89 of UHl.pdb, with clear density for the corresponding residue F89 of AKR1C3. Diagram produced 
using BOBSCRIPT (Esnouf 1997) and RASTER 3D (Meritt and Bacon 1997).
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Crystal Form
Ligands
Spacegroup
Refinement
Resolution Range (A)
No. of Non-hydrogen 
Atoms 
No. Water Molecules
R factor3
R b 
Kfree
Average B factor (A2)
RMSD Bond Angles0 (°)
RMSD Bond Lengths'1 (A)
Acetate 
Low Salt
NADP+ 
acetate
P3 221
30-2.1
2889 
296
15.2%
19.5%
13.87
1.35
0.012
Acetate 
High Salt
NADP+ 
Acetate
P2.2.2,
30-1.2
3075 
434
12.7%
14.4%
8.91
2.02
0.020
Indomethacin 
Soak
NADP+ 
indomethacin
P2,2,2,
30-1.7
2964 
363
17.2%
19.8%
16.03
1.60
0.009
Flufenamic 
Acid Soak
NADP+ 
Flufenamic 
acid
P2.2.2,
30-1.8
2858
237
15.7%
20.3 %
11.66
1.82
0.016
a R factor = Ihkl |F0 | - |FC | |/2hkl |F0|.
bR factor based on 5 % of the data withheld from refinement
CRMSD bond angles and dbond lengths are the root mean square deviations from ideal values
Table 8.3. Refinement statistics of HSD structures.
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NADP+
b)
NADP+
Figure 8.4. Refined electron density from both crystal form structure determinations. Both maps are 2mFo-DFc, 
SIGMAA-weighted, contoured at la. a) P3221 crystal form (2.1 A), showing the nicotinamide headgroup of the 
NADP' cofactor, bound acetate molecule, Y55 and HI 17. b) entirety of NADP' cofactor, P2|2|2, crystal form 
(1.2 A). Diagram produced using BOBSCRIPT (Esnouf 1997) and RASTER 3D (Meritt and Bacon 1997).
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by PROCHECK, Laskowski et al. 1993) is given in Figure 8.5. Secondary structure 
nomenclature is adapted from aldose reductase (Wilson et al. 1992).
The barrel is closed at the N-terminal end by an antiparallel p-hairpin formed from residues 7- 
17 of the protein. The hairpin then feeds into the first stave of the barrel, p-strand 1. The a8 (38 
compact fold is augmented by an extra two a-helices, HI preceding a7, and H2 following oc8. 
These two extra helices contact one another on the periphery of the barrel. Smaller helical 
regions are present in some of the loops. Several loops extend from the C-terminal end of the 
barrel, forming the active site of the enzyme. Loop A is composed of residues 118-144, loop 
B from residues 217-238, and loop C from the C-terminal of the protein sequence (from H2 
onward). Residues 1-5, residue 321 onwards and the C-terminal His tag are presumably 
disordered as no electron density for these was observed in experimental maps. The overall 
protein fold and loop structure can be seen in Figure 8.6.
8.3.4.2 The Active Site 
8.3.4.2.1 The Cofactor
All four structures have a bound NADP+ molecule, indicative of the tight binding constant of 
the nucleotide (Kd = 40 nM, personal communication, J.P. Ride). The electron density for all 
parts of the NADP+ cofactor is excellent in all of the maps, especially so in the P2 \2\2\ 
acetate complex at 1.2 A (Figure 8.4). The NADP+ is present in an extended conformation, 
bound by the loops present at the C-terminal end of the barrel. Looking along the axis of the 
barrel, down at the cofactor (Figure 8.6b), loops A and B are roughly opposite one another, 
with loop C on one side and an open pocket on the other. Another opening at 90° to the barrel 
axis allows entry of the nucelotide.
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HAIRPIN
1 MDSKQQCVKLNDGHFMPVLGFGTYAPPEVPRSKALEVSKLAIEAGFRHID 50
51 SAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWSTFHRPELVRPALE 100
Loop A
101 NSLKKAQLDYVDLYLIHSPMSLKPGEELSPTDENGKVIFDIVDLCTTWEA 150
5 a5 6 cc6
151 MEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNRS 200
L o o p B HI
201 KLLDFCKSKDIVLVAYSALGSQRDKRWVDPNSPVLLEDPVLCALAKKHKR 250 
ocl (iS a8 H2
251 TPALIALRYQLQRGWVLAKSYNEQRIRQNVQVFEFQLTAEDMKAIDGLD 300
Loop C
301 RNLHYFNSDSFASHPNYPYSDEYHHHHHH 329
Figure 8.5. Secondary structure assignments for AKR1C3. N-terminal hairpin, beta strands 1-8, alpha helices 1- 
8, HI and H2 labelled. Smaller helices present in some of the loops remain unnumbered. Colouring corresponds 
to Figure 8.6. Secondary structure was assigned to the final model by use of PROCHECK (Laskowski et al. 
1993). Nomenclature adapted from aldose reductase (Wilson et al. 1992)
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Loop A
a)
b)
LoopB
al
Figure 8.6. Two orthogonal views of secondary structure of AKR1C3. Nucleotide present as ball-and-stick 
model. Labelling is as follows : N, N-terminus; C, C-terminus; Ade, adenine ring of NADP 1 ; Nic, nicotinamide 
ring of NADP; secondary structure elements labelling identical to that of Figure 8.5. Figure produced using 
MOLSCRIPT(Kraulis 1991).
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Residues K270 and R276 form salt bridges with the 2' phosphate, and S271 and Y272 
contribute hydrogen bonds. AKR1C3 shows a preference for NADP(H) over NAD(H), which 
can be attributed to these charged contacts to the 2" phosphate group of the nucleotide. The 
diphosphate of NADP^ sits between a gap at the ends of 0-strands 7 and 8, hydrogen bonding 
to S217N, S2170G, L219N, S221N, Q222NE2 and K270N. Several members of the AKR 
family possess a salt bridge covering the diphosphate moiety of the bound nucleotide, known 
as the "safety belt" (e.g. AKR1 Al, Wilson et al. 1992). This is not observed in AKR1C3, 
which has a hydrogen-bonding arrangement instead. The bulk of the adenine ring of NADP+ 
forms Van der Waals contacts between the R276, L219, L236 and A253 sidechains, whilst the 
edges of the ring hydrogen bond to the protein - N6 of NADP+ with N280OD1 and 
Q279NE2, and N7 of NADP+ with N280ND2. Ordered water molecules hydrogen bond with 
Nl and N3 of the adenine ring.
Due to inconsistencies between the traditional nucleotide labelling system of dehydrogenases 
and AKR enzymes, the labelling used in the first AKRrnucleotide complex will be used here 
(Wilson et al. 1992). This defines the A side of the nicotinamide ring as the side with atom 
numbers increasing in a clockwise fashion, and the B side with atom numbers increasing in a 
counter-clockwise fashion. The nicotinamide ring of NADP+ is positioned above the centre of 
the barrel, with the A side stacked against the side chain of Y216, and the B side exposed to 
solvent. This orientation of the cofactor allows substrates to bind over the B face, with the 
C4-pro-R position available to take part in hydride transfer. The nicotinamide O7 hydrogen 
bonds to N167ND2, and the N7 hydrogen bonds to both S166OG and Q190OE1.
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8.3.4.2.2 Acetate Complexes & Active Site Residues
Despite the difference in crystal packing, loops A, B and C retain the same conformation in 
both spacegroups. Both crystal structures show the presence of a molecule of acetate in the 
active site, bound over the NADP+ cofactor, no crystals could be grown in the absence of 
acetate. Both the acetate complexes have a bound molecule of MPD, which sits at the edge of 
the active site pocket near the base of loop A. The MPD makes one hydrogen bond to the 
protein, atom O2 of MPD to S129OG.
Besides the stacking arrangement with the nucleotide, each acetate makes contacts to several 
of the conserved active site amino acids. Oxygen O of the acetate hydrogen bonds to an 
ordered water molecule. The other oxygen forms one standard hydrogen bond to HI 17 NE2 
(2.9 A), and another shorter hydrogen bond to Y55OH (2.5 A). The methyl group of the 
acetate molecule points into a hydrophobic pocket comprised of Y24, Y55, L54, W227 and 
F306.
The residues that form the active site steroid binding pocket (as observed from studies on 
AKR1C2, see section 8.4.4) are largely hydrophobic. A list of these residues showing the 
variance between different AKR family members is presented in Table 2.3.
8.3.4.2.3 NSAID Complexes
Both the indomethacin (IMN) and the flufenamic acid (FLA) AKR1C3 complexes show 
strong, clear electron density for the NSAID compound at the active site (Figures 8.7 and 8.8). 
The carboxylate of FLA is in approximately the same orientation as the acetate in the acetate 
complex structures, FLA forming a short hydrogen bond with Y55OH (2.55 A). The two rings
163
a) b)
X v
c)
t>rTX;
•5^ YT.Jt^i i *
Y24
Figure 8.7. Binding of IMN to AKR1C3. (a) Fit of IMN into active site. Ligands in stick form, NADP C grey, 
IMN C yellow. Loop A coloured magenta, loop B green, loop C blue, (b) Electron density map of IMN, 
2mFo-DFc, SIGMAA-weighted, contoured at 10, 1.7 A resolution, (c) Contacts of IMN to AKR1C3. Coloured 
according to atom type : protein C, grey; NADP* C, black; IMN & DMSO C, yellow; O, red; K blue; P, 
magenta; S, orange; Cl, white. Hydrogen bonding shown as dotted green lines. Amino acid numbering using 
standard single letter code. Water molecules represented as red spheres. Diagrams prepared using MOLSCRIPT 
(Kraulis 1991), BOBSCRIPT (Esnouf 1997) and RASTER 3D (Meritt and Bacon 1997).
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a8
b)
0
Figure 8.8. Binding of FLA to AK.R1C3. (a) Fit of FLA into active site. Ligands in stick form, NADP C grey, 
FLA C yellow. Loop A coloured magenta, loop B green, loop C blue, (b) Electron density map of FLA, 
2mFo-DFc, SIGMAA-weighted, contoured at la, 1.8 A resolution, (c) Contacts of FLA to AKR1C3. Coloured 
according to atom type : protein C, grey; NADP+ C, black; FLA C, yellow; O, red; N, blue; P, magenta; S, 
orange; F, white. Hydrogen bonding shown as clashed green lines. Amino acid numbering using standard single 
letter code. Water molecules represented as red spheres. Diagrams prepared using MOLSCRIPT (Kraulis 1991), 
BOBSCR1PT (Esnouf 1997) and RASTER 3D (Meritt and Bacon 1997).
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of FLA lie at -70° to each other. The proximal aromatic ring of FLA (the ring with the 
carboxylate group) sits in a hydrophobic pocket comprised of L54, F306, W227, Y24 and 
Y55. The secondary amine linkage participates in a bifurcated hydrogen bond between the 
FLA nitrogen, FLA Ol atom, and the nicotinamide amide oxygen O7. The distal ring of FLA 
(the ring with the trifluoromethyl group) sits in a more hydrophilic pocket comprised of 
residues HI 17, W86, SI 18, M120, N167 and Y216. The Fl atom of FLA also hydrogen 
bonds to Y216OH (2.9 A). With residuesY55 and Y216, FLA forms a "molecular clamp" 
around the nicotinamide, surrounding it on all sides.
A second, lower occupancy molecule of FLA can be observed near the N-terminal end of the 
barrel. The FLA sits in a groove formed between residues 6-8 and 258-264. Electron density 
for this second molecule is better for the proximal ring than for the trifluoromethyl group of 
the distal ring.
The carboxylate of IMN is in a different orientation than the carboxylate of FLA. Instead of 
binding near the nicotinamide of the nucleotide, the carboxylate binds next to the diphosphate 
moiety (in the oxyanion hole), hydrogen bonding to oxygens NO1 and NO2. This mode of 
binding indicates that the IMN carboxylate group must be protonated - avoiding charge 
repulsion. Atom O2 of the IMN carboxylate also makes a contact to the protein, hydrogen 
bonding to Q222 backbone nitrogen. The carbonyl linkage of IMN points in toward the 
oxyanion hole, with the classical carboxylate oxygen position occupied by a solvent peak (see 
discussion).
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The chlorobenzoyl part of IMN sits between where the two rings of FLA were situated, just 
out of the plane of the proximal ring. The chlorine atom forms a hydrogen bond with an 
ordered water molecule. The IMN indole ring system sits orthogonal to the nicotinamide, 
displacing F306 from its position in the acetate-bound form. The movement of F306 away 
from the active site causes the corresponding movement of F311, which rotates away to allow 
the NSAID to bind. The two planes of the IMN rings are roughly perpendicular to one 
another. An ordered DMSO molecule binds where the distal ring of FLA sat, the oxygen atom 
of DMSO hydrogen bonding to SI 18OG. No bound DMSO can be observed in the FLA soak 
structure.
8.4 Discussion
8.4.1 Acetate Binding & Implications for Catalysis
The interaction of acetate with HI 17 and Y55 is particularly relevant, with these two residues 
forming the proposed catalytic tetrad (see Chapter 2) along with K84 and D50. The residues 
are positioned such that the D50O2 hydrogen bonds to K84NZ, which in turn hydrogen bonds 
to Y55OH. In the context of comparing the tetrad to the arrangement observed in serine 
proteases (see Figure 8.10), one of the acetate oxygens occupies the oxyanion hole. This 
acetate oxygen forms an extremely short hydrogen bond with Y55OH (2.5 A).
The residue arrangement in serine proteases functions to stabilise any negative charge present 
at the position of the oxyanion hole. AKR1C3 was crystallized at pH 4.6, equivalent to the 
pKa of acetate, so 50 % of the free acetate in solution will be charged and the other 50 % will 
be neutral. Due to the symmetry of the acetate molecule and electron delocalisation effects, it 
would normally be assumed that each oxygen of a charged acetate molecule would carry half
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a)
NADP+
acetate
b)
H57
peptide 
substrate
G193 backbone D194 backbone
Figure 8.10. Analogy of AKR1C3 active site residues with those of the serine proteases. a) AKR1C3 acetate 
complex, b) chymotrypsin with bound peptide (PDB code 1AB9, Yennawar et al. 1994). Atoms coloured by 
atom type : protein C, yellow; nucleotide C, grey; substrate C, green; O, red; N, blue. Hydrogen bonding 
represented by dotted green lines. In the chymotrypsin structure, the peptide ligand (only tyrosine section shown) 
is covalently bound to the active site serine (Tyr Ca to Ser Oy). The substrate carbonyl is sat in the oxyanion 
hole, with two hydrogen bonds to backbone amides. The catalytic serine is positioned by a histidine, itself held 
in place by an aspartate. With AKR1C3, the catalytic Tyr residue forms part of the oxyanion hole, in association 
with an active site histidine. The positioning of the catalytic residue is via a lysine : aspartate relay. Although 
differences are apparent, both function to stabilise the build up of charge on the substrate, and hold a catalytic 
acid or base in place. Diagram prepared using MOLSCRIPT (Kraulis 1991) and RASTER 3D (Meritt and Bacon 
1997).
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a formal negative charge. The hydrogen bond distance between acetate and Y55OH is 2.5 A, 
far shorter than normal hydrogen bonds and classified as a LBHB (low barrier hydrogen bond, 
review in Cleland et al. 1998). This type of bond is favoured by a charged atom and so it was 
decided that the acetate molecule in the active site carries a negative charge, entirely localised 
on the OXT atom.
The observation of acetate in this orientation matches several other structural studies on the 
AKR family. Nine polypeptide chains (from 8 structures) of AKR members in the Protein 
Data Bank (Berman et al. 2000) possess a compound with a carboxylic acid group bound at 
the active site. In all of these structures, a carboxylate oxygen is hydrogen bonded to an active 
site tyrosine and histidine. The group can take one of two orientations, seven of the nine 
agreeing with the orientation found in the presented AKR1C3 acetate/FLA complexes. A 
further three family members from the PDB have acetate itself bound. One of these, 
AKR1C2, binds acetate concurrently with testosterone, displacing the substrate (Nahoum et 
al. 2001). The ubiquity of observing a carboxylate oxygen in this position may indicate that it 
is acting as an analogue of the oxyanion intermediate when reducing ketones/aldehydes or 
oxidizing alcohols (see Chapter 2).
The LBHB between acetate and Y55 is only present in the P2 } 2\2\ complex. This may be 
attributed to the higher resolution of this crystal form, where the model is more accurate. The 
overall estimated co-ordinate error is ± 0.037 / 0.034 / 0.028 A based on R value / FreeR 
value / maximum likelihood, respectively. Of the AKR family members with a bound 
compound at the active site, 5 show a LBHB (< 2.6 A) to the tyrosine, 3 show a LBI IB to the 
histidine.
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The importance of LBHBs remains highly controversial. At short hydrogen bonding distances 
(ideally at 2.5 A), the energy barrier for proton transfer between the two hydrogen bonding 
atoms is overcome, and the hydrogen is proposed to be able to move freely between them. 
Such a scenario has been proposed to provide a large part of the catalytic power of 
oxidoreductase enzymes. A review by Warshel (Warshel 1998) documents the argument for 
other possible explanations of catalytic power, but it can be agreed that LBHBs provide a 
significant contribution to substrate or transition state binding.
8.4.2 NSAID Complexes
The electron density maps for both NSAID compounds were excellent and it was easy to 
model the drug complexes. However, one complication arose when analysing the IMN 
inhibitor soak. A prospective solvent peak was observed in the oxyanion hole, just 2.0 A away 
from the IMN carbonyl oxygen, and 2.6 A from Y55OH. The latter interaction is indicative of 
a LBHB but the former is far too short to be any kind of hydrogen bond. Due to the 
replacement of ammonium acetate with sodium chloride in the NSAID soaks, and the 
preference of LBHBs for a charged species, it is highly likely that a chloride ion occupies this 
position. It has also been noted that IMN inhibition (but not FLA inhibition) is sensitive to 
chloride ions when assaying steroid turnover (personal communication, J.P. Ride).
Although the data for the IMN dataset are good, chlorine does not have enough of an 
anomalous signal (0.27 e at 0.933 A) to be able to test the above hypothesis by the 
construction of an anomalous difference map. Whilst refining the IMN complex structure, a
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test refinement using a hydroperoxide derivative of IMN ruled out a covalent linkage of this 
solvent peak to the NSAID.
Having analysed the amino acid residue shifts of AKR1C3 upon binding the different 
NSAIDs, it is immediately apparent that more of a change is seen upon IMN binding than that 
of FLA. In both cases, residues on loops near the solvent exposed end of the active site show 
more of a shift than those at the bottom of the pocket, near the barrel edge. The largest 
changes take place on the C-terminal loop, around residues 310-311 (Figure 8.9a). The 
binding of the IMN indole moiety in the region of F306 causes the sidechain to rotate away 
from the nicotinamide. The FLA complex imposes no such steric clash and F306 retains the 
same conformation observed in the acetate complex. The binding of the MPD cryoprotectant 
molecule in the acetate complexes leads to F311 being bent away from that part of the pocket, 
towards W227. Although no MPD is present in the FLA soak, F311 in the FLA complex is in 
much the same position but has a completely different Ca position and ring orientation. This 
may be to place the ring of F311 orthogonal to F3 of the trifluoromethyl group, much like the 
interactions observed between methyl groups and aromatic sidechains. Strikingly, F311 of the 
IMN complex shows no such main chain movement, simply rotating 90° around the Ca-Cp 
bond. This rotation allows F306 of the IMN complex to occupy part of the space occupied by 
F311 in the other structures - this is due to the displacement of F306 from its normal position 
by the indole of IMN. Indeed, F306 and F311 show the largest positional changes upon 
NSAID binding, but smaller shifts can be seen in residues such as W227, S310 and W86, all 
of which line the active site pocket. No large changes are observed in the residues of the 
catalytic tetrad, small variations in HI 17 orientation can be seen in both NSAID structures,
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a)
Loop 309-312
NADP
IMN MPD
b)
FLA
Figure 8.9. Amino acid shifts upon NSAID binding. Acetate complex coloured in grey, indomethacin soak in 
green (a), and flufenamic acid soak in red (b). Diagrams only show largest amino acid shifts for clarity, full list 
of changes given in body of text. The indole ring of indomethacin binds where F306 is normally placed, shifting 
both F306 and F311. The flufenamic acid soak shows a change in orientation of F311, causing a re-arrangement 
of the C-terminal loop, most apparent between residues 309-312 shown above. Diagram prepared using 
MOLSCRIPT (Kraulis 1991) and RASTER 3D (Meritt and Bacon 1997).
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presumably due to the proximity of this sidechain to the chlorobenzoyl ring of IMN or distal 
ring of FLA.
The binding mode of both NSAIDs may possibly be influenced by several factors. The FLA 
carboxylate group has a lower pKa than that of IMN (3.9 versus 4.5), and so is more likely to 
be charged at the pH of crystallization (4.6), making it more likely to bind in the oxyanion 
hole. More experiments testing the pH sensitivity of the AKR1C3 crystals and feasibility of a 
pH range of NSAID soaks would be required to test this hypothesis in a structural manner. 
However, no change in the Kf of either NSAID (when varying the pH around this region) is 
observed in kinetic studies (personal communication, J.P. Ride). Similar kinetic studies do, 
however, show a 10-20 fold increase in Kj for the NSAID inhibitors when inhibiting reductive 
compared to oxidative reactions. This may indicate a higher affinity for the enzyme : NADP+ 
complex than the enzyme : NADPH complex, and even possibly different binding modes.
An equilibrium dialysis study on AKR1C9 inhibition by IMN (Penning et al. 1983), revealed 
a low affinity enzyme:IMN binary complex (K<j = 22 uM) and a different, high affinity 
enzyme:NAD+:IMN ternary complex (K^ = 1-2 uM). It could be argued that this may 
represent two different binding modes of the NSAID, or this may show consistency with the 
observations presented here that IMN has interactions with the nucleotide as well as the 
protein.
Regarding the use of these two NSAID complexes to model other NSAID binding to 
AKR1C3 - the plasticity of the active site residues and the vastly different binding modes of 
IMN and FLA may show the difficulties inherent in attempting this. It may. however, be a
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more simple affair, with subsequent NSAID complex determinations resembling either one or 
the other. The prospect of there being just these two binding modes is clear cut when 
comparing sulindac with IMN, or meclofenamic acid with FLA, but becomes complicated 
with NSAIDs such as peroxicam. Both NSAID complex structures are attractive in terms of 
drug design - there is plenty of space in the active site to introduce new functional groups, 
and several bound water molecules exist that could be replaced by new atoms on the NSAID. 
The large positional variability observed in several of the active site residues may present 
more of a problem when optimising the fit of the drug to the protein.
8.4.3 Comparison to Cyclo-oxygenase Indomethacin Complexes
Although COX is mechanistically and structurally distinct from the AKR family, it is 
interesting to compare the reported COX : IMN complexes with the structure obtained in this 
study. The structure of COX-1 bound to IMN (Loll et al. 1996) has a high resolution limit of 
4.5 A, and so a trans model (PDB code 1PGG) and a cis model (PDB code 1PGF) were fitted 
to the ambiguous electron density. Due to the lack of confidence in the model, it was decided 
to use the COX-2 : IMN complex (PDB code 4COX, data to 3 A, Kurumbail et al. 1996) in 
comparisons with AKR1C3. It must however be stressed that at 3 A some ambiguity in fitting 
a bound ligand (with limited information in stereochemical restraints) remains.
As no structural homo logy exists between COX-2 and AKR1C3, all IMN complex 
comparisons were achieved by overlapping the indole rings of the NSAID molecule. In 
COX-2, the acid group retains a similar conformation to that seen in AKR1C3, but twisted 
around the Cl 7-C18 bond by approximately 60°. The major difference between the two IMN 
complexes involves the cis / trans placement of the carbonyl and chlorobenzoyl groups. With
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the COX-2 structure, the carbonyl group is on the other side of the indole plane to the acid, 
with the chlorobenzoyl group on the same side as the acid group. In AKR1C3 this situation is 
reversed, with the carbonyl on the same side as the acid and the chlorobenzoyl group on the 
other side. A smaller difference is observed with the O-methyl part of IMN, pointing in 
opposite directions in the two structures.
Interactions between IMN and the protein differ markedly between COX-2 and AKR1C3. In 
general, AKR1C3 has more contacts to the NSAID than COX-2 does. In the COX-2 structure, 
IMN binds between two helices near the surface of the protein, 8 A from the heme. Unlike 
AKR1C3 which had a solvent peak or chloride ion very close to the carbonyl (which itself 
was in close proximity to active site residues), the carbonyl of IMN in the COX-2 structure 
has no contacts with the protein or solvent. This may be due to the low resolution of the 
COX-2 : IMN structural data and poor solvent clarity, or due to different binding 
environments employed by the two proteins. The acid group of IMN salt bridges to COX-2 
R120, different to the uncharged indomethacin carboxyl seen in the AKR1C3 complex. The 
chlorine of the chlorobenzoyl ring is positioned in a hydrophobic pocket comprised of G526, 
F381, L384 and M522. There are no other major contacts between IMN and COX-2, just 
several Van der Waals interactions between the indole ring and the protein.
These differences are somewhat expected due to the vastly different mechanistic schemes of 
the two proteins. With AKR1C3, IMN binds in the active site, next to the nucleotide and it is 
easy to see how this would prevent substrate binding. In the case of COX-2 and IMN, the 
mode of binding is very different. Although IMN binds 8 A away from the active site heme, it 
has to be remembered that the arachidonate substrate of the COX enzymes is very long and
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flexible. Superimposition of the COX-2 : arachidonate structure (PDB code 1DIY, Malkowski 
et al. 2000) with the COX-2 : IMN complex shows that the two ligands do indeed bind in the 
same part of the structure. With the large difference in IMN : protein contacts between COX- 
2 and AKR1C3, the prospect of designing an NSAID selective for one and not the other 
becomes an attractive prospect.
8.4.4 Comparison to HSD Steroid / Bile Acid Complexes
The "traditional" view of the role of AKR1C3 is in steroid metabolism, catalysing the 
reduction or oxidation of a wide range of steroids (Penning et al. 2001). Several members of 
the hydroxysteroid dehydrogenase subgroup of the AKR family have been co-crystallized 
with steroids or steroid-like bile acids. The first, rat liver 3cc-HSD (AKR1C9) was 
co-crystallized with testosterone (PDB code 1AFS, Bennett et al. 1997). AKR1C2 was also 
co-crystallized with testosterone (PDB code 1J96, Nahoum et al. 2001), but a molecule of 
acetate used as a buffer blocks the active site, shifting the steroid out of the oxyanion hole. 
AKR1C2 has also been complexed with the bile acid ursodeoxycholate in a different study 
(PDB code llffl, Jin et al. 2001).
No binary complex (enzyme and nucleotide) has been reported for AKR1C2, but one does 
exist for AKR1C9 (PDB code 1LWI, Bennett et al. 1996). All three steroidal complexes have 
similar loop orientations. The loop orientation observed in the four structures in this study is 
different to this, resembling the AKR1C9 binary complex instead. In comparing the HSD 
enzymes with and without steroid bound, loop A shows the greatest difference, followed by 
loop C and then loop B. Smaller shifts can be seen in the other shorter loops near the active 
site. When steroid binds, loop A moves away from the active site pocket to accommodate it.
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loop C comes closer in to contact the steroid, and loop B rolls away from loop C slightly. 
Although acetate is bound in the AKR1C2 testosterone complex, the position of the steroid is 
similar to that of the four fused rings in the ursodeoxycholate complex, with the bound acetate 
molecule sat in the same position as the carboxylate of the bile acid. The AKR1C9 
testosterone complex is different, bound much further into the active site pocket, the C3 
ketone group located in the oxyanion hole. As the two testosterone complexes are different in 
nature but show a similar loop structure, this indicates perfectly the plasticity of these 
enzymes in binding substrates in a variety of orientations.
Despite the large loop movements and lack of a full understanding of the different steroid 
binding modes (for 3a, 170 and 20ot metabolism), it is possible to use the steroid complexes 
to identify residues in AKR1C3 likely to interact with any bound steroids. Comparing 
AKR1C3 with AKR1C9, residues W227 (invariant), R226 (rat T226), Y24 (T24) and F306 
(N306) would all have to move considerably to accommodate any steroid in this pocket. In 
comparison to the bile acid of AKR1C2, residues W227 (invariant), R226 (P226), Y24 
(invariant), L54 (V54), LI28 (VI28) and P27 (A27) would need to move. Obviously, the 
differences in amino acid residues may also play a part in steroid accessibility, particularly the 
bulky residue R226, only present in AKR1C3 of the HSD enzymes. Some consideration must 
also be made that loops will shift when steroids bind, but the residues involved would still 
remain in close proximity to the steroid.
Mutational studies have also implicated residues in steroid binding. A Y55F mutant in 
AKR1C9 (Pawlowski et al. 1994) led to a 30-fold increase in IQ for testosterone, and a 11117 
mutant in aldose reductase led to an 80,000-fold increase in Km for its substrate (Tarle et al.
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1993). These two observations indicate that the oxyanion hole and its surrounding residues 
play a substantial role in substrate binding as well as catalysis. Interestingly, W86 mutants 
have a moderate effect on steroid binding, but with W227 mutants the effect is more severe 
(Jez et al 1996b). This situation is reversed with NSAID binding, W86 having a large effect 
and W227 virtually no effect at all (Penning 1999). This reflects the position of the two 
residues in the active site pocket, W86 next to the chlorobenzoyl ring of IMN or distal ring of 
FLA, W227 on the opposite side of the active site, clamped against bound steroid.
For a fuller understanding of the determinants of steroid stereo specificity, it would be 
necessary to have a hydroxysteroid dehydrogenase series of co-complexes, with 3a, 170 and 
20a steroids or steroid mimics. The plasticity of the active site residues permits any 
meaningful modelling of such complexes, and it may be wise to utilise one or more of the 
AKR proteins for this purpose. It is intriguing that as well as the binding of NSAIDs and 
steroids, AKR1C3 also has the versatility to bind prostaglandins. Due to their hydrophobic 
nature these may indeed bind in much the same way as a steroid, but their increased flexibility 
may mean much of the molecule is disordered in an electron density map if the contacts to 
protein are not strong (given that crystals could be obtained). If the co-crystallization of such 
short-lived labile species as prostaglandins is a problem, and they are too large to soak into 
the active site, small analogues of the prostaglandin headgroups may have to be used. No 
complex of any protein with a prostaglandin is available in the PDB at present. Any complex 
of AKR1C3 with a prostaglandin would also hopefully reveal why this enzyme is unique 
amongst the AKR1C subfamily in its role of prostaglandin metabolism. Simple sequence 
alignments provide little clue, apart perhaps from residue SI 18 (Fl 18 in all the other members 
of the subfamily, also a serine in bovine prostaglandin synthase).
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